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ABSTRACT 
 
INTERLEUKIN-22 REGULATES IMMUNITY, INFLAMMATION AND TISSUE 
HOMEOSTASIS AT MUCOSAL SITES 
 
Gregory Field Sonnenberg 
 
David Artis, PhD 
 
At mucosal sites, a single layer of epithelial cells separates the connective tissues of the 
mammalian body from the external environment.  The gastrointestinal tract is the largest 
mucosal surface exposed to the environment and is colonized with an estimated 300 
trillion beneficial commensal bacteria.  These properties of mucosal sites help facilitate 
critical biological processes, including nutrient absorption, gas exchange and excretion 
of wastes, yet also renders mucosal sites particularly vulnerable to infection and 
inflammation.  In order to maintain a state of health, complex immunoregulatory 
networks have evolved at mucosal sites to promote immunity, limit inflammation and 
maintain tissue homeostasis.  Interleukin (IL)-22 is a member of the IL-10 cytokine family 
that is produced by both innate and adaptive immune cells, and acts directly on the 
mucosal epithelium to promote anti-microbial, reparative and inflammatory responses.  
Chapter 2 of this thesis examines the role and regulation of IL-22 production by innate 
lymphoid cells (ILCs) in promoting immunity to the enteric bacterial pathogen Citrobacter 
rodentium.  The data identify that following infection, IL-23 promotes an IL-22+ CD4+ ILC 
response that is necessary and sufficient to promote enteric immunity, limit bacteria 
dissemination and prevent host morbidity and mortality.  In addition to pathogenic 
vi 
bacteria, loss of containment and peripheral dissemination of beneficial commensal 
bacteria results in dysregulated systemic immune cell homeostasis, and is a hallmark of 
numerous chronic human diseases.  Chapter 3 of this thesis demonstrates a novel role 
for IL-22-producing ILCs in containing intestinal commensal bacteria, limiting peripheral 
dissemination and induction of systemic inflammation.  Finally, studies have identified 
both pathologic proinflammatory and beneficial tissue-protective functions for IL-22 in 
distinct models of infection and inflammation.  Chapter 4 of this thesis identifies that the 
pathologic proinflammatory versus tissue-protective properties of IL-22 in a model of 
airway inflammation are regulated by Th17 cell-derived IL-17A.  Collectively, studies 
presented in this thesis identify novel regulatory and functional aspects of IL-22 and 
ILCs, and demonstrate a critical role for this pathway in the immunoregulation of tissue 
homeostasis at mucosal sites. 
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Chapter 1  
Introduction 
 
At mucosal sites, such as the intestinal tract and airway, a single layer of epithelial cells 
separates the connective tissues of the mammalian body from the external environment.  
Mucosal sites, such as the intestine, are the largest surface of the mammalian body 
exposed to the environment and are colonized with an estimated 300 trillion beneficial 
commensal bacteria.  These properties facilitate the critical biological functions of 
mucosal sites including nutrient absorption, gas exchange and waste excretion, yet 
renders mucosal sites highly vulnerable to infection with pathogenic microorganisms and 
pathologic inflammation.  Mammals have evolved complex immunoregulatory networks 
to maintain a homeostatic balance in mucosal tissues.  The importance of 
immunoregulation at mucosal sites is evident, as a loss of tissue homeostasis at these 
locations is a hallmark of numerous chronic human diseases including progressive 
human immunodeficiency virus (HIV) infection, inflammatory bowl disease (IBD), 
hepatitis and cancer (Chin et al., 2007; Douek et al., 2009; Fava and Danese, 2011; 
Sandler et al., 2011a; Sandler et al., 2011b).  Therefore elucidating the mechanisms of 
immunoregulation at mucosal sites will be essential in understanding the pathogenesis 
of these chronic human diseases and will promote the identification of novel targets and 
immunotherapies for their treatment and prevention. 
 This thesis will interrogate mechanisms of immunoregulation at mucosal surfaces 
in the context of immunity, inflammation and tissue homeostasis, with a particular focus 
on a pathway involving interleukin (IL-)22 and its role in an emerging population of innate 
lymphoid cells (ILCs).  Chapter 2 of this thesis will explore the role and regulation of the 
ILC-IL-22 pathway in promoting intestinal innate immunity to the enteric bacterial 
 2 
pathogen Citrobacter rodentium, and Chapter 3 will examine the role of this pathway in 
containing beneficial commensal bacteria to intestinal tissues and maintaining peripheral 
immune cell homeostasis.  Finally, the role and regulation of IL-22 in acute airway 
damage and inflammation will be explored in Chapter 4. 
 Chapter 1 of this thesis will serve as an introduction to the structure and function 
of mucosal surfaces and their associated lymphoid tissues, known immunoregulatory 
networks that exist at mucosal surfaces, the functional biology of the IL-22-IL-22R 
pathway, the emerging family of innate lymphoid cells and the use of infectious and 
inflammatory model systems to interrogate mechanisms of immunoregulation at mucosal 
sites. 
 
1.1 Immunoregulation at mucosal sites 
Mammals have evolved multiple immunoregulatory networks to maintain tissue 
homeostasis at mucosal sites.  In this section the structural anatomy of mucosal sites 
and their associated lymphoid tissues, and the importance and challenges of maintaining 
tissue homeostasis at such a dynamic interface will be discussed. 
 
1.1.1 Structural anatomy of mucosal sites and associated lymphoid tissues 
Mucosal surfaces, such as the intestinal tract and airway, are typically composed of a 
single layer of epithelial cells that separate the mammalian body from the external 
environment (Artis, 2008).  In the intestine, this epithelial layer is organized into folding 
crypts, which includes several specialized cell lineages to aid in digestion and uptake of 
nutrients (Figure 1A).  In the lung, a single layer of epithelial cells line the airway and are 
designed to facilitate gas exchange and respiration (Figure 1B).  Although this single-cell 
thick epithelial lining is beneficial to the transfer of materials across the interface, it also 
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serves as a vulnerable access point to the rest of the mammalian body that is 
continuously exposed to numerous potentially harmful pathogens or other environmental 
stimuli (outlined in Chapter 1.1.2).  To combat this challenge, mucosal-associated 
lymphoid tissues evolved to maintain tissue homeostasis at barrier surfaces and limit the 
potential systemic invasion by microbes or environmental stimuli.   
 The intestine is densely populated with immune cells that are found diffusely 
distributed in connective tissue or in organized components of the gut-associated 
lymphoid tissue (GALT).  The GALT is composed of lymphoid follicles, Peyer’s patches 
and mesenteric lymph nodes (mLN).  The Peyer’s patches and mLN are both formed 
during fetal development.  Development of these tissues is dependent upon interactions 
of resident stromal cells with hematopoietic fetal lymphoid tissue inducer (LTi) cells 
(Mebius, 2003; van de Pavert and Mebius, 2010).  The biology of LTi cells, a member of 
the innate lymphoid cell family, and their regulation of GALT formation will be discussed 
further discussed in Chapter 1.3.2.  The Peyer’s patches are organized lymphoid 
structures dispersed throughout the small intestine directly underneath the single layer of 
intestinal epithelial cells (Figure 1A).  Specialized epithelial cells directly above the 
Peyer’s patch known as microfold (M) cells function to permit enhanced sampling of the 
intestinal lumen by immune cells residing in the Peyer’s patch (Suzuki et al., 2010).  For 
this purpose, Peyer’s patches are one of the major inductive sites of immunoglobulin 
(Ig)A production (Artis, 2008; Hooper and Macpherson, 2010; Suzuki et al., 2010).  The 
lymphoid follicles, Peyer’s patches and several other sites of the intestine are drained by 
lymphatics to the mLN (Figure 1A), an additional organized lymphoid structure 
associated with intestinal tissues.  For this reason, the mLN is predicted to be the major 
inductive site of antigen-specific adaptive immune responses (Suzuki et al., 2010).  In 
addition to these organized lymphoid structure; immune cells are present throughout the 
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intestine, including the presence of leukocytes dispersed throughout the lamina propria 
(Lp) and intra-epithelial layer (IEL), two anatomical locations located directly below the 
intestinal epithelium or directly between individual intestinal epithelial cells respectively 
(Artis, 2008; Duerkop et al., 2009; Hooper and Macpherson, 2010).  Further, several 
smaller, less well-organized lymphoid structures develop in the intestine following birth.  
These tissues include cryptopatches (CPs), which are smaller lymphoid structures, 
containing and dependent upon LTi cells for formation (Eberl and Littman, 2004; Eberl et 
al., 2004).  CPs have the capacity to mature to larger isolated lymphoid follicles (ILFs) 
with the recruitment of B cells and increased lymphoid organization (Eberl, 2005; van de 
Pavert and Mebius, 2010).  ILFs share many characteristics with Peyer’s patches and 
have been proposed to serve similar functions, however ILF development occurs 
following birth and is uniquely dependent on the acquisition of commensal flora (Bouskra 
et al., 2008; Eberl and Littman, 2004; Suzuki et al., 2010). 
 The airway also contains numerous organized lymphoid structures that are 
formed pre- and post- fetal development (Figure 1B).  Similar to the intestine, the 
airways possess organized draining lymph nodes that form prior to birth, as well as 
leukocytes dispersed throughout IEL and parenchyma fractions (Holt et al., 2008).  The 
airways also possess leukocytes within the bronchiolar and alveolar lumens, which are 
capable of immunologically monitoring exposure to foreign material while effectively 
outside the mammalian body (Holt et al., 2008).  Following birth, the airways have the 
capacity to form inducible organized lymphoid structures, often referred to as inducible 
bronchus associated lymphoid tissues (iBALT) (Randall, 2010).  Areas of iBALT can be 
found in many different locations of the airways, are often indicative of inflammation and 
contribute to pulmonary immunity (Moyron-Quiroz et al., 2006; Randall, 2010; Rangel-
Moreno et al., 2011).  Maintenance of tissue homeostasis in the intestine and airway 
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relies on a balance of immunological surveillance for pathogen recognition and tolerance 
to the beneficial commensal bacteria and innocuous environmental antigens, and the 
mammalian immune system has evolved a number of regulatory strategies to achieve 
this balance.   
 
1.1.2 Maintaining immune cell homeostasis at mucosal sites 
Due to their structure, function and location, mucosal sites are particularly vulnerable to 
disruptions of tissue homeostasis.  As discussed above, a single layer of epithelial cells 
provides an easily accessible point of entry from the surrounding environment for 
numerous innocuous, beneficial and potentially harmful microbes or environmental 
agents (Artis, 2008; Duerkop et al., 2009; Holt et al., 2008; Hooper and Macpherson, 
2010).  The ability to distinguish between these agents creates a considerable challenge 
for the mucosal-associated immune system.  Given the large exposed surface areas of 
the intestine and lung, a number of pathogens have evolved mechanisms to colonize 
and invade these sites (Mathers et al., 2009), and therefore the mucosal immune system 
must be prepared to react to these pathogens in order to limit replication, dissemination 
and transmission.  Studies discussed in Chapter 2 of this thesis identify a novel pathway 
of innate immunity to an enteric bacterial pathogen.  In addition to pathogenic microbes, 
an estimated 100 trillion beneficial commensal bacteria, composed of 15,000-40,000 
different species, colonize the mammalian intestine (Abt and Artis, 2009; Frank and 
Pace, 2008; Hill and Artis, 2010; Ley et al., 2006).  These bacteria promote numerous 
beneficial processes including maintaining normal intestinal physiology, aiding in 
digestion, promoting immune cell development and function and limiting colonization 
with pathogenic microorganisms (Hill and Artis, 2010; Hooper and Gordon, 2001; 
Macpherson and Harris, 2004).  Under homeostatic conditions these commensal 
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bacteria are limited to the intestinal lumen and associated lymphoid tissues to prevent 
exposure of these microbes to peripheral organs (Duerkop et al., 2009; Hooper and 
Macpherson, 2010).  Loss of containment and peripheral dissemination of commensal 
bacteria results in induction of systemic inflammation and is a hallmark and potentially 
contributing factor to the pathogenesis of numerous chronic human diseases including 
HIV infection, IBD, hepatitis and cancer (Chin et al., 2007; Douek et al., 2009; Fava and 
Danese, 2011; Sandler et al., 2011a; Sandler et al., 2011b).  Studies discussed in 
Chapter 3 of this thesis identify a novel pathway regulating the containment of 
commensal bacteria to the intestine, which is essential in maintaining systemic immune 
cell homeostasis in the steady state.  In addition to microbial agents, the intestine and 
lung are continuously exposed to innocuous antigens in the environment that pose no 
threat of invasion or hazard to the mammalian body, and generation of an immune 
response is unnecessary (Artis, 2008; Duerkop et al., 2009; Holt et al., 2008; Hooper 
and Macpherson, 2010).  Immune responses to these innocuous stimuli such as 
allergens or pollutants can be detrimental to the mammalian hosts, causing 
inappropriate inflammation and unnecessarily interfering with the ability of mucosal sites 
to perform their biological functions (Artis, 2008; Duerkop et al., 2009; Holt et al., 2008; 
Hooper and Macpherson, 2010).  Studies discussed in Chapter 4 of this thesis 
interrogate the role and regulation of an IL-22-dependent pathway in the induction and 
resolution of acute airway inflammation. 
 
1.1.3 Regulation of mucosal immunity, inflammation and homeostasis 
Numerous immunoregulatory pathways have been identified in states of immunity, 
inflammation and homeostasis at mucosal sites.  Pathogenic microbes are first identified 
at mucosal sites by the innate immune system, which recognizes conserved pathogen 
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associated molecular patterns (PAMPs) present on or in the microbes (Barbalat et al., 
2011; Medzhitov, 2007; Philpott and Girardin, 2004; Schenten and Medzhitov, 2011).  
These PAMPs are recognized by pattern recognition receptors (PRRs) that are 
expressed by numerous innate immune cell types to initiate an immune response 
(Barbalat et al., 2011; Medzhitov, 2007; Philpott and Girardin, 2004; Schenten and 
Medzhitov, 2011).  Innate immunity includes the direct killing or phagocytosis of 
microbes and the production of soluble effector molecules, which can recruit additional 
immune cells and induce inflammation (Barbalat et al., 2011; Medzhitov, 2007; Philpott 
and Girardin, 2004; Schenten and Medzhitov, 2011).  Importantly, innate immunity is 
essential for initiating antigen-specific from T cells and B cells responses to promote 
clearance of pathogenic microbes by cytotoxic-, cytokine- and antibody-mediated 
pathways, and for the generation of immunologic memory to provide protection from 
secondary infection (Cheroutre and Madakamutil, 2005; Lefrancois and Puddington, 
2006; Medzhitov, 2007; Philpott and Girardin, 2004). 
 Commensal bacteria also express PAMPs capable of activating PRRs on 
immune cell populations (Duerkop et al., 2009; Hill and Artis, 2010; Hooper and 
Macpherson, 2010).  Therefore, to maintain mucosal and immune cell homeostasis 
without causing potentially damaging inflammation, mammals evolved numerous 
immunoregulatory pathways (Artis, 2008; Duerkop et al., 2009; Hill and Artis, 2010; 
Hooper and Macpherson, 2010).  Most commensal bacteria species are non-invasive 
and therefore one mechanism to avoid immune recognition is to create physical space 
between the intestinal epithelial barrier and commensal bacteria.  Production of mucins 
by specialized intestinal epithelial cells known as goblet cells can create physical space 
by forming of a thick mucus layer directly between the epithelium and intestinal lumen 
(Duerkop et al., 2009; Johansson et al., 2008).  The importance of this mucus layer is 
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highlighted by the finding that mice deficient in the mucin gene Muc2 exhibit substantially 
increased intestinal inflammation (Johansson et al., 2008).  Interactions between 
commensal bacteria and mucosal immune cells are further limited by epithelial cell 
production and luminal secretion of anti-microbial peptides, which have the capacity to 
form pores and lyse bacterial membranes (Duerkop et al., 2009; Hooper and 
Macpherson, 2010; Mukherjee et al., 2008).  Anti-microbial peptides include defensins, 
cathelicidins and C-type lectins that are produced in a constitutive or inducible manner 
by specialized intestinal epithelial cells known as Paneth cells (Duerkop et al., 2009; 
Mukherjee et al., 2008).  Cells in the mucosal epithelial barrier also express tight junction 
proteins that create a physical barrier to passive translocation of any interacting 
commensal bacteria (Artis, 2008; Shen and Turner, 2006).  Finally, numerous 
immunoregulatory pathways exist to promote containment of commensal bacteria 
including the presence of intra-epithelial lymphocytes that can directly mount responses 
to bacteria, phagocytosing macrophages and dendritic cells, and B cell-derived IgA 
which can be directly transcytosed by epithelial cells to the intestinal lumen to bind and 
limit interactions of commensal bacteria with the epithelial barrier (Artis, 2008; Duerkop 
et al., 2009; Hooper and Macpherson, 2010).  
 One critical mechanism by which immunoregulation is carried out at mucosal 
sites is through the production of cytokines.  Cytokine are surface bound or soluble 
secreted proteins that serve as signaling molecules for intercellular communication.  
Cytokines act in an autocrine, paracrine or endocrine manner by binding cytokine 
receptors on hematopoietic and non-hematopoietic cells (McInnes and Schett, 2007; 
Rubtsov and Rudensky, 2007; Yoshimura et al., 2007).  Cytokine-receptor interactions 
induce cascades of intracellular signal transduction pathways that promote changes in 
gene transcription and influence numerous cellular processes involved in immunity, 
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inflammation and tissue homeostasis (McInnes and Schett, 2007; Rubtsov and 
Rudensky, 2007; Yoshimura et al., 2007).  Section 1.2 will review the IL-22-IL-22R 
pathway, which is the central focus of this thesis. 
 
1.2 Functional biology of the IL-22-IL-22R pathway at mucosal surfaces 
Expression of interleukin (IL) -22, a member of the IL-10 cytokine family, has recently 
been reported in a number of human diseases, including mucosal-associated infections 
and inflammatory disorders of the intestine, skin and joints (Sonnenberg et al., 2010, 
2011; Wolk and Sabat, 2006).  Both T cells and an emerging category of innate 
lymphoid cells are sources of IL-22, while the IL-22 receptor complex is reported to be 
restricted to cells of non-hematopoietic origin (Tachiiri et al., 2003; Wolk et al., 2004).  
The ligand-receptor distribution of IL-22-IL-22R permits immune cells to regulate 
responses of epithelial cells, endothelial cells, fibroblasts, and other tissue-resident 
stromal cells.  This pathway appears to be critically important at barrier surfaces where 
epithelial cells play an active role in the initiation, regulation and resolution of immune 
responses.  Functional studies in murine model systems indicate that IL-22 has 
immunoregulatory properties in infection, inflammation, autoimmunity and cancer 
(Sonnenberg et al., 2010, 2011; Sugimoto et al., 2008; Zheng et al., 2007; Zheng et al., 
2008).  Therefore, advancing our understanding of the biology of IL-22-IL-22R may yield 
novel therapeutic targets in multiple human diseases. 
 
1.2.1 The IL-10 cytokine family 
Sequence comparisons of cDNA from novel transcripts identified the existence of the IL-
10 family of cytokines.  Similar to interferons, this family is presumed to be derived from 
gene duplication of an ancestral type-2 cytokine.  While primary sequences show 
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relatively low homology, the resolved crystal structures of the IL-10 family of type-2 
cytokines show structural conservation (Pestka et al., 2004).  The IL-10 family 
encompasses IL-10, IL-19, IL-20, IL-22, IL-24 and IL-26, which are expressed by innate 
and adaptive cells of the immune system.   Members of the IL-10 family exhibit receptor 
subunit sharing and signal through the Jak/STAT pathway inducing phosphorylation of 
STAT1, STAT3, and STAT5 (Table 1) (Pestka et al., 2004).  Putative functions of the IL-
10 family members are diverse.  IL-10 acts on hematopoietic cells and promotes anti-
inflammatory responses, while IL-22 acts on non-hematopoietic cells and promotes anti-
microbial, reparative and inflammatory responses (Moore et al., 2001; Pestka et al., 
2004; Sonnenberg et al., 2010, 2011).  Recently, examination of the expression and 
function of IL-22 have demonstrated that this cytokine has profound roles in 
immunoregulation at mucosal sites.  Below, I will discuss recent findings on the 
expression, regulation and functions of IL-22 and IL-22R at mucosal sites. 
 
1.2.2 Expression of the IL-22 receptor is restricted to non-hematopoietic cells 
The IL-22 receptor is a type-2 cytokine receptor composed of two subunits (Kotenko et 
al., 2001a; Xie et al., 2000).  IL-22 first binds to IL-22R1 and then IL-10R2 sequentially 
binds the IL-22/IL-22R1 complex (Li et al., 2004; Logsdon et al., 2002).  While IL-10R2 is 
ubiquitously expressed on hematopoietic and non-hematopoietic cell lineages, most 
reports indicate that the IL-22R1 subunit is restricted to cell lineages of a non-
hematopoietic origin (Tachiiri et al., 2003; Wolk et al., 2004).  In particular, non-
hematopoietic cells that have been found to constitutively express a functional IL-22 
receptor are resident in the pancreas, kidney and liver, as well as at barrier surfaces 
such as the skin, intestine, and lung (Wolk et al., 2004).  The restricted distribution of the 
IL-22R governs the functions of IL-22 as it restricts the biological effects of IL-22 to non-
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hematopoietic tissue-resident cells.  One recent report also identified that incubation of 
DCs with recombinant (r) IL-22 augmented a model DC-induced allergic inflammation, 
suggesting that IL-22 may have some capacity to act on hematopoietic cells (Schnyder 
et al., 2010; Tachiiri et al., 2003).  Additionally, initial studies examining the effects of IL-
22 observed that incubation of purified human CD4+ T cells with rIL-22 was able to 
modestly augment IL-4 production following TH2 cell polarization, and incubation of 
murine B cells with rIL-22 was able to induce expression of reactive oxygen species 
(Wei et al., 2003; Xie et al., 2000).  However, definitive evidence of IL-22R expression 
on hematopoietic cell types is lacking at present.  
 The distribution of IL-22R has been well characterized, yet relatively little is 
known regarding the stimuli and signaling pathways that regulate IL-22R expression.  
Despite the appearance of constitutive expression on a number of non-hematopoietic 
cell types, IL-22R1 expression is upregulated following stimulation of human skin cell 
lines with rIFNγ (Wolk et al., 2004), or following con-A or LPS challenge of hepatocytes 
(Radaeva et al., 2004; Tachiiri et al., 2003).  Thus, evidence for dynamic regulation of 
the IL-22R exists and suggests that the regulated expression of IL-22R in the context of 
immunity or inflammation should be considered in future studies. 
 In addition to the surface bound receptor, a soluble secreted receptor for IL-22 
exists, termed IL-22 binding protein (IL-22BP) or IL-22RA2 (Dumoutier et al., 2001; 
Kotenko et al., 2001b; Xu et al., 2001).  IL-22BP is expressed in various tissues 
including the breast, lungs and colon.  IL-22BP expression has been found in the 
epithelium and various mononuclear cells, and can be upregulated in macrophages 
following exposure to LPS (Dumoutier et al.; Kotenko et al., 2001b; Wei et al., 2003; Xu 
et al., 2001).  IL-22BP binds IL-22 with a sufficient affinity to block IL-22R binding, 
therefore acting as a natural cytokine antagonist (Dumoutier et al., 2001; Kotenko et al., 
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2001b; Xu et al.).  Furthermore, IL-22BP is dynamically regulated in murine models of 
infection and colitis, suggesting that it may be important in regulating the in vivo 
biological consequences of IL-22 expression (Sugimoto et al., 2008; Wilson et al., 
2010a; Wolk et al., 2007). Consistent with its ability to abrogate IL-22 signaling and 
function in vitro, delivery of IL-22BP in vivo abrogated IL-22-mediated protection in a 
model of chemical-induced colitis (Sugimoto et al., 2008).  Despite these insights, further 
investigations are required to advance our understanding of the regulation and functions 
of IL-22BP in the context of infection and inflammation, as it may be an important 
pathway to consider when targeting IL-22. 
 
1.2.3 Signal transduction induced by IL-22-IL-22R interactions 
Binding of IL-22 to its type-2 cytokine receptor induces a cascade of downstream 
signaling pathways.  Initial studies utilizing a murine kidney cell line revealed that IL-22R 
ligation induced phosphorylation of STAT3, and to a lesser extent STAT5 (Dumoutier et 
al., 2000a), while other studies observed phosphorylation of STAT1, STAT3, and STAT5 
in a human kidney cell line (Xie et al., 2000).  Further analysis concluded that IL-22 
signaling utilizes Jak1 and Tyk2 to propagate downstream phosphorylation signals, 
including several MAPK pathways (ERK1/2, MEK1/2, JNK, and p38 kinase), and STAT1, 
STAT3, and STAT5 (Lejeune et al., 2002).  STAT3-mediated signaling is a common 
pathway utilized by members of the IL-10 cytokine family (Table 1), however, IL-22 
signaling exhibits a number of unique properties.  For example, in comparison to IL-10 
stimulation that induces phosphorylation of tyrosine residues on STAT3, IL-22 
stimulation induces STAT3 phosphorylation on both tyrosine and serine residues, and 
also strongly activates the ERK1/2 pathway (Lejeune et al., 2002).  The IL-22-induced 
phosphorylation of serine-727 on STAT3 was found to be required for maximal 
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transactivation of STAT3, thus identifying unique requirements in the IL-22 versus IL-10 
signal transduction pathways (Lejeune et al., 2002).  As both IL-10 and IL-22 utilize IL-
10R2, Jak1 and Tyk2, the observed differences in signal transduction pathways may be 
attributed to differences between IL-10R1 and IL-22R1.  This is consistent with a recent 
report identifying that IL-22R1 is responsible for recruiting STAT3 in a tyrosine-
independent manner (Dumoutier et al., 2009).  STAT3 phosphorylation appears to be an 
essential pathway in mediating the effects of IL-22 on epithelial cells at mucosal 
surfaces, as phosphorylation of STAT3 in intestinal epithelial cells following chemical-
induced colitis is IL-22-dependent, and furthermore, conditional deletion of epithelial-
intrinsic STAT3 from intestinal epithelial cells phenocopied that of Il22-/- mice during 
chemical-induced colitis (Pickert et al., 2009).  Collectively, this body of literature 
identified that similar to all members of the IL-10 family, IL-22 utilizes Jak-STAT 
signaling predominantly through STAT3, yet reveals a unique signaling pathways 
including differential activation of MAPK pathways and phosphorylation of STAT3 on 
distinct tyrosine and serine residues. 
 
1.2.4 The IL-22-IL-22R pathway in human disease 
Human IL-22 shares a 25% identity with human IL-10 and a 79% amino acid homology 
with murine IL-22 (Dumoutier et al., 2000b).  Evidence supporting a role for IL-22 in 
human disease has come from increased expression patterns and naturally arising 
mutations in the IL-22 pathway that correlate with increased or decreased disease 
susceptibility (Table 2).  STAT3 is a critical transcription factor involved in the induction 
and downstream signaling of IL-22.  Humans with hyper-IgE syndrome or Job’s 
syndrome have a hypomorphic mutation in STAT3, have impaired Th17 cell 
differentiation and IL-22 production, and exhibit recurrent severe infections with 
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extracellular bacteria and fungi in the intestine, skin, and lungs (Holland et al., 2007; 
Lewden et al., 2008; Milner et al., 2008; Minegishi et al., 2007).  Additionally patients 
with autoimmune polyendocrine syndrome 1 (APECED), exhibit high serum titers of 
neutralizing autoantibodies against IL-17A, IL-17F, and, at the highest frequency, IL-22; 
which correlates with the development of chronic mucocutaneous candidiasis (Kisand et 
al., 2010; Puel et al., 2010).  Finally, in cystic fibrosis patients undergoing clinical 
exacerbation with Pseudomonas aeruginosa, elevated production of IL-22 was observed 
in T cells isolated from the lung draining lymph nodes (Aujla et al., 2008).  Collectively, 
these correlations suggest that the IL-22-IL-22R pathway in humans may contribute to 
mucosal immunity following fungal or extracellular bacterial infections. 
 In addition to infection, elevated expression of IL-22 and naturally occurring 
mutations in the IL-22 pathway are found in patients with several inflammatory and 
autoimmune disorders.  In a genome-wide association study, the IL23R was identified as 
an inflammatory bowel disease (IBD) gene, and furthermore, increased IL-23 expression 
was observed in patients with IBD (Duerr et al., 2006; Schmidt et al., 2005).  Consistent 
with a role of IL-23 in the in vivo induction of IL-22, increased expression of IL-22 is 
found in intestinal samples and peripheral blood of IBD patients, however the role of IL-
22 in human IBD remains controversial as conflicting reports suggest protective or 
pathologic functions (Brand et al., 2006; Kleinschek et al., 2009; Pene et al., 2008; 
Schmechel et al., 2008; Sekikawa et al., 2010; Wolk et al., 2007; Yamamoto-Furusho et 
al., 2010).  Despite this controversy, initial clinical trials utilizing an anti-IL-12/23p40 
monoclonal antibody (mAb), targeting a shared subunit of the IL-22 inducing cytokine IL-
23, have demonstrated some efficacy in the treatment of Crohn’s disease patients 
(Mannon et al., 2004), yet it is unlikely that the observed effects are solely due to the 
impairment of IL-22 expression. 
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 Elevated levels of IL-22 are also observed in the peripheral blood, skin, and joints 
of patients with autoimmune disorders including psoriasis and arthritis, and increased IL-
22 production has been predicted to promote inflammation in these diseases (Boniface 
et al., 2007; Colin et al., 2010; Ikeuchi et al., 2005; Liu et al., 2007; Pene et al., 2008; 
Shen et al., 2009; Wolk et al., 2006).  Also, substantially increased numbers of IL-22-
producing CD4+ Th22 cells have recently been observed in the peripheral blood of 
psoriasis patients (Kagami et al., 2010). 
 Finally, several studies have examined a role for IL-22 in human cancer.  One 
study found a correlation between individuals possessing a specific genetic 
polymorphism in IL22 and an increased risk of developing colon cancer (Thompson et 
al.).  An additional study examining anaplasic large cell lymphomas (ALK+), 
characterized by constitutive activation of STAT3, revealed an auto-stimulatory loop 
involving IL-22 that is predicted to contribute to tumorigenicity (Bard et al., 2008).  
Collectively, these correlative studies suggest that IL-22 plays diverse roles in a range of 
human diseases.   
 
1.2.5 IL-22 promotes immunity, inflammation and tissue-protection at mucosal 
surfaces 
IL-22 appears to act exclusively on non-hematopoietic cells, with basal IL-22R 
expression in the skin, pancreas, intestine, liver, lung and kidney (Tachiiri et al., 2003; 
Wolk et al., 2004).  Ligation of the IL-22R modulates expression of genes including those 
involved in chemotaxis, proliferation, an acute phase response, innate immunity and 
inflammation (Aujla et al., 2008; Liang et al., 2010; Liang et al., 2006; Radaeva et al., 
2004; Wolk et al., 2004; Wolk et al., 2006; Zenewicz et al., 2007; Zheng et al., 2008).  
Therefore, it is perhaps not surprising that with the development of reagents to ablate 
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the IL-22-IL-22R pathway, IL-22 was found to play critical roles in regulating host 
defense, inflammation and tissue homeostasis, in particular at barrier surfaces (Figure 
2A-C).  Below the contributions of the IL-22-IL-22R pathway in regulating immunity, 
inflammation and tissue repair are discussed. 
 Initial studies characterizing the functions of IL-22 revealed that stimulation of 
keratinocytes with IL-22 resulted in a marked induction of genes encoding proteins 
involved in anti-microbial host defense, including S100A7, S100A8, S100A9, β-defensin-
2 and β-defensin-3 (Boniface et al., 2005; Liang et al., 2006; Wolk et al., 2004; Wolk et 
al., 2006).  Subsequent studies also identified that induction of two intestinal anti-
microbial peptides RegIIIβ and RegIIIγ were also dependent on IL-22 production, and 
stimulation of airway epithelial cells with IL-22 resulted in upregulation of a number of 
genes involved in mammalian host defense against bacterial infection, including the 
chemokines CXCL1, CXCL5 and CXCL9, and the cytokines IL-6 and G-CSF (Aujla et 
al., 2008; Zheng et al., 2008).  IL-22 can act synergistically or additively with IL-17A, IL-
17F or TNF to promote expression of many of the genes involved in host defense in the 
skin (Figure 2A), airway (Figure 2B) or intestine (Figure 2C) (Aujla et al., 2008; Eyerich 
et al., 2009; Liang et al., 2006).  Two studies determined that IL-22 was essential for 
host protective immunity to the extracellular gram-negative pathogens Klebsiella 
pneumoniae in the lung and Citrobacter rodentium in the intestine (Aujla et al., 2008; 
Zheng et al., 2008), demonstrating the functional significance of IL-22 in promoting 
mucosal immunity.  IL-22 was critical to limit bacterial replication and dissemination, 
likely in part through induction of anti-microbial peptide expression from epithelial cells at 
these mucosal sites.  IL-22 production has also been shown to contribute to 
maintenance and organization of ILFs during Citrobacter rodentium infection (Ota et al., 
2011).  However, mice deficient in IL-22 or IL-23, the latter a cytokine produced by 
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activated DCs that is critical for IL-22 expression in vivo, exhibited rapid mortality to both 
pathogens, suggesting a potent early IL-22-dependent innate response was essential for 
protective immunity to infection (Aujla et al., 2008; Zheng et al., 2008).   
 The influence of IL-22 on eliciting host protective immunity appears to be 
pathogen-specific, as IL-22 does not play a significant role in host defense following 
infection with either Mycobacterium tuberculosis, Mycobacterium avium, Listeria 
monocytogenes or Schistosoma mansoni (Wilson et al., 2010a; Zenewicz et al., 2007).  
IL-22 may not be required for immunity to these specific infectious agents because 
unlike C. rodentium or K. pneumoniae, these pathogens do not become intimately 
associated with the mucosal surface or selectively induce functional or pathologic 
changes in epithelial cells.  Furthermore, although not reported to play a direct role in 
immunity, IL-22 appears to promote intestinal inflammation following oral Toxoplasma 
gondii infection (Munoz et al., 2009; Wilson et al., 2010a), demonstrating that some 
infectious agents elicit a non-beneficial proinflammatory IL-22-dependent response.   
 Although still in the early stages of investigation, IL-22 does not appear to directly 
play a substantial role in immunity to viral pathogens, as IL-22-deficiency did not 
influence the outcome of influenza infection (Guo and Topham, 2010; Monticelli et al., 
2011).  However, IL-22 may play an important role in providing protective innate 
immunity when the adaptive immune system is impaired.  This is evident in immunity to 
gastric Candida albicans, as IL-22 promotes protective immunity to infection when Th1 
cell-dependent immunity is impaired (De Luca et al., 2010).  Additionally, in Rag1-/- mice, 
IL-22 is sufficient to promote protective innate immunity to C. rodentium for several 
weeks post-infection (Zheng et al., 2008), suggesting that the IL-22-IL-22R pathway may 
be harnessed to increase mechanisms of innate immunity in a case of impaired adaptive 
immunity. 
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 In addition to regulating expression of anti-microbial peptides and defensins, IL-
22 contributes to the expression of a range of genes involved in inflammatory responses, 
including IL-6, G-CSF, IL-1α, LPS binding protein, serum amyloid A, α1-
antichymotrypsin and haptoglobin (Aujla et al., 2008; Boniface et al., 2005; Eyerich et al., 
2009; Liang et al., 2010; Wolk et al., 2006).  Local or systemic delivery of exogenous IL-
22 to mice is sufficient to promote local and/or systemic inflammation (Liang et al., 2010; 
Zheng et al., 2007).  In several models of inflammatory disorders at barrier surfaces, IL-
22 was necessary and sufficient to promote tissue inflammation (Figure 2A-C).  For 
example, in the skin, local delivery of exogenous IL-23 was sufficient to induce dermal 
inflammation and epidermal acanthosis in an IL-22-dependent manner (Zheng et al., 
2007).  IL-22 was also necessary for induction of dermal inflammation in a T cell transfer 
model of psoriasis-like inflammation (Ma et al., 2008).  In the intestine, IL-23-dependent 
induction of IL-22 was necessary for pathologic T. gondii-induced ileitis (Munoz et al., 
2009; Wilson et al., 2010a) and IL-22 could promote pathologic inflammation in a 
memory/effector T cell transfer model of colitis (Kamanaka et al., 2011).  Beyond barrier 
surfaces, IL-22 is also critical for promoting arthritic inflammation in the joints (Geboes et 
al., 2009), but is dispensable for induction of experimental autoimmune encephalitis 
(Kreymborg et al., 2007).  Collectively, these data demonstrate that dysregulated IL-22 
responses can lead to pathologic inflammation and significantly damage mucosal sites. 
 The functional significance of IL-22 expression is context dependent.  For 
example, in contrast to promoting pathologic inflammatory responses, IL-22 can also 
promote epithelial cell proliferation, survival and repair in the skin (Figure 2A), airway 
(Figure 2B) or intestine (Figure 2C).  These properties of IL-22 were observed in 
hepatocytes and intestinal and airway epithelial cells in which delivery of exogenous IL-
22 induced expression of the pro-survival genes Bcl-2, Bcl-xl and Mcl-1, proliferative 
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genes c-myc, cyclin D-1, Rb2 and CDK4, and genes involved in producing protective 
mucus Muc1, Muc3, Muc10 and Muc13 (Radaeva et al., 2004; Sugimoto et al., 2008; 
Zenewicz et al., 2007).  IL-22 can also promote the in vitro survival and repair of 
epithelial cells following mechanical disruption of monolayers (Aujla et al., 2008; Eyerich 
et al., 2009).  Consistent with these reports, IL-22 ameliorates tissue destruction in 
several model systems.  For example, in the liver, several groups identified that IL-22 is 
tissue-protective in murine models of hepatitis (Radaeva et al., 2004; Zenewicz et al., 
2007).  Additionally, in the intestine, IL-22-deficiency exacerbated tissue destruction in 
DSS-mediated or a T cell transfer model of colitis (Pickert et al., 2009; Sugimoto et al., 
2008; Zenewicz et al., 2008), and delivery of exogenous IL-22 was sufficient to 
ameliorate intestinal inflammation spontaneously observed in TCRα-deficient mice 
(Sugimoto et al., 2008).   IL-22 also limits excessive fibrosis in a model of 
hypersensitivity pneumonitis (Simonian et al., 2010). 
 The findings that IL-22 can both promote pathologic inflammation and also 
prevent tissue destruction are somewhat paradoxical.  However, it is possible that the 
functional outcomes of IL-22 expression are regulated by the context in which it is 
expressed.  For example, IL-22 acts synergistically with a number of cytokines including 
IL-17A, IL-17F and TNF (Eyerich et al., 2009; Guilloteau et al., 2010; Liang et al.).  
Studies discussed in Chapter 4 of this thesis explore the proinflammatory and 
pathologic versus tissue-protective functions of IL-22 in a model of acute airway damage 
and inflammation, and conclude that IL-17A is a critical factor regulating the functional 
outcome of IL-22 expression. 
 
1.2.6 IL-22 expression in the immune system 
 20 
IL-22 was originally found to be expressed in murine and human T cells, but not B 
lymphocytes (Dumoutier et al., 2000a; Wolk et al., 2002).  Since then, IL-22 expression 
has been reported in a broad range of T cell populations.  In humans, the major T cell 
producers of IL-22 appear to be T helper (Th)1, Th22 and T cytotoxic (Tc)22 cells, with 
expression also observed in Th17, Tc17 and γδ T cells.  In mice, high levels of IL-22 
expression is observed in Th17 and Tc17 cells, as well as the innate-like γδ T cells and 
natural killer T cells (NKT cells) (Figure 3).  Below the differentiation, regulation and 
functions of these IL-22-producing T cell populations is discussed and the current 
knowledge of IL-22 expression in the innate immune system is reviewed. 
 IL-22 is produced by CD3+ (CD4- CD8-) oligoclonal γδ T cells that are detected in 
the skin epidermis, gut and lung epithelia and at low frequencies in human blood 
(Bonneville et al., 2010).  These cells are proposed to be phylogenetically ancient 
population of T cells that contribute to a temporally innate-like immune response, with 
the potential to contribute rapidly to immunity against a broad spectrum of pathogens 
(Bonneville et al., 2010).  Expression of IL-22 by γδ T cells can be driven by the 
cytokines IL-1β, IL-23 and aryl hydrocarbon (AhR) agonists, and is co-expressed with IL-
17A, IL-17F, IFN-γ or TNF (Martin et al., 2009; Sutton et al., 2009).   In humans, rare 
circulating Vγ2Vδ2 T cells express either IL-22 or IL-17A but not both (Ness-
Schwickerath et al., 2010).  Similarly, mouse NKT cells also have the capability to rapidly 
express IL-22.  Splenic invariant NKT (iNKT) cells produce substantial amounts of IL-22 
after brief anti-CD28 and/or anti-CD3 mAb stimulation (Goto et al., 2009).  Optimal 
expression of IL-22 from lymph node-derived, iNKT-enriched cells requires a CD1d-
dependent signal as well as concomitant IL-1β and IL-23 (Doisne et al., 2010).  
 Human Th1 cells produce substantial amounts of IL-22 (Volpe et al., 2008) and 
were the initial subset demonstrated to produce this cytokine (Wolk et al., 2002).  While 
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human Th17 cells also make IL-22, human IL-22 gene expression correlates more with 
expression of the IFN-γ and T-bet, than with the IL-17A and AhR (Volpe et al., 2009).  
However, an associative relevance for IL-22 expression in human Th1 cells has yet to be 
defined in relation to either an immune or inflammatory response.  In contrast to 
humans, murine Th1 cells appear to express IL-22 relatively poorly (Liang et al., 2006).  
 A major producer of IL-22 in mice are Th17 cells (Liang et al., 2006).  
Differentiation of naïve T cells to the Th17 lineage requires cognate TCR—peptide-MHC 
class II-interactions, and IL-6, IL-1β and TGF-β cytokine stimulation for differentiation 
(Liang et al., 2007; Liang et al., 2006; Zheng et al., 2007).  Upon lineage commitment IL-
23 is critical for maintaining the population expansion of differentiated Th17 cells and 
promoting optimal IL-22 expression (Liang et al., 2007; Liang et al., 2006; Zheng et al., 
2007).  Similar to mice, human Th17 cell production of IL-22 depends on TGF-β, IL-1β, 
IL-23 and AhR (Veldhoen et al., 2008; Wilson et al., 2007).  Mouse and human CD8+ T 
cells can also express IL-22 when differentiated into Tc17 cells by mechanisms similar to 
those of Th17 cells (Ciric et al., 2009), and substantial numbers of these cells are found 
in the blood and/or tissue of humans and mice following infection, cancer and 
autoimmunity (Hamada et al., 2009; Kuang et al., 2010; Res et al., 2010). 
 In addition to Th1, Th17 and Tc17 cells, CD4+ and CD8+ T cells can differentiate 
into Th22 and Tc22 cell lineages, respectively, that express IL-22, but not IFN-γ or IL-
17A.  Human CD4+ Th22 and CD8+ Tc22 subsets have been detected in inflamed and 
diseased skin and human T cell clones established with this stable expression profile 
(Eyerich et al., 2009; Nograles et al., 2009).  The existence of Th22 cells in mice 
remains unclear, however, immunization of mice with ovalbumin in complete Freund’s 
adjuvant (CFA) induced the expansion of a subset of CD4+ T cells that secrete IL-22 in 
the absence of either IL-17A or IFN-γ (Liang et al., 2006).  Circulating human Th22 
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memory cells that are proposed to be skin homing, based on expression of CCR10+, 
CCR6+, CCR4+ CLA+, are detected in healthy humans and can be induced from naive T 
cells following TCR-stimulation in the presence of IL-6 and TNF (Duhen et al., 
2009).  Th22 cell clones express AhR transcript similar to Th17 cells but with 
considerably less RORC mRNA than detected in Th17 cells (Trifari et al., 2009), 
suggesting that modulation of RORγt functionality that is closely associated with IL-17A 
expression may contribute to the fate determination of naïve T cells into Th17 or Th22 
cells.  Epidermal Langerhans cells and dermal DCs are potent stimulators of memory 
Th22 cells in peripheral blood and promote their differentiation from naive T cells (Fujita 
et al., 2009).  Th22 cells have recently been characterized, at least in part, as a 
polyclonal TCRαβ+ CD4+ T cell population which contains cells that are reactive to 
CD1a, an MHCI class 1-like molecule that presents glycolipids on Langerhans cells (de 
Jong et al., 2010).  The existence of Th22 and Tc22 cells in normal and inflamed human 
skin, as well as the surface phenotype consistent with circulating memory cells, suggest 
that these cell populations contribute to homeostasis of the cutaneous barrier in health 
and disease.  
 In addition to expression of IL-22 by T cells, innate immune cells also have the 
capacity to express IL-22.  IL-22 was reported to be expressed by activated human NK 
cells derived from the blood (Wolk et al., 2002).  In studies examining IL-22 production 
following infection with a gram-negative bacterium, Immunofluorescent staining of 
colonic tissue revealed co-staining of IL-22 and CD11c, suggesting that dendritic cells 
(DCs) can express IL-22 (Zheng et al., 2008).  Other studies utilizing an IL-23R-reporter 
mouse identified IL-22 expression in a splenic IL-23R+ CD11c+ CD11b+ myeloid cell 
population (Awasthi et al., 2009).  A number of studies have also observed IL-22 
production by conventional NK cells (Guo and Topham, 2010; Zenewicz et al., 2008).  
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Despite these reports, the specific subsets of DCs and NK cells that express IL-22 have 
yet to be delineated.  Furthermore, these data are complicated by the recent findings 
that an emerging population of innate lymphoid cells (ILCs) have the capacity to produce 
IL-22 and co-express NK cell and myeloid cell markers (Satoh-Takayama et al., 2008).  
The functional biology of IL-22-expressing innate lymphoid cells will be discussed in 
depth in Section 1.3. 
 
1.2.7 Regulation of IL-22 production in T cells 
IL-23 is a potent stimulus for induction of IL-22 expression in both innate and adaptive 
immune cells, and in a number of models, IL-23 is required for expression of IL-22 in 
vivo (Aujla et al., 2008; Liang et al., 2006; Munoz et al., 2009; Zheng et al., 2007; Zheng 
et al., 2008).  Additionally, factors that promote or inhibit Th17 cell differentiation can 
differentially regulate IL-22 expression (Zheng et al., 2007).  Several transcription factors 
including STAT3, RORγt and the aryl hydrocarbon receptor (AhR) have also been found 
to be essential in the regulation of IL-22 in multiple cell lineages (Nurieva et al., 2007; 
Veldhoen et al., 2008; Yang et al., 2007).  Finally, in addition to expression, several 
functional properties of IL-22 can be regulated by different inflammatory cytokines in a 
synergistic or inhibitory manner.  
 IL-23 is a member of the IL-12 cytokine family that is a heterodimer composed of 
p19 and p40.  The cellular sources of IL-23 are predominantly macrophages and 
dendritic cells (Tato and Cua, 2008).  IL-23 stimulation of activated T cells has been 
found to induce IL-22 expression (Liang et al., 2006; Zheng et al., 2007).  However, the 
IL-23R is not expressed on naïve T cells, but rather requires TCR-stimulation in the 
presence of IL-6 and/or IL-21 (Tato and Cua, 2008; Zhou et al., 2007), suggesting that 
IL-22 expression in the adaptive immune system is tightly regulated by two distinct 
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signals, antigen recognition and the local cytokine milieu.  In contrast to this regulation of 
IL-22 in Th17 cells, γδ T cells and several cell populations of the innate immune system 
constitutively express the IL-23R, and do not require additional stimulation to express IL-
22 following exposure to IL-23 (Awasthi et al., 2009; Buonocore et al., 2010; Cella et al., 
2009; Martin et al., 2009; Sanos et al., 2009; Sutton et al., 2009; Takatori et al., 2009).  
Therefore, these innate populations may represent a more primitive form of cytokine-
producing lymphoid cells in which the threshold for expression of IL-22 is lower. 
 The importance of IL-23 in the induction of IL-22 in vivo is evident in several 
models of infection.  Following infection with gram-negative bacteria or the intracellular 
parasite T. gondii, IL-22 expression was observed in the lung and/or intestinal tissue, 
however, the induction of IL-22 was completely abrogated in the absence of IL-23 (Aujla 
et al., 2008; Munoz et al., 2009; Zheng et al., 2008).  Consistent with this, Il23a-/- mice 
and Il22-/- mice are both highly susceptible to infection with extracellular gram-negative 
bacteria (Mangan et al., 2006; Zheng et al., 2008), suggesting that a critical function of 
IL-23 in infection is to induce IL-22 expression.  Additionally, IL-23 has also been found 
to be important in the terminal differentiation of Th17 cells, aiding in their proliferation 
and effector functions (McGeachy et al., 2009).  The ability of IL-23 to enhance Th17 cell 
proliferation appears to be linked to IL-22 expression, as increased proliferation was only 
observed in IL-22+ Th17 cells, but not in IL-17A+IL-22- Th17 cells (Liang et al., 2006).  
However, whether this is also the case in IL-23R-expressing innate populations has yet 
to be determined. 
 In addition to IL-23, other cytokines have been found to induce IL-22 expression, 
albeit to a lesser extent, and several other cytokines have been found to inhibit IL-22 
expression.  As discussed above, IL-6 and TCR stimulation can upregulate the IL-23R 
(Zhou et al., 2007).  However, in cultures of purified naïve murine CD4+ T cells, IL-6 and 
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TCR stimulation, or IL-6, TNFα, IL-1β and TCR stimulation, was sufficient to induce IL-
22 expression (Nurieva et al., 2007).  As T cells do not express IL-23, this suggests that 
TCR-stimulation and IL-6 can induce IL-22 expression in vitro in the absence of IL-23.  
Further, it has recently been shown in an enteric bacteria infection model, that 
lymphotoxin-β is critical for optimal infection-induced IL-22 expression (Ota et al., 2011; 
Tumanov et al., 2011) 
 In mice, Th17 cell differentiation requires TCR stimulation in the presence of IL-6 
and TGFβ (Mangan et al., 2006).  However, despite Th17 cells constituting a population 
that co-expresses IL-17A, IL-17F and IL-22 (Liang et al., 2006), co-expression is 
dependent on an optimal concentration of TGFβ (Zheng et al., 2007).  Increasing 
concentrations of TGFβ dose-dependently inhibited IL-22 expression, while maintaining 
stable IL-17A expression (Zheng et al., 2007).  This distinct regulation of IL-17A versus 
IL-22 is further evident when examining effects of Th1 or Th2 cell-associated cytokines 
on expression of IL-22.  Addition of IFNγ or IL-4 to Th17 cell cultures effectively inhibited 
IL-17A production, while only moderately reducing IL-22 expression, however, in more 
differentiated Th17 cell populations, neither IL-17A or IL-22 expression can be inhibited 
by IL-4 or IFNγ (Zheng et al., 2007).  In addition to Th17 cells, it was found that Th22 cell 
differentiation is promoted by TCR-stimulation in the presence of IL-6 and TNFα (Duhen 
et al., 2009; Trifari et al., 2009).  IL-22 expression in gamma delta T cells can also be 
induced independent of IL-23 and TCR-stimulation by IL-1β, as well as TLR1, TLR2, and 
dectin-1 ligands (Martin et al., 2009; Sutton et al., 2009).  Taken together, significant 
advances in understanding the cytokine-mediated induction and suppression of IL-22 in 
T cells have been made.  However, whether these same complex pathways of regulation 
also exist in IL-22-expressing innate cell populations remains to be examined.  Data 
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presented in Chapter 2 of this thesis examines what regulatory factors influence in vivo 
IL-22 production by ILCs.  
 Similar to cytokine-mediated regulation of IL-22, much of the transcriptional 
regulation of IL-22 was first identified in the context of Th17 cells.  A number of the 
cytokines required for Th17 cell differentiation signal through STAT3, including IL-6, IL-
21 and IL-23.  Consistent with a central role for STAT3, Th17 cell differentiation and 
expression of IL-22 is severely impaired in STAT3-deficient T cells (Yang et al., 2007).  
In contrast, cells expressing a hyper-activated form of STAT3 exhibited enhanced Th17 
cell differentiation, with the most substantially increased effector cytokine being IL-22 
(Yang et al., 2007).  This suggests that STAT3 is critically involved in the induction of IL-
22 expression in T cells.  Similarly, RORγt, a lineage-specifying transcription factor for 
the differentiation of Th17 cells, is also required for optimal expression of IL-22 (Nurieva 
et al., 2007).  Both STAT3 and RORγt control expression of the IL-23R (Nurieva et al., 
2007; Yang et al., 2007), and this regulation may account for their ability to promote IL-
22 production in Th17 cells.  Therefore, many of the same transcription factors involved 
in Th17 cell differentiation are also required for IL-22 expression in CD4+ T cells. 
 The AhR is a ligand-dependent transcription factor that is best known for its role 
in mediating toxicity to the organic compound dioxin.  A number of exogenous 
environmental ligands and endogenously produced ligands for the AhR have been 
reported.  AhR also partially contributes to the differentiation of Th17 cells, and is 
required for expression of IL-22, thus linking IL-22 and Th17 cells to toxicity following 
exposure to different environmental compounds (Veldhoen et al., 2008).  Furthermore, 
during Th17 cell development in vitro, maximal IL-22 expression is reported in culture 
media containing high levels of natural AhR agonists (Veldhoen et al., 2009).  This 
transcription factor network occurs independently of RORγt, but may require the 
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production of endogenous AhR ligands via the Notch signaling pathway (Alam et al., 
2010).  Initial studies suggest that AhR acts independently of IL-23 (Veldhoen et al., 
2009; Veldhoen et al., 2008), however it is not known if AhR may act either upstream or 
downstream of the IL-23-IL-23R pathway. 
 In addition to the regulation of IL-22 expression, several cytokines have been 
found to regulate other properties of IL-22 by either synergistically enhancing or 
inhibiting its functions.  IL-22 stimulation alone can induce expression of anti-microbial 
peptides and inflammatory cytokines and chemokines in keratinocytes and epithelial 
cells.  However, IL-22 expression alone is not sufficient to induce recruitment of 
neutrophils to the airway (Aujla et al., 2008; Guilloteau et al., 2010; Liang et al., 2007; 
Liang et al., 2006).  Yet, co-expression with the cytokines IL-17A, IL-17F, TNFα, or 
oncostatin M can act synergistically with IL-22 to significantly enhance anti-microbial and 
inflammatory gene expression, and promote significant airway neutrophilia (Aujla et al., 
2008; Eyerich et al., 2009; Guilloteau et al., 2010; Liang et al., 2006).  Thus, the 
presence of inflammatory cytokines appears to enhance the proinflammatory and anti-
microbial properties of IL-22.  Studies in Chapter 4 of this thesis examine the regulation 
of the functional outcomes of IL-22 expression IL-17A. Collectively, these findings 
identify that various proinflammatory cytokines are able to positively and negatively 
regulate specific functions of IL-22. 
 
1.3 Innate lymphoid cells are critical regulators of immunity, inflammation 
and tissue homeostasis at mucosal surfaces 
A great deal of research has focused on immunoregulatory properties of CD4+ T helper 
cells at mucosal sites.  Naïve CD4+ T cells differentiate into effector and memory cell 
populations following recognition of their cognate antigen.  When in the context of a 
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particular cytokine milieu, naïve CD4+ T cell differentiate into Th1, Th2, Th17 or 
regulatory T cell (Treg) lineages, are directed by lineage-specifying transcription factors 
and express signature effector cytokines (Figure 4) (Harrington et al., 2006; Reiner, 
2007; Stockinger and Veldhoen, 2007; Zhu et al., 2010).  This heterogeneity in the 
adaptive arm of the immune system has permitted a range of immunoregulatory 
functions in infectious and inflammatory diseases (Figure 4) (Harrington et al., 2006; 
Reiner, 2007; Stockinger and Veldhoen, 2007; Zhu et al., 2010).  Recently, it has been 
identified that a similar degree of functional heterogeneity exists in cells of the innate 
immune system.  Innate lymphoid cells (ILCs) develop from an Id2-dependent precursor 
and differentiate into cell populations that respond to and express Th1-, Th2- or Th17-
associted cytokines (Figure 5) (Spits and Di Santo, 2010), and emerging evidence 
suggests that may also play critical roles in immunity, inflammation and homeostasis at 
mucosal sites.  Studies in Chapter 2 and Chapter 3 of this thesis interrogate the role of 
IL-22-producing ILCs in innate immunity following challenge with an enteric bacterial 
pathogen and containment of non-pathogenic commensal bacteria to intestinal tissues in 
the steady state.  Below I will discuss the ILC family with a particular emphasis on IL-22-
producing ILCs. 
 
1.3.1 The innate lymphoid cell family 
ILCs develop from an Id2 dependent precursor, differentiate into heterogeneous fates, 
and are responsive to numerous epithelial cell and accessory cell derived cytokines to 
express signature effector cytokines (Figure 5) (Spits and Di Santo, 2010).  The most 
well known innate lymphoid cells are NK cells, which are most analogous to the Th1 cell 
or Tc1 cell lineage of CD4+ and CD8+ T cells.  NK cells require the cytokine IL-15 and 
the transcription factor NFIL3 for development, express IFNγ and cytotoxic molecules 
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and promote inflammation and immunity to intracellular pathogens and neoplastic 
tissues (Spits and Di Santo, 2010; Yokoyama et al., 2004).  A lineage of Id2-dependent 
ILCs has also been identified that are most analogous to the Th2 cell lineage of CD4+ T 
cells.  This population has previously been termed nuocytes, natural helper cells (NHCs) 
and innate helper type 2 cells, are responsive to the epithelial cell derived cytokines IL-7, 
IL-25 and IL-33, express IL-5 and IL-13 and are involved in immunity, inflammation and 
tissue homeostasis in response to helminths or viral infection (Chang et al., 2011; 
Monticelli et al., 2011; Saenz et al., 2010; Spits and Di Santo, 2010).  Finally, a 
population of Id2-dependent ILCs has been identified that are most analogous to the 
Th17 cell lineage of CD4+ T cells.  This population has previously been termed 
lymphoid-tissue inducer-like cells or NK-22 cells.  These cells are responsive to IL-7 and 
IL-23, express RORγt and effector cytokines including IL-17A, IL-17F, IL-22 and IFNγ, 
and are proposed to be involved in intestinal immunity to extracellular bacterial 
pathogens (Cella et al., 2009; Colonna, 2009; Satoh-Takayama et al., 2008; Takatori et 
al., 2008).  The regulation and functions of IL-22-producing ILC is the focus of Chapter 2 
and Chapter 3 of this thesis and are discussed in depth below. 
 
1.3.2 IL-22-producing RORγt+ innate lymphoid cells 
All IL-22-producing ILCs share several common phenotypic and transcriptional 
similarities, lacking expression of most lineage markers (TCRαβ, TCRγδ, CD3, CD8, 
CD5, CD19, B220, Gr-1, CD11b, F4/80, Ter119, NK1.1), while expressing several 
characteristic markers of ILCs (CD90, CD127, CD132).  IL-22-producing ILCs are 
responsive to common gamma chain cytokines, such as IL-7, which can promote the 
population expansion of different ILC populations (Meier et al., 2007; Schmutz et al., 
2009; Vonarbourg et al., 2010).  In addition to Id2, the IL-22-producing ILCs also require 
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the orphan nuclear receptor RORγt for their development, and express the IL-23R (Spits 
and Di Santo, 2010), whose ligation is sufficient to induce IL-22 production (Figure 6A).   
 Among the IL-22-producing ILCs, specific cell populations can be defined based 
on surface marker expression, co-expression of other cytokines, localization, 
transcriptional regulation and biological functions (Figure 6A).  For example, NKp46+ 
ILCs express only IL-22, but not IL-17A or IFN-γ, and are present in the small intestine 
and skin (Cella et al., 2009; Luci et al., 2009; Sanos et al., 2009; Satoh-Takayama et al., 
2008).  Functionally, NKp46+ ILCs are proposed to participate in innate host defense to 
infection and tumor suppression in murine model systems (Cella et al., 2009; Eisenring 
et al., 2010; Satoh-Takayama et al., 2008).  Additionally, CD4+ ILCs express IL-22 and 
IL-17A, but not IFN-γ, and are present in the small intestine, large intestine, lymph node 
and spleen (Cupedo et al., 2009; Takatori et al., 2009).  CD4+ ILCs appear to be 
phenotypically similar to fetal CD4+ lymphoid-tissue inducer (LTi) cells that promote 
prenatal lymphoid-organogenesis (Schmutz et al., 2009; Takatori et al., 2009), however 
development of these two lineages appears to be distinct, as Notch signaling is required 
for adult ILC development but not fetal LTi cell development (Possot et al., 2011).  
Despite this developmental difference, cells with a CD4+ LTi-like phenotype, termed 
CD4+ ILCs, persist in the intestinal tissues of adults and participate in tertiary lymphoid 
formation and restoration of lymphoid tissues following viral infection (Eberl and Littman, 
2004; Scandella et al., 2008; Tsuji et al., 2008).  However, whether other functions for IL-
22-producing CD4+ ILCs exist is undetermined.  Chapter 2 of this thesis will interrogate 
the functional role of adult IL-22-producing CD4+ ILCs following enteric bacterial 
infection.   
 CD4+ and NKp46+ ILCs express the AhR (Cella et al., 2009; Takatori et al., 
2009), a cytosolic transcription factor that recognizes a number of endogenous 
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metabolites and environmental toxins as activating ligands and is critical for IL-22-
production in other cell populations (Veldhoen et al., 2008).  However, the role of AhR in 
ILCs has not yet been characterized.  Finally, populations of NKp46- CD4- ILCs express 
IL-22, IL-17A and IFN-γ, and are present in the colon, small intestine, liver and spleen, 
and appear most prevalent in models of intestinal inflammation (Buonocore et al., 2010).  
These cells exhibit surface marker expression and transcriptional profiles consistent with 
an LTi-like cell population, except they lack expression of c-kit and CD4, but do express 
the Th1 cell-associated transcriptional regulator T-bet (Buonocore et al., 2010), likely 
accounting for their ability to produce IFN-γ (Figure 6A).  This population of CD4- NKp46- 
ILCs plays a pathologic role in promoting Helicobacter hepaticus- or anti-CD40 mAb-
induced intestinal inflammation in an IFNγ- and/or IL-17A-dependent manner 
(Buonocore et al., 2010).  
 
1.3.3 Lineage relationships among IL-22-producing RORγt+ innate lymphoid cells 
The cell lineage relationships and stability of these IL-22-producing ILCs has recently 
been an intense area of investigation. These ILC populations develop independently of 
conventional NK cells, as they are present in Rag-/-Il2rb-/- mice (Satoh-Takayama et al., 
2008).  Additionally, fate-mapping experiments revealed that conventional NK cells do 
not develop from RORγt-expressing progenitors (Crellin et al., 2010a; Satoh-Takayama 
et al., 2010), ruling out that IL-22-producing ILCs can give rise to conventional NK cells.  
However, what is less clear is the degree of plasticity and relationships between the 
different populations of IL-22-producing ILCs.  One recent report identified that all 
subsets of RORγt+ ILCs are stable lineages that maintain RORγt expression and that 
CD4+ ILCs do not give rise to the NKp46+ ILCs, but rather each population independently 
arises from fetal liver progenitors (Sawa et al., 2010).  In contrast, a separate report 
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identified that ILCs with an LTi-like phenotype can upregulate NK cell receptors (NKRs) 
and give rise to NKp46+ ILCs (Vonarbourg et al., 2010).  Furthermore, the latter study 
demonstrated that NKp46+ ILCs progressively lose RORγt expression, which in turn 
upregulated IFN-γ expression and this subset of RORγt- NKp46+ cells could contribute to 
intestinal inflammation (Vonarbourg et al., 2010).   Although it is clear that ILCs 
represent a unique and important innate source of IL-22, further investigation into the 
lineage relationships and plasticity of IL-22-producing ILCs will be critical to fully 
understand the developmental and regulatory pathways that exist within and between 
these novel innate cell populations.  
 
1.3.4 Regulation of IL-22-producing RORγt+ innate lymphoid cells 
A number of regulatory factors are critical for the development and function of IL-22-
producing ILCs (Figure 6A).  Although not required for their differentiation, IL-7 and the 
IL-7-related cytokine TSLP are important factors in the regulation, survival and 
proliferation of murine and human IL-22-producing ILCs, and are also critical in their 
functional ability to promote lymphoid-organogenesis (Meier et al., 2007; Satoh-
Takayama et al., 2010; Schmutz et al., 2009; Vonarbourg et al., 2010).  IL-23 can induce 
IL-22 expression in ILCs and IL-1β is suggested to stabilize and enhance cytokine 
production (Cella et al., 2009; Cella et al., 2010; Hughes et al., 2010; Takatori et al., 
2009).  In contrast, recent reports have identified that IL-2 and IL-12 can destabilize IL-
22 production in ILCs, perhaps by partially antagonizing RORγt expression, and 
promoting expression of NKRs and IFN-γ (Cella et al., 2010; Vonarbourg et al., 2010).  
An array of chemokines and their receptors influence IL-22-producing ILCs including 
CXCR5, which promotes recruitment to intestinal sites following CXCL13 over-
expression (Marchesi et al., 2009), and CCR6, which influences the localization and IL-
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22 expression of ILCs (Sawa et al., 2010).  IL-22-producing ILCs also express an array 
of regulatory transcription factors, including RORγt, which is required for development, 
as well as STAT3 and AhR (Cella et al., 2009; Takatori et al., 2009), which can influence 
IL-22 production in adaptive immune cells.  However, further investigation of the 
influence of these pathways on ILC populations is required.  Finally, commensal 
bacterial communities that are intimately associated with barrier surfaces appear to 
influence ILC development and function, although there are conflicting reports on how 
commensal-derived signals influence ILCs.  Initial reports demonstrated that in the 
absence of commensal bacteria, LTi-like ILCs are present in cryptopatches at normal 
frequencies (Bouskra et al., 2008); however, NKp46+ ILCs are greatly reduced in 
numbers (Sanos et al., 2009; Satoh-Takayama et al., 2008).  In contrast, a recent study 
reported that frequencies of NKp46+ ILCs remain unchanged (Sawa et al., 2010), while 
another cited a progressive loss of RORγt and destabilization of the NKp46+ ILC lineage 
in the absence of commensal bacteria (Vonarbourg et al., 2010).  Further investigation 
will be required to clarify the influence of the host-derived regulatory factors and 
environmental triggers such as microbial colonization on the development, function and 
plasticity of IL-22-producing ILCs.  
 
1.3.5 Human IL-22-producing RORγt+ innate lymphoid cells  
Two populations of IL-22 expressing human ILCs have been observed in tonsil and fetal 
mesentery (Cella et al., 2009; Cupedo et al., 2009).  Similar to mice, both cell 
populations are lineage negative and express CD127, RORγt and the IL-23R (Figure 
6B).  One of these cell populations has an LTi-like phenotype while the other expresses 
NK cell markers including CD56 and NKp44 (Cella et al., 2009; Cupedo et al., 2009).  
When cultured in the presence of IL-15, the LTi-like ILCs upregulated expression of 
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NKRs (Crellin et al., 2010a; Cupedo et al., 2009).  Human stage 3 immature NK cells 
have also been proposed to express IL-22 and share an LTi-like phenotype (Hughes et 
al., 2010; Hughes et al., 2009), and it has recently been suggested that the stage 3 
immature NK cell populations contain heterogeneous populations of CD127+ LTi-like 
cells and CD127- immature conventional NK cells (Crellin et al., 2010a).  Similar to mice, 
human NKp44+ ILCs express IL-22, while the LTi-like cells express IL-17A and IL-22 
(Cella et al., 2009; Cupedo et al., 2009).  IL-1β appears to stabilize IL-22 expression in 
human NKR+ ILCs (Cella et al., 2010; Hughes et al., 2010), while IL-2 reduces IL-22 
expression and promotes IFN-γ expression (Cella et al., 2010).  Intriguingly, IL-22-
producing ILCs isolated from humans also express toll-like receptors (TLRs), and in 
addition to IL-17A and IL-22, have the capacity to express IL-2, IL-5, IL-13 and B cell 
activating factor (BAFF) (Cella et al., 2010; Crellin et al., 2010b), suggesting that human 
ILCs can directly sense bacterial signals, participate in Th1-, Th2- or Th17-cytokine 
associated inflammation and potentially influence B cell responses.  The heterogeneity 
of human ILCs (Figure 6B) and the relative importance of human IL-22-producing ILCs 
to respond to TLR ligands, co-express type-2 cytokines or promote B cell responses are 
in the early stages of investigation.  However, future work will likely yield critical insights 
into the regulation and potential therapeutic possibilities of targeting ILC populations in 
human disease.  Studies discussed in Chapter 3 of this thesis investigate innate 
lymphoid cells in the intestinal tissues of healthy humans. 
 
1.4 Murine model systems to examine immunoregulation of immunity, 
inflammation and tissue homeostasis at mucosal surfaces 
Two models of infection and inflammation are utilized in this thesis to interrogate the role 
of the ILC-IL-22 pathway in immunoregulation of mucosal sites.  In Chapter 2 of this 
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thesis Citrobacter rodentium is employed as a natural enteric pathogen of mice.  In 
Chapter 4 of this thesis bleomycin is employed to induce acute airway damage and 
inflammation. 
 
1.4.1 Citrobacter rodentium is a natural enteric bacterial pathogen of mice 
Infection with enteropathogenic or enterohemorrhagic Escherichia coli (EPEC or EHEC) 
is a leading cause of bacterial-induced diarrhea, causing an estimated four to six million 
deaths per year worldwide.  In developing countries, EPEC is a major cause of neonatal 
diarrhea, killing an estimated one million children each year due to dehydration, 
malnutrition and other complications of the disease, while in industrialized countries, 
outbreaks have also resulted in significant public health crises (Currie et al.; Higgins et 
al.; MacDonald et al., 2003; Mundy et al., 2005; Warshawsky et al., 2002).  However, 
EPEC and EHEC are not pathogens in rodents and therefore cannot be used as model 
system to experimentally examine intestinal immunity to these pathogens.  In contrast, 
Citrobacter rodentium is a natural bacterial pathogen of mice that exhibits a similar 
pathogenesis to human infection with EPEC or EHEC (MacDonald et al., 2003; Mundy et 
al., 2005).  Citrobacter rodentium is a gram-negative extracellular bacterium that forms 
attaching-effacing lesions on intestinal epithelial cells and cause acute colonic 
inflammation in mice (MacDonald et al., 2003; Mundy et al., 2005).  In C57BL/6 mice, 
Citrobacter rodentium levels in the colon peak between day 5 and 14 post-infection with 
clearance by day 21-28.  Immunity to Citrobacter rodentium appears to be bi-phasic: 
innate immunity in the first 6-8 days of infection is critically mediated by IL-22 production 
(Mangan et al., 2006; Zheng et al., 2008), while later in infection lymphocytes, IFNγ and 
immunoglobulin are critical for host protection and bacterial clearance (Figure 7) 
(Maaser et al., 2004; Shiomi et al., 2010; Simmons et al., 2003; Simmons et al., 2002; 
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Spahn et al., 2008).  In the absence of adaptive immunity, Rag1-/- mice survive up to 3-4 
weeks before succumbing to infection, identifying a critical role for the innate immune 
system (Simmons et al., 2003; Zheng et al., 2008).  While significant advances have 
been made in delineating how T and B cell responses clear infection, how the IL-22 
pathway successfully protects Rag1-/- mice for up to four weeks post-infection remains 
poorly defined.  Further understanding of the mechanisms and regulation of these innate 
immune pathways could prove useful in the development of novel immunotherapies and 
oral vaccines that can promote innate immunity in the context of lymphopenia, such as in 
human conditions including AIDS, cancer and transplantation, where secondary bacterial 
infections are a leading cause of mortality (Bonnet et al., 2007; Douek et al., 2003; 
Holmes et al., 2003; Lewden et al., 2008; Wallace et al., 1993).  Studies discussed in 
Chapter 2 of this thesis employ Citrobacter rodentium infection as a model to examine 
the role of the ILC-IL-22 pathway in innate anti-bacterial immunity in the intestine. 
 
1.4.2 Bleomycin induces acute airway damage and inflammation 
Airway damage is a hallmark feature of many human diseases including chronic 
obstructive pulmonary disease, influenza infection, acute respiratory distress syndrome, 
asthma and allergy, which collectively afflict millions worldwide (Crosby and Waters, 
2010; Rock and Hogan, 2011).  Bleomycin is an antibiotic produced by the soil-dwelling 
microbe Streptomyces verticillus, that when introduced into cells can form a complex 
with metal ions and oxygen to produce free oxygen radicals and subsequently DNA 
breaks and cell death (Matute-Bello et al., 2008; Umezawa, 1965).  This damaging 
reaction can be prevented by cellular expression of a bleomycin hydrolase.  Due to 
reduced expression of bleomycin hydrolase in the epithelial cells of murine lungs, intra-
tracheal administration of bleomycin results in destruction of the airway epithelium and 
 37 
induction of inflammation (Matute-Bello et al., 2008; Sebti et al., 1989).  Low doses of 
bleomycin result in prolonged inflammation, followed by a repair phase that can lead to 
the onset of fibrosis (Huaux et al., 2003).  High doses of bleomycin result in acute and 
severe tissue damage and inflammation, subsequently leading to host mortality (Huaux 
et al., 2003).  Studies discussed in Chapter 4 employ administration of high dose 
bleomycin to interrogate the role and regulation of the IL-22 pathway in acute airway 
damage and inflammation. 
 Collectively, studies discussed in this thesis interrogate the role of the ILC-IL-22 
pathway in regulating immunity, inflammation and homeostasis at mucosal sites.  
Chapter 2 explores the role of IL-22-producing ILCs in innate immunity to the enteric 
bacterial pathogen Citrobacter rodentium.  Chapter 3 interrogates whether ILCs and IL-
22 are involved in the containment of commensal bacteria to intestinal tissues in the 
steady state, to maintain systemic immune cell homeostasis.  Chapter 4 investigates the 
function and regulation of IL-22 in an acute model of airway damage and inflammation. 
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Figure 1. Structural anatomy of mucosal sites and associated lymphoid tissues.  
The anatomy of the intestine (A) and lung (B) are designed to facilitate essential 
biological processes.  To safeguard these mucosal sites a diverse array a lymphoid 
tissues are associated with these mucosal sites.  CP, cryptopatch; iBALT, inducible 
bronchus associated lymphoid tissue; ILF, isolated lymphoid follicle; LN, lymph node. 
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Table 1.  The IL-10 cytokine family, shared receptors, and signaling pathways.  
Members of the IL-10 cytokine family share a number of different type-1 and type-2 
cytokine receptors and signal through the Jak/STAT signal transduction pathways.  
Adapted from Sonnenberg et al., 2010, Advances in Immunology. 
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Table 2.  The IL-22-IL-22R pathway in human disease.  Several disruptions in the IL-
22-IL-22R pathway correlate with human diseases occurring at barrier surfaces.  HIES, 
hyper-IgE syndrome; APECED, autoimmune polyendocrine syndrome 1; IBD, 
inflammatory bowel disease.  Adapted from Sonnenberg et al., 2010, Advances in 
Immunology. 
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Figure 2.  Functional consequences of IL-22-IL-22R signaling at barrier surfaces.  
IL-22 is dynamically regulated at barrier surfaces including the skin (A), lung (B) and 
intestine (C).  Depending on the cytokine milieu and tissue in which it is expressed, IL-22 
can regulate expression of genes associated with inflammation, repair, chemotaxis or 
anti-microbial peptide expression, that can orchestrate host protective immunity, tissue 
inflammation, repair or homeostasis.  IBD, inflammatory bowel disease.  Adapted from 
Sonnenberg et al., 2011, Nature Immunology. 
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Figure 3.  Differentiation, regulation and function of IL-22-producing T cell 
populations.  IL-22 expression can be induced in a broad range of T cell populations 
including the innate-like γδ T cells and NKT cells, as well as αβ TCR-expressing CD4+ 
Th1, Th17 and Th22 cells and CD8+ Tc17 and Tc22 cells.  Generation of these cell 
populations depends on particular cognate interactions and cytokine milieus.  Upon 
lineage commitment, these cells are transcriptionally regulated by a number of factors 
and co-express a range of effector cytokines. AhR, aryl hydrocarbon receptor. Adapted 
from Sonnenberg et al., 2011, Nature Immunology. 
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Figure 4. CD4+ T helper cells are critical regulators of inflammation, immunity and 
homeostasis at mucosal sites.  Naïve CD4+ T cells can differentiate into different 
lineages depending upon the cytokine milieu present during recognition of cognate 
antigen in the context of MHCII.  Upon lineage commitment, particular transcription 
factors and effector cytokines are expressed and promote diverse functional outcomes. 
DC, dendritic cells; Th, T helper cell; TN, naïve T cell; Treg, regulatory T cell. 
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Figure 5. The emerging family of innate lymphoid cells.  Innate lymphoid cells 
differentiate from an Id-2 dependent precursor cell, depend on production of stimulatory 
cytokines from accessory and epithelial cells, exhibit specific transcriptional and cytokine 
profiles, and have previously been identified by several other names. 
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Figure 6. Regulation, function and lineage relationships of IL-22-producing innate 
lymphoid cells.  Innate lymphoid cells have recently been identified to be a critical 
source of IL-22.  Murine (A) and human (B) IL-22-producing ILCs can be distinguished 
by phenotypic surface marker expression, transcriptional profile, effector cytokine 
expression or functional capacity.  The origins, lineage relationships, plasticity, 
regulation and functions of IL-22-producing ILCs are not fully understood and are 
currently an area of intense research.  AhR, aryl hydrocarbon receptor; BAFF, B cell 
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Activating Factor; ILC, innate lymphoid cell; LTi, lymphoid tissue inducer. Adapted from 
Sonnenberg et al., 2011, Nature Immunology. 
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Figure 7.  Immunity to the enteric bacterial pathogen Citrobacter rodentium.  A 
successful host response to C. rodentium is mediated by phases of both innate and 
adaptive immunity.  Specific factors and cells have been found to be critical for immunity 
in each phase. 
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Chapter 2 
IL-22-producing CD4+ innate lymphoid cells promote innate immunity in 
the gut 
 
2.1 Abstract 
Fetal CD4+ lymphoid tissue inducer (LTi) cells play a critical role in the development of 
lymphoid tissues.  Recent studies identified that cells with a fetal CD4+ LTi cell-like 
phenotype persist in adults and are a member of the heterogeneous population of innate 
lymphoid cells (ILCs) that have been implicated in inflammatory responses.  However, 
whether adult CD4+ ILCs contribute to protective immunity remains poorly defined.  Data 
presented in this Chapter demonstrate that following infection with Citrobacter 
rodentium, a murine enteric bacterial pathogen, CD4+ ILCs were a dominant source of 
interleukin-22 (IL-22) early during infection.  Infection-induced CD4+ ILC responses were 
IL-23-dependent, and ablation of IL-23 impaired innate immunity.  Further, depletion of 
CD4+ ILCs abrogated infection-induced IL-22 responses and expression of anti-microbial 
peptides, and was associated with elevated bacterial replication and dissemination to the 
liver and exacerbated host mortality.  CD4+ ILCs were also found to be essential for host 
protective immunity in lymphocyte-replete hosts.  Collectively these data demonstrate 
that adult CD4+ ILCs are a critical source of IL-22 and identify a previously unrecognized 
function for CD4+ ILCs in promoting innate immunity in the intestine of adult mice.  
 
2.2 Introduction 
CD4+ lymphoid tissue inducer (LTi) cells are the first hematopoietic cells recruited to the 
sites of secondary lymphoid tissue organogenesis during fetal development (Mebius et 
al., 1997).  Production of interleukin-7 (IL-7) and RANKL by resident stromal cells 
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induces LTi cell expression of lymphotoxin-α1β2 that activates resident stromal cells to 
express adhesion molecules and chemokines that promote the formation and 
organization of secondary lymphoid tissues (Mebius, 2003).  The development of fetal 
LTi cells (defined as Lin-, c-kit+, CD4+, CD44+, CD127+, CD25+, CD90+, and CCR6+) is 
dependent on the transcription factors RORγt and Id-2, and IL-7 has been shown to 
regulate their survival and function (Eberl et al., 2004; Mebius, 2003; Mebius et al., 1997; 
Meier et al., 2007; Sun et al., 2000; Yokota et al., 1999).   
 Following birth, cells with a phenotype consistent with LTi cells persist in the 
secondary and mucosa-associated lymphoid tissues of adult humans and mice (Cupedo 
et al., 2009; Eberl and Littman; Tsuji et al., 2008).  In mice, these populations are 
generated in the bone marrow and are a member of an emerging category of innate 
lymphoid cells (ILCs) that are phenotypically and functionally heterogeneous (Colonna, 
2009; Cua and Tato, 2010; Kim et al., 2008; Sawa et al., 2010; Schmutz et al., 2009; 
Veiga-Fernandes et al., 2010).  Although the development, lineage relationships, and 
fates of adult CD4+ ILCs and other ILC populations are not fully understood, they appear 
to influence immunity and inflammation in multiple settings.  For example, CD4+ ILCs 
promote the maturation of tertiary lymphoid tissues following birth and the restoration of 
secondary lymphoid tissues following viral infection (Scandella et al., 2008; Tsuji et al., 
2008).  Additionally, an IL-23-responsive CD4- c-kit- CD90+ ILC population was recently 
found to express IL-17A and IFNγ and promote innate intestinal inflammation in a murine 
model of colitis (Buonocore et al., 2010).  Another ILC-like population characterized by 
expression of the NK cell cytotoxicity receptor NKp46 was found to express IL-22 in 
response to IL-23 stimulation or following exposure to the enteric pathogen Citrobacter 
rodentium, and was implicated in promoting host protective immunity (Cella et al., 2009; 
Cupedo et al., 2009; Luci et al., 2009; Sanos et al., 2009; Satoh-Takayama et al., 2008). 
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 Early production of IL-22 is essential for innate immunity to enteric bacterial 
infection with C. rodentium (Zheng et al., 2008).  IL-22 induces expression of anti-
microbial peptides and promotes the maintenance of the epithelial cell barrier, 
preventing systemic bacterial dissemination, morbidity and host mortality (Zheng et al., 
2008).  Analysis of intestinal tissues following C. rodentium infection revealed that 
CD11c+ cells expressed IL-22 (Zheng et al., 2008).  More recently, an NKp46+ ILC 
population was found to express CD11c and IL-22 in the small intestine following C. 
rodentium infection (Cella et al., 2009; Satoh-Takayama et al., 2008).  However, 
depletion of a fraction of the NKp46+ ILC population, which co-expresses NK1.1, 
resulted in only a modest reduction in innate immunity to C. rodentium (Cella et al., 
2009).  Analysis of conventional NK cells and NKp46+ ILCs revealed that both 
populations were absent in Rag1-/-IL2rg-/- mice, whereas only conventional NK cells were 
absent in Rag1-/-Il2rb-/- mice (Satoh-Takayama et al., 2008).  Rag1-/-IL2rg-/- mice, but not 
Ra1g-/-Il2rb-/- mice, had an increased susceptibility to C. rodentium infection, suggesting 
that NKp46+ ILCs and not conventional NK cells contribute to innate anti-bacterial 
immunity (Satoh-Takayama et al., 2008).  However, in addition to defective NKp46+ ILC 
development, Rag1-/-Il2rg-/- mice exhibit impaired development and cytokine responses 
in multiple innate cell populations, including CD4+ ILCs and other IL-22-producing ILC 
populations (Kim et al., 2005; Satoh-Takayama et al., 2008; Takatori et al., 2009).  
Therefore, the potential influence of adult CD4+ ILCs versus other IL-22-producing ILC 
populations on innate immunity to bacterial infection remains to be determined. 
 Data presented in this Chapter demonstrate that adult CD4+ ILCs are the critical 
population required for early immunity to oral infection with C. rodentium.  Following 
infection with C. rodentium, IL-22+ innate cells outnumbered IL-22+ adaptive immune 
cells during the first six days of infection, and CD4+ ILCs were the dominant source of IL-
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22 following infection.  A substantial infection-induced population expansion of CD4+ 
ILCs and an increased frequency of IL-22+ CD4+ ILCs occurred in the colon and 
mesenteric lymph node (mLN).  Infection-induced IL-22 production by CD4+ ILCs was 
found to be IL-23-dependent, and blockade of IL-23 in Rag1-/- mice substantially 
impaired innate immunity to C. rodentium.  Furthermore, selective depletion of CD4+ 
ILCs in C. rodentium infected Rag1-/- mice resulted in reduced expression of IL-22 and 
anti-microbial peptides in the colon, failure to control bacterial replication and 
dissemination, and more rapid host mortality.  Finally, utilizing reconstitution of Rag1-/- 
mice and adoptive transfer approaches, it is demonstrate that CD4+ ILCs are critical for 
the promotion of IL-22-dependent innate immunity in lymphocyte-replete hosts.  Taken 
together, results presented in this Chapter identify adult CD4+ ILCs as a critical IL-23-
dependent innate source of IL-22 following enteric bacterial infection in mice and reveals 
a previously unrecognized function for CD4+ ILCs in contributing to innate immunity. 
 
2.3 Methods 
2.3.1 Mice and use of monoclonal antibodies in vivo 
C57BL/6 mice, C57BL/6 Rag1-/-, and C57BL/6 CD90.1 mice were purchased from the 
Jackson Laboratory (Bar Harbor, ME).  Il23a-/- mice on a C57BL/6 background were 
generated by Lexicon Pharmaceuticals, Inc. (The Woodlands, TX) and were provided by 
M. Elloso (Centocor, Radnor, PA).  129 Il22-/- mice were generated at Lexicon Genetics 
in collaboration with Pfizer and subsequently backcrossed to Balb/cBy at the Jackson 
Laboratory with colony mates used for all groups.  All mice were maintained in specific 
pathogen-free facilities at the University of Pennsylvania.  All protocols were approved 
by the University of Pennsylvania Institutional Animal Care and Use Committee 
(IACUC), and all experiments were performed according to the guidelines of the 
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University of Pennsylvania IACUC.  Generation of the anti-IL-23p19 mAb (CNTO 6163) 
was previously described (Fitch et al., 2009).  Anti-CD4 mAb (GK1.5) was purified from 
ascites and anti-CD90.2 mAb (30H12) was purchased from BioXCell (West Lebanon, 
NH).  Anti-IL-22 mAb (IL22-01) was provided by Pfizer.  All mAb treatments were 
administered i.p. every 3 days at a dose of 250 µg/mouse starting on day 0 of infection 
or the designated day post-infection.  
 
2.3.2 Citrobacter rodentium infection and assessment of CFU 
Citrobacter rodentium (formerly Citrobacter freundii, biotype 4280) strain DBS100 
(provided by Bruce Vallance, University of British Columbia, Vancouver, British 
Columbia, Canada) was prepared by selecting a single colony and culturing in LB broth 
overnight.  Mice were inoculated with approximately 1 x 1010 CFU in 200 µL via oral 
gavage.  Analysis of CFU from overnight cultures, mechanically homogenized fecal 
pellets, or mechanically homogenized livers were determined via serial dilutions on 
MacConkey’s agar.  
 
2.3.3 Isolation of cells and flow cytometric analysis 
Spleens and mLNs were harvested and single-cell suspensions were prepared at 
necropsy.  For IEL isolation, colons were isolated, attached fat removed, and tissues cut 
open longitudinally.  Luminal contents were removed by shaking in cold PBS and tissue 
was cut into 1-2 cm pieces and washed in RPMI containing 5% FCS.  Epithelial cells 
were removed by incubating tissue in stripping buffer (1 mM EDTA, 1 mM DTT, and 5% 
FCS) for 10 minutes at 37°C.  The remaining tissue was then incubated for an additional 
20 minutes in stripping buffer to collect leukocytes from the IEL compartment.  
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 For flow cytometric analysis, cells were stained with antibodies to the following 
markers TCRβ, CD5, CD3 (conjugated to PE-Cy7, eBioscience), CD19, Sca-1 
(conjugated to PerCP-Cy5.5, eBioscience), CD4 (conjugated to PE-Texas Red, 
Invitrogen), CD90.2 (conjugated to Alexa Fluor-700, Biolegend), CD11c, B220 
(conjugated to APC-eFluor780, eBioscience) c-kit, CD127, CD25, NKp46 (conjugated to 
FITC, eBioscience), NK1.1 (conjugated to PE, eBioscience) and CCR6 (conjugated to 
PE, R&D Systems).  For intracellular staining of transcription factors, cells were fixed 
and permeabilized utilizing a commercially available kit (eBioscience) and stained with 
an antibody to RORγt (conjugated to PE, eBioscience).  For cytokine production, cells 
were stimulated directly ex vivo by incubation for 4 h with 50 ng/mL PMA, 750 ng/mL 
ionomycin, 10 µg/mL Brefeldin A (all obtained from Sigma-Aldrich) and 10 ng/mL rIL-23 
(eBioscience).  Cells were fixed and permeabilized as indicated above and stained with 
IL22-02 (Pfizer) conjugated to Alexa Fluor 647 according to manufacturer’s instructions 
(Molecular Probes).  Dead cells were excluded from analysis using a violet viability stain 
(Invitrogen).  Flow cytometry data collection was performed on a FACSCanto II (BD 
Biosciences).  Files were analyzed using FlowJo software (Tree Star Inc.).  CD4+ ILCs 
were sorted from naïve Rag1-/- splenocytes by excluding cells positive for the lineage 
markers CD11c, B220 (conjugated to APC-eFluor-780, eBioscience), Gr-1, NK1.1, and 
NKp46 (conjugated to FITC, eBioscience) and gating for CD90+ CD4+ cells on a 
FACSAria (BD Bioscience).  Cytocentrifuge preparations of sorted cells were stained 
with H&E (Thermo Fisher Scientific). 
 
2.3.4 In vitro cell stimulations 
Total Rag1-/- splenocytes or total Rag1-/- IELs were cultured overnight in the presence or 
absence of 10 ng/mL rIL-23 (eBioscience).  Cells were then stimulated for 4 h with 50 
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ng/mL PMA, 750 ng/mL ionomycin, and 10 µg/mL Brefeldin A for analysis of intracellular 
cytokine production as described above.  Sorted CD4+ ILCs from Rag1-/- splenocytes 
were cultured for 72 h in complete media containing 10 ng/mL rIL-7 (Peprotech) to 
enhance survival in the presence or absence of rIL-23 10 ng/mL for analysis of IL-22 
secretion from cell-free supernatants.  
 
2.3.5 ELISA 
Tissue from the terminal colon was mechanically homogenized in PBS, centrifuged and 
the resultant supernatant measured for IL-22 protein by sandwich ELISA using IL22-01 
(Pfizer) as a capture antibody and biotin-conjugated IL22-03 (Pfizer) as a detection 
antibody. 
 
2.3.6 Serum ALT measurement 
Blood from infected animals was obtained, allowed to clot, and centrifuged to obtain 
serum.  Serum ALT was measured with a commercially available kit according to 
manufacturers directions (Biotron Diagnostics Inc, Hemet, CA) adapted to a 96-well 
plate format. 
 
2.3.7 Quantitative real-time PCR 
RNA was isolated from colon tissue using mechanical homogenization and TRIzol 
(Invitrogen).  RNA from sorted populations was isolated using RNeasy mini kits 
(QIAGEN).  cDNA was generated using Superscript reverse transcription (Invitrogen).  
Real-time PCR (RT-PCR) was performed on cDNA using SYBR green chemistry 
(Applied Biosystems) and commercially available primer sets (QIAGEN).  Reactions 
were run on a real-time PCR system (ABI7500; Applied Biosystems).  Samples were 
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normalized to β-actin and displayed as a fold induction over naïve controls unless 
otherwise stated.   
 
2.3.8 Histological sections 
Livers were fixed with 4% paraformaldehyde, embedded in paraffin, and 5 µm sections 
were used for staining with H&E. 
 
2.3.9 CD90-disparate Rag1-/- chimeras and Il22-/- adoptive transfers 
Cells from mLN and spleen of CD90.1 C57BL/6 mice were obtained and approximately 
60-80 x 106 sort purified B (CD19+) and T cells (CD3+, CD5+) were transferred i.v. to 
CD90.2 Rag1-/- mice.  Reconstitution was permitted for 8-10 weeks post-transfer and 
subsequently confirmed by examination of peripheral blood lymphocytes. 
 C. rodentium infected Il22+/+ mice were sacrificed on days 2, 3 and 4 post-
infection and approximately 1 x 106 CD4+ T cells (CD4+, CD3+, CD5+) or 1.5 x 103 CD4+ 
ILCs (CD4+, CD3-, CD5-) from the spleen and mLN were sort purified and briefly 
stimulated for 1-2 hours in vitro with 10 ng/mL rIL-23 and 10 ng/mL IL-1β (eBioscience).  
Cells were then transferred i.v. into infection-matched Il22-/- recipients. 
 
2.3.10 Statistical analysis 
Results represent the mean ± SEM.  Statistical significance was determined by the 
Student’s t test unless otherwise stated.  For survival curves significance was 
determined using the log rank (Mantel-Cox) test. (*, p < 0.05; **, p < 0.01; ***, p < 0.001). 
 
2.4 Results 
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2.4.1 IL-22+ innate populations outnumber IL-22+ adaptive populations following 
Citrobacter rodentium infection 
It has been previously reported that IL-22 is necessary for immunity to C. rodentium 
during the first 8-days of infection (Zheng et al., 2008).  However, the cellular sources of 
IL-22 following C. rodentium infection remain unclear.  As IL-22 can be expressed by a 
number of innate and adaptive immune cells, C57BL/6 mice were infected with C. 
rodentium and IL-22 production was examined in non-T cells (CD3-, CD5-) versus T cells 
(CD3+, CD5+).  In naïve mice (day 0) the majority of IL-22+ cells were non-T cells, 
accounting for 68% and 79% of all IL-22+ cells in the mLN and colonic intra-epithelial 
lymphocyte (IEL) compartment respectively (Figure 8A, B).  Furthermore, non-T cells 
were the dominant IL-22+ cell population until day 6 and day 8 following C. rodentium 
infection in the mLN and IEL compartment respectively (Figure 8A, B).  Substantially 
increased total numbers of IL-22+ non-T cells compared to IL-22+ T cells were observed 
at days 2 and 4 post-infection in both the mLN (Figure 8C) and IEL compartment (Figure 
8D).  These data suggest that innate cells are the dominant source of IL-22 at early time 
points following infection.  To more thoroughly define the temporal requirements for IL-
22 in host defense to C. rodentium, anti-IL-22 mAb was administered to mice at different 
time points following infection.  All mice that received anti-IL-22 mAb starting on day 0 or 
day 2 post-infection succumbed to infection by day 13 (Figure 8E).  However, blockade 
of IL-22 starting on day 4 post-infection resulted in an intermediate degree of mortality 
(Figure 8E).  Moreover, mice receiving anti-IL-22 mAb beginning on day 6 or day 8 post-
infection did not succumb to C. rodentium (Figure 8E), suggesting that IL-22 is only 
essential for immunity to C. rodentium during the first six days of infection.  Collectively, 
these data demonstrate that following C. rodentium infection, innate immune cells are 
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the dominant sources of IL-22 production required for early resistance to enteric 
bacterial infection. 
 
2.4.2 Adult CD4+ ILCs proliferate and are a dominant source of IL-22 following 
Citrobacter rodentium infection 
Several innate immune cell sources of IL-22 have previously been identified including 
dendritic cells (DCs), conventional NK cells, NKp46+ ILCs, CD4- ILCs and CD4+ ILCs 
(Buonocore et al., 2010; Cella et al., 2009; Satoh-Takayama et al., 2008; Takatori et al., 
2009; Zenewicz et al., 2008; Zheng et al., 2008).  To investigate the innate sources of IL-
22 following C. rodentium infection, the frequency of IL-22+ cells was examined in 
multiple cell populations in the mLN of naïve or infected mice.  In comparison to naïve 
mice, C. rodentium-infected mice exhibited minimal changes in the frequency of IL-22+ 
DCs (CD3-, CD5-, CD11c+), NKp46-expressing cells (CD3-, CD5-, NKp46+), conventional 
NK cells (CD3-, CD5-, NK1.1+) or CD4- ILCs (CD3-, CD5-, CD4-, CD90+, Sca-1+) (Figure 
9A, B).  In contrast, analysis of the CD4+ ILC population (CD3-, CD5-, CD11c-, CD90+, 
CD4+) revealed an infection-induced increase in the frequency of IL-22+ cells that was 
higher than other cell populations examined (Figure 9A, B).  CD4+ ILCs also exhibited 
the highest frequency of IL-22+ cells in the IEL compartment of infected mice (Figure 
10A).  Furthermore, a comparison of IL-22-expression in CD4+ T cells versus CD4+ ILCs 
in the mLN at early time points following infection with C. rodentium revealed no 
increase in the frequency of IL-22+ CD4+ T cells until day 6 post-infection (Figure 10B), 
whereas increases in the frequency of IL-22+ CD4+ ILCs were observed at all early time 
points post-infection (Figure 10C).  Collectively these data demonstrate that CD4+ ILCs 
are a dominant source of IL-22 production early following C. rodentium infection. 
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 Further analysis of CD4+ ILCs (CD3-, CD5-, CD11c-, CD90+, CD4+) from infected 
mice revealed expression of c-kit, CD127 (IL-7Rα), CD25 (IL-2Rα), CCR6, and the 
intracellular transcription factor RORγt (Figure 9C).  To examine whether CD4+ ILCs 
were proliferating, cells from naïve or infected mice were stained for the nuclear antigen 
Ki-67.  In comparison to naïve mice, CD4+ ILCs from the mLN or IEL compartment of 
infected mice exhibited an increase in the frequency of Ki-67+ cells (Figure 9D), 
suggesting that C. rodentium infection induced a proliferative response of CD4+ ILCs.  
Consistent with these results, significantly increased total numbers of CD4+ ILCs were 
observed in the mLN and IEL compartment of infected mice in comparison to naïve mice 
(Figure 9E, p < 0.01).  Collectively, these data demonstrate that infection with C. 
rodentium induces a population expansion of IL-22-producing CD4+ ILCs in the gut.  
 
2.4.3 Infection-induced IL-22 production by CD4+ ILCs is dependent on IL-23 
In vitro, IL-23 can induce IL-22 expression in a number of cell types including Th17 cells 
and other ILC populations (Buonocore et al., 2010; Cella et al., 2009; Liang et al., 2006; 
Satoh-Takayama et al., 2008; Takatori et al., 2009).  To test whether in vivo infection-
induced IL-22 production from CD4+ ILCs was IL-23 dependent, Il23a+/+ and Il23a-/- mice 
were infected with C. rodentium and the CD4+ ILC response was examined by flow 
cytometry.  Naïve Il23a+/+ versus Il23a-/- mice displayed similar basal frequencies of 
CD4+ ILCs (Figure 11A, top) and IL-22+ CD4+ ILCs in the mLN (Figure 11B, top).  
However, infection-induced increases in the frequency of CD4+ ILCs in the mLN of 
infected Il23a+/+ mice were not observed in infected Il23a-/- mice (Figure 11A, bottom).  
Infection with C. rodentium resulted in an increase in the frequencies of IL-22+ CD4+ 
ILCs in Il23a+/+ mice (Figure 11B, left) that was not observed in infected Il23a-/- mice 
(Figure 11B, right), demonstrating that infection-induced CD4+ ILC-derived IL-22 
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responses are predominantly IL-23-dependent.  Consistent with IL-23-dependent IL-22 
production in innate cells, further examination of the innate lymphoid compartment 
revealed that stimulation of splenocytes from naïve Rag1-/- mice with rIL-23 resulted in 
an increased frequency of IL-22+ cells compared to cells cultured in media alone (Figure 
11C).  Phenotypic analysis of IL-22+ cells from rIL-23-stimulated cultures revealed that 
the majority co-expressed CD90 and CD4 (Figure 11D).  The IL-22+ innate cells were 
confirmed to be CD4+ ILCs as this population co-expressed c-kit, CD127 (IL-7Rα), CD25 
(IL-2Rα), CCR6, and the intra-cellular transcription factor RORγt (Figure 11E).  The non-
CD4+ IL-22+ cells in spleen cultures most closely resembled CD4- ILCs as they also 
expressed c-kit and CD90, but lacked expression of NK1.1, NKp46 and CD11c (Figure 
12A).  CD4+ ILCs were also the dominant source of IL-23-induced IL-22 in innate cells 
isolated from the IEL compartment (Figure 12B).  Examination of sorted CD4+ ILCs 
(Figure 11F) revealed a mononuclear morphology (Figure 12C) and significant elevated 
expression of mRNA encoding Id2 (Figure 11G, p < 0.05) and Il23r (Figure 11H, p < 
0.05).  Sorted CD4+ ILCs secreted increased amounts of IL-22 protein following 
stimulation with rIL-23 (Figure 11I), demonstrating that IL-23 could directly induce IL-22 
expression in CD4+ ILCs.  Collectively these data indicate that CD4+ ILCs are a 
dominant IL-23-responsive, IL-22 producing innate cell population, and that in vivo 
infection-induced CD4+ ILC responses are regulated by IL-23. 
 
2.4.4 Innate immunity to Citrobacter rodentium is dependent on IL-23 
Following C. rodentium infection, Il23a-/- mice exhibit elevated bacterial loads and 
succumb to infection (Mangan et al., 2006), and it has been proposed that this defective 
immunity may be the result of impaired Th17 cell effector responses observed in the 
absence of IL-23 (McGeachy et al., 2009).  However, whether IL-23 is required for innate 
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immunity to C. rodentium has not been examined.  To test the role of IL-23 in innate 
immunity to C. rodentium, Rag1-/- mice were infected and administered either isotype 
control or anti-IL-23p19 mAb.  Examination of the colonic tissue following infection 
revealed that isotype mAb-treated Rag1-/- mice exhibited an increase in Il22 mRNA 
(Figure 13A) and IL-22 protein (Figure 13B) over naïve Rag1-/- mice.  Administration of 
multiple doses of anti-IL-23p19 mAb to infected Rag1-/- mice reduced both intestinal Il22 
transcript (Figure 13A) and IL-22 protein (Figure 13B) in comparison to isotype treated 
and infected Rag1-/- mice.  Consistent with a decrease in IL-22 expression, infected 
Rag1-/- mice administered anti-IL-23p19 mAb also exhibited reduced mRNA encoding 
the IL-22-dependent anti-microbial peptides RegIIIβ and RegIIIγ in the colon (Figure 
13C).  Furthermore, anti-IL-23p19 mAb treated Rag1-/- mice displayed an increase in 
fecal colony forming units (CFU) at day 10 post-infection compared to isotype control 
mAb (Figure 13D).  Reduced expression of IL-22 and lower amounts of anti-microbial 
peptides in the colon have previously been reported to result in systemic dissemination 
of C. rodentium to peripheral tissues resulting in substantial tissue inflammation, 
morbidity and mortality (Zheng et al., 2008).  Consistent with this, in comparison to 
isotype mAb treatment, anti-IL-23p19 mAb treatment of Rag1-/- mice resulted in 
increased CFU of C. rodentium in the liver (Figure 13E), increased inflammatory cell 
infiltrates (black arrows, Figure 13F) and necrosis in the liver (white arrow, Figure 13F).  
Anti-IL-23p19 mAb treatment also resulted in elevated amounts of the liver enzyme 
alanine transaminase (ALT) in comparison to isotype mAb treatment (Figure 13G), 
consistent with hepatocyte damage.  Finally, in comparison to Rag1-/- mice receiving an 
isotype mAb treatment, those receiving an anti-IL-23p19 mAb treatment exhibited an 
increased rate of weight loss (Figure 13H) and succumbed to infection at earlier time 
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points (Figure 13I).   Taken together, these data demonstrate that CD4+ ILC responses 
and innate immunity to C. rodentium are IL-23-dependent. 
 
2.4.5 Depletion of CD4+ ILCs substantially impairs innate immunity to Citrobacter 
rodentium 
To test the contribution of adult CD4+ ILCs to innate immunity in the gut, anti-CD90 mAb 
was administered to infected Rag1-/- mice.  Anti-CD90 mAb treatment resulted in efficient 
depletion of CD4+ ILCs in comparison to isotype mAb treatment (Figure 14A).  Despite 
complete depletion of CD4+ ILCs, analysis of cells expressing NK cell receptors revealed 
that anti-CD90 mAb administration did not result in substantial changes in the frequency 
of NK1.1+ cells in the spleen (Figure 15A, B) or NKp46+ cells in the IEL compartment 
(Figure 15C).  Rag1-/- mice receiving mAb treatments were analyzed for innate immunity 
to C. rodentium.  Infection-induced increases in both Il22 mRNA (Figure 14B) and IL-22 
protein (Figure 14C) were reduced in colon tissue of Rag1-/- mice that received anti-
CD90 mAb in comparison to isotype mAb treatment.  The reduction of IL-22 expression 
in anti-CD90 mAb treated Rag1-/- mice also correlated with a reduction in colonic mRNA 
for the genes encoding RegIIIβ and RegIIIγ (Figure 14D).  Furthermore, examination of 
fecal burdens revealed that anti-CD90 mAb treated Rag1-/- mice exhibited higher C. 
rodentium CFU compared to control treated mice (Figure 14E), increased dissemination 
of C. rodentium to the liver (Figure 14F), and augmented liver pathology characterized 
by increased inflammatory infiltrates (Figure 14G, black arrows) and liver necrosis 
(Figure 14G, white arrow) in comparison to isotype mAb treated mice.  Finally, similar to 
anti-IL-23p19 mAb treated Rag1-/- mice, those treated with anti-CD90 mAb exhibited 
increased serum concentrations of ALT (Figure 14H), an elevated rate of weight loss 
(Figure 14I), and decreased survival in comparison to isotype mAb treated Rag1-/- mice 
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(Figure 14J).  Taken together, these results demonstrate that depletion of CD90+ cells in 
Rag1-/- mice impairs IL-22 production and substantially reduces innate resistance to C. 
rodentium.   
 Anti-CD90 mAb administration depletes both CD4+ and CD4- innate cell 
populations (Figure 14A), including an IL-22-expressing c-kit- CD4- ILC population that 
was recently reported to contribute to intestinal inflammation (Buonocore et al., 2010).  
Therefore, to examine whether the anti-CD90 mAb-mediated loss in innate immunity to 
C. rodentium was due to depletion of the CD4+ ILCs or CD4- ILCs, infected Rag1-/- mice 
were treated with either control or anti-CD4 mAb.  Examination of spleens from mAb 
treated mice revealed that CD4+ ILCs, but not CD4- CD90+ cells, were successfully 
depleted following administration of anti-CD4 mAb in comparison to isotype mAb treated 
mice (Figure 16A).  Similar to anti-CD90 mAb administration, anti-CD4 mAb 
administration did not result in substantial changes in the frequency of NK1.1+ cells in 
the spleen (Figure 15B) or NKp46+ cells in the IEL compartment (Figure 15C).  
Treatment of infected Rag1-/- mice with anti-CD4 mAb also abrogated C. rodentium 
infection-induced increases in both colonic Il22 mRNA (Figure 16B) and IL-22 protein 
(Figure 16C) in comparison to isotype mAb treatment.  In addition, anti-CD4 mAb treated 
Rag1-/- mice demonstrated a reduction in colonic mRNA for genes encoding RegIIIβ and 
RegIIIγ following infection (Figure 16D).  Analysis of fecal burdens demonstrated that 
anti-CD4 mAb treated Rag1-/- mice exhibited higher C. rodentium CFU (Figure 16E).  
Bacterial dissemination of C. rodentium was also evident in CD4-depleted Rag1-/- mice 
as higher bacterial burdens were found in the liver (Figure 16F), in addition to an 
observed increase in inflammatory infiltrates (Figure 16G, black arrows) and necrosis 
(Figure 16G, white arrow).  Finally, Rag1-/- mice treated with anti-CD4 mAb exhibited 
increased serum concentrations of ALT (Figure 16H), exaggerated weight loss (Figure 
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16I), and an increased rate of mortality in comparison to isotype mAb treated Rag1-/- 
mice (Figure 16J).  A similar defect in innate immunity was previously observed in Rag-/-
Il2rg-/- mice and attributed to defects in NKp46+ ILC populations (Satoh-Takayama et al., 
2008).  However, given that this population is reported to lack CD4 expression (Satoh-
Takayama et al., 2008) and a decrease in the frequency of NKp46+ populations following 
anti-CD4 mAb administration is not observed (Figure 15C), these collective observations 
from the effect of anti-CD90 or anti-CD4 mAb administration suggest that defective 
innate immunity to C. rodentium observed in Rag-/-IL2rg-/- mice may be attributed to 
defects in adult CD4+ ILC responses.  Notwithstanding this, these data collectively 
indicate that CD4+ ILCs are a critical innate source of IL-22 following infection and 
directly contribute to innate immunity to enteric bacterial infection.  
 
2.4.6 CD4+ ILCs promote essential innate immunity in lymphocyte-replete hosts 
T cells are an additional source of IL-22 that are not present in lymphocyte-deficient 
Rag1-/- mice.  To test whether CD4+ ILCs can promote innate immunity in a lymphocyte-
replete host, two models systems were utilized.  First, Rag1-/- mice expressing the 
CD90.2 allele were reconstituted with purified T cells (CD3+) and B cells (CD19+) from a 
C57BL/6 mouse expressing the CD90.1 allele (Figure 17A, top).  Gating on splenic CD4+ 
cells in an isotype mAb-treated CD90-disparate chimera revealed a population of donor 
CD90.2-, CD3+, CD5+, CD4+ T cells and a population of recipient CD90.2+ CD3-, CD5-, 
CD4+ ILCs (Figure 17A).  Administration of anti-CD90.2 mAb to the chimeras revealed a 
selective depletion of recipient CD4+ ILCs but not donor CD4+ T cells (Figure 17A), thus 
providing an in vivo model to interrogate ILC function in lymphocyte-replete hosts.  
CD90-disparate chimeras and unreconstituted Rag1-/- mice were infected with C. 
rodentium and treated with an isotype mAb or anti-CD90.2 mAb.  As observed 
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previously, Rag1-/- mice receiving an isotype mAb survived for approximately 26 days 
post-infection, while Rag1-/- mice receiving an anti-CD90.2 mAb succumbed to infection 
around day 12 (Figure 17B).  In contrast, while 66% of isotype mAb treated Rag1-/- 
chimeras did not succumb to infection and survived longer than isotype mAb treated 
Rag1-/- mice, 100% of ILC-depleted anti-CD90.2 mAb treated Rag1-/- chimeras 
succumbed to infection at early time points despite the presence of donor lymphocytes 
(Figure 17A, B).  These data suggest that adaptive immunity is required for protection to 
C. rodentium at later time points, however, ILCs are required for innate immunity at early 
time points in a lymphocyte-replete host. 
 The next studies investigated whether CD4+ ILCs are sufficient to provide innate 
immunity to C. rodentium in a lymphocyte-replete host.  Il22+/+ and Il22-/- mice were 
infected with C. rodentium and on days 2, 3 and 4 post-infection 1 x 106 CD4+ T cells or 
1.5 x 103 CD4+ ILCs from Il22+/+ hosts were purified and adoptively transferred into 
infected Il22-/- hosts (Figure 17C).   Analysis of host mortality revealed that consistent 
with a previously published study (Zheng et al., 2008), 100% of C. rodentium infected 
Il22-/- mice succumbed to infection at early time points (Figure 17D).  All infected Il22-/- 
mice receiving Il22+/+ CD4+ T cells also succumbed to infection at early time points.  
However, 50% of Il22-/- mice receiving Il22+/+ CD4+ ILCs survived infection beyond day 
20 (Figure 17D).  Collectively, these studies indicate that CD4+ ILCs play a critical role in 
innate immunity in the intestine of lymphocyte-replete hosts. 
 
2.5 Discussion 
Data presented in this Chapter demonstrate that following infection with the murine 
enteric pathogen C. rodentium, adult CD4+ ILCs proliferate and upregulate IL-22 
production within the first six days post-infection.  CD4+ ILCs were found to be the 
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dominant source of IL-22 and infection-induced CD4+ ILC responses were predominantly 
IL-23-dependent.  Furthermore, this Chapter demonstrates that IL-23 is critical in 
mediating innate immunity to C. rodentium in mice.  Consistent with being a dominant 
source of infection-induced IL-22, depletion of CD4+ ILCs in C. rodentium infected Rag1-
/- mice resulted in an abrogation of infection-induced IL-22 and anti-microbial peptide 
expression, enhanced bacterial replication and dissemination, and exacerbated host 
morbidity and mortality.  Furthermore, in lymphocyte-replete hosts, CD4+ ILCs were 
found to be critical in promoting innate immunity in the intestine. 
 Previous studies examining the functions of adult CD4+ ILCs revealed that they 
have the capacity to promote lymphoid-tissue organogenesis and the maintenance of 
lymphoid tissue architecture following CD8+ T cell-mediated lysis of virally-infected 
resident stromal organizer cells (Scandella et al., 2008; Schmutz et al.).  These studies 
provoke the hypothesis that the function of CD4+ ILCs in adults might be to promote 
lymphoid tissue maintenance and tertiary lymphoid-tissue formation.  Other studies have 
demonstrated that ILCs in adult mice and humans constitutively express RORγt and 
have the capacity to express IL-22 in vitro (Eberl and Littman, 2004; Takatori et al., 
2009).  As IL-22 has been found to play important roles in promoting inflammation, 
tissue-protection and/or protective immunity (Sonnenberg et al., 2010a; Zenewicz et al., 
2008; Zheng et al., 2007; Zheng et al., 2008), this provokes the hypothesis that the role 
of CD4+ ILCs in adults, in contrast to their fetal CD4+ LTi cell counterparts, may extend 
beyond lymphoid-tissue generation and maintenance.  Consistent with this, CD4+ ILCs 
are a member of an emerging family of heterogeneous IL-22-producing ILCs, in which all 
members share a developmental requirement for RORγt, and several ILC populations 
have been implicated in promoting innate immunity and intestinal inflammation via 
production of host protective and/or inflammatory cytokines (Buonocore et al., 2010; 
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Cella et al., 2009; Colonna, 2009; Cua and Tato, 2010; Eberl et al., 2004; Satoh-
Takayama et al., 2008; Sawa et al., 2010; Spits and Di Santo, 2010).  For example, a 
population of c-kit- CD4- ILCs has recently been suggested to promote intestinal 
inflammation through production of IL-17A and IFNγ (Buonocore et al., 2010).  Further, a 
population of NKp46+ ILCs was implicated in promoting innate immunity to C. rodentium 
(Cella et al., 2009; Satoh-Takayama et al., 2008), however loss-of-function and gain-of-
function experiments were difficult to interpret due to the lack of specific reagents to 
deplete this cell population.  In contrast to these studies, data presented in this Chapter 
now demonstrate that CD4+ ILCs proliferate and are the dominant source of IL-22 during 
C. rodentium infection.  Through loss-of-function and gain-of-function approaches it was 
demonstrated that CD4+ ILCs are critical for promoting infection-induced increases in 
anti-microbial peptide expression, controlling bacterial replication and dissemination, and 
protecting from host morbidity and mortality.  Collectively these data identify a previously 
unrecognized role for CD4+ ILCs in innate immunity to enteric bacterial infection. 
 The regulatory signals that influence ILC function are poorly defined.  Recently it 
has been shown that IL-23 can promote innate cell-driven colitis, and that IL-23 can 
promote ILC production of IL-22, IL-17A and IFNγ in vitro (Buonocore et al., 2010; Cella 
et al., 2009; Satoh-Takayama et al., 2008; Takatori et al., 2009; Uhlig et al., 2006).  IL-23 
has previously been found to be necessary for immunity to C. rodentium in wild-type 
mice (Mangan et al., 2006; Zheng et al., 2008), however the impaired resistance to 
infection was thought to be due to defective generation and/or maintenance of CD4+ 
Th17 cells.  Data presented in this Chapter demonstrate that IL-23 promotes infection-
induced expression of IL-22 in CD4+ ILCs and is essential for innate immunity to enteric 
bacterial infection in vivo.   
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 These data provide evidence that CD4+ ILCs are critical for innate immunity in 
the lymphopenic environment of a Rag1-/- mouse, and these findings may have 
important clinical implications.  For example, several clinical conditions in patients are 
characterized by the development of severe lymphopenia, including AIDS, cancer and 
tissue transplantation, and a leading cause of mortality in these patients is secondary 
bacterial infections at mucosal sites (Bonnet et al., 2007; Douek et al., 2003; Lewden et 
al., 2008; Segel et al., 2003; Storek et al., 1997; Wallace et al., 1993; Zitvogel et al., 
2008).  The ability to specifically target and promote CD4+ ILC-dependent innate 
immunity with novel immunotherapies could be beneficial in managing these conditions.  
Thus, these studies and future investigations on the development and regulation of both 
CD4+ ILCs and innate immunity to enteric bacterial infections in lymphocyte-deficient 
mice could be of substantial value in the design of new intervention strategies for these 
human conditions. 
 Notwithstanding this, it is important to consider the potential functions of CD4+ 
ILCs in promoting innate immunity in lymphocyte-replete hosts.  Employing CD90-
disparate chimeras and adoptive transfer approaches, data presented in this Chapter 
provides the first report that CD4+ ILCs are necessary and sufficient to partially restore 
innate immunity and prolong survival following enteric bacterial infections in lymphocyte-
replete hosts.  This was surprising given that CD4+ T cells outnumber CD4+ ILCs in the 
lymphoid and intestinal tissues.  However, it is consistent with data that CD4+ ILCs are 
the dominant source of IL-22 early during infection, while infection-induced T cell-derived 
IL-22 is not detectable until time points when IL-22 is no longer required for immunity to 
infection.  Therefore, CD4+ ILCs appear to be sentinel innate cells at mucosal sites, 
which represent an essential early source of IL-22.  CD4+ T cells and B cells are also 
required for immunity to Citrobacter, yet appear to be critical at later time points as mice 
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deficient in these cells survive for several weeks post infection (Simmons et al., 2003).  
Collectively, these data provoke a model in which CD4+ ILCs expand and produce IL-22 
to control early enteric bacterial infection until a sufficient adaptive immune response can 
be initiated to effectively clear the pathogen. 
 All IL-22-producing ILC populations require RORγt for their development 
(Buonocore et al., 2010; Eberl et al., 2004; Sanos et al., 2009), and RORγt has been 
suggested to regulate expression of IL-23R in CD4+ T cells (Ivanov et al., 2006; Zhou et 
al., 2007).  The development of ILC populations may render them constitutively 
responsive to IL-23-mediated signals, suggesting that IL-23 may represent a conserved 
pathway that stimulates innate cell cytokine responses to promote either intestinal 
inflammation (Buonocore et al., 2010) or innate host defense following enteric bacterial 
infection.  Therefore, in addition to influencing adaptive immune responses through the 
induction and maintenance of secondary lymphoid tissues, CD4+ ILCs also influence 
innate immune responses through the production of host-protective cytokines, increasing 
IL-22-dependent expression of anti-microbial peptides and promoting innate immunity.   
 Cellular immunity evolved prior to organized secondary lymphoid tissues (Burnet, 
1968), and it has been proposed that ILCs may represent a primitive form of cellular 
immunity (Kim et al., 2009; Lane et al., 2008).  Given that these data demonstrate that 
CD4+ ILCs promote innate immunity, it is likely that host-protective functions of CD4+ 
ILCs evolutionarily preceded the acquisition of lymphoid tissue-inducing functions and 
that CD4+ ILCs represent an ancient precursor to more elaborate forms of cellular anti-
bacterial immunity.  Collectively these data provide insights into the evolution of the IL-
23-Th17 cell axis in the context of inflammation and immunity at mucosal sites.  
Moreover, the identification of a role for CD4+ ILCs in lymphopenic and lymphocyte-
replete hosts highlights the potential to target this cell population in promoting innate 
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immunity and efficacy of vaccination while limiting debilitating chronic inflammation at 
mucosal sites. 
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Figure 8. Innate immune cells are the first population to expand with exposure to 
C. rodentium infection and are the dominant source of IL-22 required for 
immunity.  C57BL/6 mice were infected with C. rodentium on day 0 and sacrificed on 
days 2, 4, 6 and 8.  Cells were briefly stimulated ex vivo and the frequency of IL-22+, 
CD3+, CD5+ cells versus IL-22+, CD3-, CD5- cells were examined in the (A) mLN and (B) 
colon IEL compartment.  Absolute numbers of IL-22+ CD3+/CD5+ cells versus IL-22+, 
CD3-, CD5- cells in the (C) mLN and (D) IEL compartment.  (E) Percent survival of IL-22 
neutralizing mAb treated and infected C57BL/6 mice.  Antibody treatment was initiated 
on the indicated day and continued every 3 days.  All data are representative of 2 
independent experiments with a minimum of 3 mice per group or time point.  Data shown 
are the mean ± SEM.  * p < 0.05  ** p < 0.01. mLN, mesenteric lymph node; IEL, 
intraepithelial lymphocytes. 
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Figure 9. Adult CD4+ ILCs expand and are a dominant innate source of IL-22 
following C. rodentium infection.  C57BL/6 mice were infected with C. rodentium on 
day 0 and sacrificed on day 4.  Frequency of ex vivo stimulated IL-22+ innate cells in the 
mLN of (A) naïve and (B) infected mice gated as indicated for various surface markers.  
(C) The gated CD3- CD5- CD11c- CD90+ CD4+ population in the mLN of C. rodentium 
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infected mice was stained with anti- c-kit, CD127, CD25, CCR6 and RORγt antibodies 
(bold black line) and corresponding isotype and negative control antibodies (solid grey 
histograms).  C57BL/6 mice were infected with C. rodentium on day 0 and sacrificed on 
day 8.  (D) Frequency of Ki-67+ CD4+ ILCs (CD3- CD5- CD11c- CD90+ CD4+) in the mLN 
and IEL compartment.  (E) Absolute numbers of CD4+ ILCs in the mLN and IEL 
compartment of naïve (N) and infected (INF) mice.  All data are representative of 2 or 
more independent experiments with a minimum of 3-4 mice per group.  Data shown are 
the mean ± SEM. ** p < 0.01.  
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Figure 10. Adult CD4+ ILCs are a dominant innate source of IL-22 in the gut 
following C. rodentium infection.  (A) C57BL/6 mice were infected with C. rodentium 
on day 0 and sacrificed on day 4.  Frequency of ex vivo stimulated IL-22+ innate cells 
gated as indicated in IEL of infected mice.  All data are representative of 2 or more 
independent experiments with a minimum of 3-4 mice per group.   (B) C57BL/6 mice 
were infected with C. rodentium on day 0 and sacrificed on days 2, 4 and 6.  Cells from 
the mLN were briefly stimulated ex vivo and the frequency of IL-22+ cells were examined 
in CD4+, CD3+, CD5+ T cells, and (C) CD4+, CD3-, CD5- ILCs.  All data are 
representative of 2 independent experiments with a minimum of 3 mice per time point.  
 74 
 
Figure 11. Citrobacter rodentium-induced adult CD4+ ILC responses are dependent 
on IL-23.  Il23a+/+ and Il23a-/- mice were infected with C. rodentium on day 0 and 
sacrificed on day 8.  (A) Frequency of CD4+ ILCs in the mLN of naïve and infected mice.  
Populations are gated on live CD3- CD5- CD90+ CD4+ cells.  (B) Frequency of ex vivo 
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stimulated IL-22+ CD4+ ILCs in the mLN.  Populations are gated on live CD3- CD5- 
CD90+ CD4+ cells.  All data are representative of 2 or more independent experiments 
with a minimum of 3-4 mice per group.  Naïve Rag1-/- mouse splenocytes were cultured 
overnight with or without rIL-23.  (C) Frequency of IL-22+ cells with gating on live cells.  
(D) Frequency of CD90+ CD4+ cells in the IL-22+ gated population of (C).  (E) The IL-22+ 
CD90+ CD4+ population of (D) was stained with c-kit, CD127, CD25, CCR6 and RORγt 
antibodies (bold black lines) and corresponding isotype and negative control antibodies 
(solid grey histograms).  (F) CD4+ ILCs were purified from naïve Rag1-/- splenocytes and 
stained with CD4, CD11c and B220 antibodies.  Fold induction of (G) Id2 and (H) Il23r 
mRNA in purified CD4+ ILCs relative to total unfractionated Rag1-/- splenocytes (SPL).  
(I) IL-22 protein in culture supernatants from purified CD4+ ILCs stimulated in the 
presence or absence of rIL-23.  All in vitro data are representative of 2 or more 
independent experiments with a minimum of 2-3 replicate wells.  Data shown are the 
mean ± SEM. * p < 0.05  ** p < 0.01.   
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Figure 12.  CD4+ ILCs are the dominant IL-23-responsive and IL-22-producing 
innate population in the spleen and IEL.  (A) Frequency of CD90+ CD4- cells in the IL-
22+ gated population of Rag1-/- splenocytes (SPL) subsequent to culturing with rIL-23 
overnight; cells were also stained with anti- c-kit, NK1.1, NKp46 and CD11c antibodies 
(bold black lines) and corresponding isotype and negative control antibodies (solid grey 
histograms). (B) Frequency of IL-22+ cells in naïve Rag1-/- mice IEL cultures following 
overnight incubation with rIL-23, and the frequency of CD90+ CD4+ and CD90+ CD4- cells 
in the IL-22+ gated population.  All in vitro data are representative of 2 or more 
independent experiments with a minimum duplicate wells.  (C) CD4+ ILCs were purified 
from naïve Rag1-/- splenocytes and stained with H&E.  Scale bar, 10 µm. 
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Figure 13. Innate immunity to Citrobacter rodentium is dependent on IL-23.  
C57BL/6 Rag1-/- were administered an isotype control mAb or an anti-IL-23p19 mAb 
starting on day 0, infected with C. rodentium on day 0, and sacrificed on day 10.  (A) 
Fold induction of Il22 transcript in colonic RNA from antibody treated and infected (INF) 
mice compared to naïve mice.  (B) IL-22 protein in the supernatant of colon 
homogenates and (C) Fold induction of Reg3b and Reg3g transcript in colonic RNA from 
antibody treated and infected mice compared to naïve mice.  C. rodentium CFU in the 
(D) fecal pellets and (E) liver of antibody treated and infected mice.  (F) H&E stained 
histological sections of the liver of antibody treated and infected mice; inflammatory cell 
infiltrates (black arrows) and necrotic lesions (white arrow). Scale bar, 100 µm. (G) 
Serum ALT levels, (H) Percent of original whole body weight and (I) percent survival of 
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antibody treated and infected mice.  All data are representative of 3 or more independent 
experiments with a minimum of 3-4 mice per group.  Data shown are the mean ± SEM.  * 
p < 0.05  ** p < 0.01  *** p < 0.001.  
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Figure 14. Anti-CD90 mAb treatment impairs innate immunity to Citrobacter 
rodentium.  C57BL/6 Rag1-/- were administered an isotype control mAb or an anti-CD90 
mAb starting on day 0, infected with C. rodentium on day 0, and sacrificed at day 10.  (A) 
Frequency of CD4+ CD90+ cells in Lin- gated splenocytes from antibody treated Rag1-/- 
mice.  (B) Fold induction of Il22 transcript in colonic RNA from antibody treated and 
infected (INF) mice compared to naïve mice.  (C) IL-22 protein in the supernatant of 
colon homogenates and (D) fold induction of Reg3b and Reg3g transcript in colonic RNA 
from antibody treated and infected mice compared to naïve mice.  C. rodentium CFU in 
the (E) fecal pellets and (F) liver of antibody treated and infected mice.  (G) H&E stained 
histological sections of the liver of antibody treated and infected mice; inflammatory cell 
infiltrates (black arrows) and necrotic lesions (white arrow). Scale bar, 100 µm.  (H) 
Serum ALT levels, (I) percent of original whole body weight and (J) percent survival of 
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antibody treated and infected mice.  All data are representative of 3 or more independent 
experiments with a minimum of 3-4 mice per group.  Data shown are the mean ± SEM. * 
p < 0.05  ** p < 0.01  *** p < 0.001. 
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Figure 15. CD4 mAb administration specifically depletes CD4+ ILCs.  C57BL/6 
Rag1-/- were administered an isotype control mAb, anti-CD90 mAb or anti-CD4 mAb 
starting on day 0, infected with C. rodentium on day 0, and sacrificed at day 10.  (A) 
Frequency of CD4+ CD90+ cells in Lin- gated splenocytes (SPL) from antibody treated 
Rag1-/- mice.  (B) Frequency of NK1.1+ cells in splenocytes (SPL) from antibody treated 
Rag1-/- mice.  (C) Frequency of NKp46+ cells in IEL compartment from antibody treated 
Rag1-/- mice.  All data are representative of 2 independent experiments with a minimum 
of 2 mice per time point.  
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Figure 16. Adult CD4+ ILCs mediate innate immunity to Citrobacter rodentium.  
C57BL/6 Rag1-/- were administered an isotype control mAb or anti-CD4 mAb starting on 
day 0, infected with C. rodentium on day 0, and sacrificed at day 10.  (A) Frequency of 
CD4+ CD90+ cells in Lin- gated splenocytes from antibody treated Rag1-/- mice.  (B) Fold 
induction of Il22 transcript in colonic RNA from antibody treated and infected (INF) mice 
compared to naïve mice.  (C) IL-22 protein in the supernatant of colon homogenates and 
(D) fold induction of Reg3b and Reg3g transcript in colonic RNA from antibody treated 
and infected mice compared to naïve mice.  C. rodentium CFU in the (E) fecal pellets 
and (F) liver of antibody treated and infected mice.  (G) H&E stained histological 
sections of the liver of antibody treated and infected mice; inflammatory cell infiltrates 
(black arrows) and necrotic lesions (white arrow). Scale bar, 100 µm.  (H) Serum ALT 
levels, (I) Percent of original whole body weight and (J) percent survival of antibody 
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treated and infected mice.  All data are representative of 3 or more independent 
experiments with a minimum of 3-4 mice per group.  Data shown are the mean ± SEM. * 
p < 0.05  ** p < 0.01  *** p < 0.001.  
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Figure 17. Adult CD4+ ILCs are necessary and sufficient to promote innate 
immunity to C. rodentium infected lymphocyte-replete hosts.  (A) Diagram of the 
generation of CD90-disparate chimeras with representative flow cytometry plots 
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demonstrating depletion of recipient CD4+ ILCs but not donor CD4+ T cells in anti-
CD90.2 mAb treated chimeras in comparison to isotype mAb treated chimeras.  (B) 
Percent survival of isotype and anti-CD90.2 mAb treated and infected (INF) mice.  
Displayed data are from two independent experiments with 3 mice per group per 
experiment.   (C) Diagram of innate and adaptive immune cell adoptive transfer 
approaches utilizing Il22+/+ donors and Il22-/- recipients with representative flow cytometry 
plots demonstrating purity of transferred populations.  (D) Percent survival of antibody 
treated and infected (INF) mice.  Displayed data are from two independent experiments 
with 2 mice per group per experiment. 
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Chapter 3 
IL-22 and innate lymphoid cells regulate containment of commensal 
bacteria and maintain systemic immune cell homeostasis 
 
3.1 Abstract 
Data presented in Chapter 2 of this thesis demonstrate the critical importance of the 
innate lymphoid cell (ILC)-IL-22 pathway in promoting immunity to an enteric pathogen. 
In addition to pathogenic bacteria, the mammalian intestine contains trillions of beneficial 
commensal bacteria that are restricted to the intestine and gut-associated lymphoid 
tissues.  This Chapter explores the potential role of the ILC-IL-22 pathway in the 
compartmentalization of non-pathogenic commensal bacteria that constitutively inhabit 
intestinal tissues.  Loss of compartmentalization of commensal bacteria can promote 
systemic inflammation and is linked to the pathogenesis and progression of numerous 
chronic human diseases, including progressive HIV infection, IBD, hepatitis and cancer.  
However, mechanisms that regulate peripheral dissemination of commensal bacteria in 
health and disease are poorly understood.  Data presented in this Chapter identify that 
IL-22 producing ILCs are constitutively present in the intestine and gut-associated 
lymphoid tissues of healthy humans and mice, and loss of murine ILCs or IL-22 
promoted peripheral dissemination of commensal bacteria and induction of systemic 
inflammation.  Systemic inflammation was associated with commensal bacteria-specific 
adaptive immune cell responses, and was prevented by depletion of commensal 
bacteria with the administration of broad-spectrum antibiotics.  Thus, these data identify 
a previously unrecognized pathway by which ILCs and IL-22 regulate the 
compartmentalization of enteric commensal bacteria, preventing their peripheral 
dissemination and subsequent disruption of systemic immune cell homeostasis. 
 87 
 
3.2 Introduction 
The mammalian gastrointestinal tract is colonized by an estimated 100 trillion 
commensal bacteria, which are essential for promoting normal intestinal physiology, 
aiding in digestion, influencing development of the immune system and preventing 
colonization of the intestine by pathogenic microbes (Hill and Artis, 2010).  Co-evolution 
of mammals with commensal bacteria is dependent on numerous mechanisms to 
maintain a state of symbiosis with these diverse bacterial species (Hill and Artis, 2010).  
Under steady state conditions, the restricted compartmentalization of commensal 
bacteria to the intestinal lumen and gut-associated lymphoid tissues (GALT) limits 
exposure of bacteria to peripheral organs and prevents subsequent induction of 
systemic inflammation (Hill and Artis, 2010; Hooper and Macpherson, 2010; Obata et al., 
2010).  
 Loss of compartmentalization of commensal bacteria and the peripheral 
dissemination can disrupt systemic immune cell homeostasis by promoting chronic 
inflammation and the generation of commensal bacteria-specific immune responses 
(Duerkop et al., 2009; Hooper and Macpherson, 2010; Slack et al., 2009).  Peripheral 
dissemination of commensal bacteria to systemic organs is a hallmark of numerous 
chronic human infectious and inflammatory diseases including progressive HIV infection, 
inflammatory bowel disease (IBD), cancer and hepatitis (Brenchley et al., 2006; Lescut 
et al., 1990; McGuckin et al., 2009; Parlesak et al., 2000).  Dissemination of commensal 
bacteria has been proposed to cause systemic inflammation associated with these 
diseases and significantly contribute to disease pathogenesis and progression (Chin et 
al., 2007; Douek et al., 2009; Fava and Danese, 2011; Sandler et al., 2011a; Sandler et 
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al., 2011b).  However, the mechanisms that regulate containment of commensal bacteria 
to the intestine and GALT in health and disease remain poorly understood. 
 Several mechanisms have been proposed to contribute to the 
compartmentalization of commensal bacteria.  These mechanisms include the physical 
separation of commensal bacteria from mammalian cells by the production of mucus 
layers, tight junctions between intestinal epithelial cells that prevent bacterial 
translocation across the epithelium, and the production of anti-microbial proteins that 
directly lyse bacterial cells (Duerkop et al., 2009; Hooper and Macpherson, 2010).  In 
addition, multiple immunoregulatory networks contribute to containment of commensal 
bacteria including intra-epithelial lymphocytes, phagocytosing macrophages and 
commensal-bacteria specific IgA-secreting B cells (Duerkop et al., 2009; Hooper and 
Macpherson, 2010).  For example, Macpherson and colleagues recently identified that 
bacterial compartmentalization is tightly regulated by a continuum of innate and adaptive 
immune cell components (Hooper and Macpherson, 2010; Macpherson and Uhr, 2004; 
Slack et al., 2009).  Mice deficient in either toll-like receptors (TLRs) or oxidative bursts 
exhibited enhanced dissemination of commensal bacteria, which was subsequently 
controlled by the generation of high-titer serum antibodies specific for the bacteria, 
suggesting that hyper-activation of the adaptive immune system in the face of impaired 
innate immunity may contribute to the pathogenesis of numerous inflammatory diseases 
(Slack et al., 2009).  Consistent with this, in immunocompetent mice, commensal 
bacteria are restricted to the intestinal tissue and GALT to induce protective IgA 
responses and limit any potential disruption of systemic immune responses 
(Macpherson and Uhr, 2004).   
 Recent studies in murine models have implicated a critical role for IL-22, a 
member of the IL-10 cytokine family, in regulating intestinal immunity, inflammation and 
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repair (Sonnenberg et al., 2010a, 2011a).  IL-22 is expressed by hematopoietic cells and 
acts primarily on stromal cell lineages to induce expression of genes that promote 
intestinal homeostasis including anti-microbial peptides, inflammatory chemokines and 
epithelial repair machinery (Sonnenberg et al., 2010a, 2011a).  Both innate and adaptive 
immune cells can produce IL-22.  CD4+ T helper (Th)17 cells are a well characterized 
source of IL-22, IL-17A and IL-17F that have been proposed to promote immunity to 
extracellular pathogenic bacteria and play a role in the pathogenesis of autoinflammatory 
diseases (Ivanov et al., 2007; Ouyang et al., 2008).  Recent studies have also 
recognized antigen receptor-independent innate lymphoid cells (ILCs) as a critical 
source of IL-22 in the context of intestinal immunity and inflammation (Sawa et al., 2010; 
Sonnenberg et al., 2011a; Spits and Di Santo, 2010).  However, whether IL-22 
production by ILCs or Th17 cells contributes to the compartmentalization of commensal 
bacteria and maintenance of systemic immune cell homeostasis in the steady state 
remains unclear. 
 Data presented in this Chapter identify that intestinal tissues of healthy humans 
and mice contain a constitutive population of IL-22+ cells with an ILC phenotype, 
suggesting that this cell lineage may be involved in maintaining bacterial 
compartmentalization in the steady state.  Consistent with this, depletion of ILCs in naïve 
Rag1-/- mice resulted in the presence of culturable bacteria in peripheral organs, 
dissemination of bacterial by-products and induction of systemic inflammation.  
Neutralization of IL-22 resulted in similar bacterial dissemination and systemic 
inflammation, and administration of exogenous IL-22 significantly limited bacterial 
dissemination in ILC-depleted mice.  ILC-depletion in lymphocyte-replete mice also 
resulted in systemic inflammation associated with the generation of commensal-specific 
T cell and immunoglobulin responses.  Further, systemic inflammation could be 
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ameliorated by depletion of commensal bacteria with broad-spectrum antibiotics.  
Collectively, these data identify a previously unrecognized role for IL-22-producing ILCs 
in maintaining systemic immune cell homeostasis by promoting compartmentalization of 
commensal bacteria, and may represent a unique therapeutic target in the treatment of 
multiple chronic human diseases. 
 
3.3 Methods 
3.3.1 Mice, antibiotics and use of monoclonal antibodies and recombinant 
cytokines in vivo 
C57BL/6 mice, C57BL/6 Rag1-/-, and C57BL/6 CD90.1 mice were purchased from the 
Jackson Laboratory (Bar Harbor, ME).  All mice were maintained in specific pathogen-
free facilities at the University of Pennsylvania.  All protocols were approved by the 
University of Pennsylvania Institutional Animal Care and Use Committee (IACUC), and 
all experiments were performed according to the guidelines of the University of 
Pennsylvania IACUC.  A previously described cocktail of antibiotics (Hill et al., 2010) 
was continuously administered via drinking water.  Anti-CD90.2 mAb (30H12) and anti-
NK1.1 (PK-136) were purchased from BioXCell (West Lebanon, NH).  Anti-IL-22 mAbs, 
IL22-01 (neutralizing) and IL22-02 (mouse cytokine detection) were developed by Pfizer.  
Neutralizing or depleting mAb treatments were administered i.p. every 3 days at a dose 
of 250 µg/mouse starting on day 0.  Recombinant IL-22 (Pfizer) was administered at a 
dose of 25 µg every 2 days starting on day 0. 
 
3.3.2 Human intestinal and GALT samples 
Human intestinal tissue and mesenteric lymph node (mLN) were obtained from cadaver 
organ donors in collaboration with the New York Organ Donor Network.  Consent for use 
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of these tissues from human cadavers for research purposes was obtained from the 
donors' families.  Single cell suspensions from mLN were obtained by cutting tissues into 
small pieces and incubating for 1 h at 37 °C with shaking in collagenase solution 
(collagenase D (1 mg/ml), and DNAse I (25 µg/ml)).  Remaining tissues were then 
mechanically dissociated, strained through a wire mesh tissue sieve and lymphocytes 
were subsequently separated by centrifugation through Ficoll (LSM; Invitrogen). Single 
cell suspensions from intestinal tissues were obtained by cutting tissues into small 
pieces and incubating for 1 h at 37 °C with shaking in stripping buffer (1 mM EDTA, 1 
mM DTT, and 5% FCS) to remove the epithelial layer.  Supernatants were then 
discarded and the lamina propria fraction was obtained by incubating the remaining 
tissue for 1 h at 37 °C with shaking in collagenase solution (collagenase D (1 mg/ml), 
and DNAse I (25 µg/ml)).  Remaining tissues were then mechanically dissociated, 
strained through a wire mesh tissue sieve and lymphocytes were subsequently 
separated by centrifugation through Ficoll (LSM; Invitrogen). 
 For flow cytometry, single cell suspensions were stimulated overnight in 
recombinant human IL-2, IL-7 and IL-23 (10 ng/mL; eBioscience) followed by incubation 
for 4-6 h with 10 µg/mL Brefeldin A (Sigma-Aldrich).  Cells were stained with antibodies 
to the following markers, anti-CD3 PE-Cy7 (clone UCHT1, eBioscience), anti-CD56 
eFluor780 (clone CMSSB, eBioscience), anti-CD20 eFluor780 (clone 2H7, eBioscience), 
anti-CD45 PerCP-Cy5.5 (clone 2D1, eBioscience) and anti-CD127 PE-Cy5 (clone 
R34.34, Beckman Coulter).  For intracellular staining, cells were fixed and permeabilized 
utilizing a commercially available kit (eBioscience) and stained with an antibody to anti-
RORγt PE (clone AFKJS-9, eBioscience) or anti-IL-22 eFluor660 (clone 22URTI, 
eBioscience).  Dead cells were excluded from analysis using a violet viability stain 
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(Invitrogen).  Flow cytometry data collection was performed on a LSR II (BD 
Biosciences).  Files were analyzed using FlowJo software (Tree Star Inc.).   
 
3.3.3 Murine tissue isolation and flow cytometry 
Spleens were harvested and single-cell suspensions were prepared at necropsy.  For 
LPL isolation, small intestinal tissues were isolated, Peyer’s patches removed, attached 
fat removed, and tissues cut open longitudinally.  Luminal contents were removed by 
shaking in cold PBS and tissue was cut into 1-2 cm pieces and washed in RPMI 
containing 5% FCS.  Epithelial cells and intra-epithelial lymphocytes were removed by 
shaking tissue in stripping buffer (1 mM EDTA, 1 mM DTT, and 5% FCS) for 30 minutes 
at 37°C.  The lamina propria layer was isolated by shaking the remaining tissue in 0.5 
mg/mL collagenase D (Roche) and 20 µg/mL DNase I (Sigma-Aldrich) for 30 minutes at 
37°C. 
 For flow cytometric analysis, cells were stained with antibodies to the following 
markers: anti-NK1.1 PerCP-Cy5.5 (clone PK136, eBioscience), anti-CD3 PE-Cy7 (clone 
145-2C11, eBioscience), CD90.2 Alexa Fluor700 (clone 30-H12, Biolegend), anti-CD127 
eFluor450 (clone A7R34, eBioscience), anti-CD45 eFluor650NC (clone 30-F11, 
eBioscience), anti-CD90.1 PerCP-Cy5.5 (clone HIS51, eBioscience), anti-CD4 PE-
Texas Red (clone GK1.5, Abcam), anti-CD8 APC-eFluor780 (clone 53-6.7, 
eBioscience), anti-CD19 Alexa Fluor700 (clone 6D5, Biolegend).   For intracellular 
staining, cells were fixed and permeabilized utilizing a commercially available kit 
(eBioscience) and stained with an antibody to anti-RORγt PE (clone AFKJS-9, 
eBioscience) or anti-Ki-67 FITC (clone B56, BD Biosciences).  For cytokine production, 
intestinal cells were stimulated directly ex vivo by incubation for 4-6 h with 10 µg/mL 
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Brefeldin A (Sigma-Aldrich) and 10 ng/mL rIL-23 (eBioscience) or splenocytes were 
incubated for 5 h with 10 µg/mL Brefeldin A following 48-72 h antigen restimulation.  
Cells were fixed and permeabilized as indicated above and stained with IL22-02 (Pfizer) 
conjugated to Alexa Fluor647 according to manufacturer’s instructions (Molecular 
Probes), anti-IL-6 FITC (clone MP5-20F3, eBioscience) and anti-TNFα APC (clone MP6-
XT22, eBioscience).  Dead cells were excluded from analysis using a violet viability stain 
(Invitrogen).  Flow cytometry data collection was performed on a LSR II (BD 
Biosciences).  Files were analyzed using FlowJo software (Tree Star Inc.).   
 
3.3.4 Measurement of CFU and liver LPS 
Organs were sterilely removed at necropsy and mechanically homogenized in sterile 
PBS.  CFU were determined via serial dilutions on LB agar (Invitrogen).  Colonies were 
counted after 1-2 days of culture at 37°C.  LPS was measured in homogenates using an 
Endpoint Chromogenic Limulus Amebocyte Lysate assay (Lonza).  
 
3.3.5 Quantitative real-time PCR 
RNA was isolated from epithelial cells stripped from the ileum using RNeasy mini kits 
(QIAGEN).  cDNA was generated using Superscript reverse transcription (Invitrogen).  
Real-time PCR (RT-PCR) was performed on cDNA using SYBR green chemistry 
(Applied Biosystems) and commercially available primer sets (QIAGEN).  Reactions 
were run on a real-time PCR system (ABI7500; Applied Biosystems).  Samples were 
normalized to β-actin and displayed as a fold reduction from naïve isotype-treated 
controls unless otherwise stated.   
 
3.3.6 Histological sections 
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Livers were fixed with 4% paraformaldehyde, embedded in paraffin, and 5 µm sections 
were used for staining with H&E. 
 
3.3.7 CD90-disparate Rag1-/- chimeras 
Cells from mLN and spleen of CD90.1 C57BL/6 mice were obtained and approximately 
60-80 x 106 sort purified B (CD19+) and T cells (CD3+, CD5+) were transferred i.v. or i.p. 
to CD90.2 Rag1-/- mice.  Reconstitution was permitted for 8-10 weeks post-transfer and 
subsequently confirmed by examination of peripheral blood lymphocytes. 
 
3.3.8 Generation of cecal bacterial antigen, antigen restimulation and ELISA 
Cecal bacteria were isolated by resuspending cecal contents of Rag1-/- mice at 1 g per 
10 mL of sterile PBS, centrifuging at the lowest setting to remove large aggregates, and 
washing the resulting supernatant with sterile PBS twice by centrifuging for 1 minute at 
8,000 rpm.  On the last wash, bacteria were resuspended in 2 mL ice-cold PBS and 
sonicated on ice.  Samples were then centrifuged at 20,000 x g for 10 minutes and 
supernatants recovered.  For T cell antigen restimulation, splenocytes were cultured with 
50 µg/mL cecal bacterial antigen for 48-72 hours followed by the addition of 10 µg/mL 
Brefeldin A for 5 hours at 37°C.  For measurement of serum antibodies by ELISA, 5 
µg/mL cecal bacterial antigen was coated on 96 well plates and sera were incubated in 
doubling dilutions.  Antigen specific mouse IgG was detected using an anti-mouse IgG-
HRP antibody (BD Biosciences) and TMB peroxidase substrate (KPL). 
 
3.3.9 Statistical analysis 
Results represent the mean ± SEM.  Statistical significance was determined by the 
Student’s t test unless otherwise stated.  (*, p < 0.05; **, p < 0.01; ***, p < 0.001). 
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3.4 Results 
3.4.1 IL-22 is constitutively produced by ILCs in intestine and GALT of healthy 
mice and humans 
To examine the cellular sources of IL-22 that are associated with the 
compartmentalization of commensal bacteria in the steady state, the intestine and GALT 
from naïve C57BL/6 mice were examined for IL-22+ cells.  In intestinal tissues, a 
population of IL-22+ cells was observed in which the majority lacked co-expression of 
lineage markers CD3 or NK1.1 (Figure 18A), but were CD127+, CD45-intermediate 
(CD45INT), RORγt+ and CD90 (Thy1)+ (Figure 18B), a phenotype consistent with IL-22-
producing ILCs (Sonnenberg et al., 2011a; Spits and Di Santo, 2010).  Similarly, 
analysis of murine mLN revealed the presence of a constitutive IL-22+ population that 
lacked expression of CD3 and NK1.1 (Figure 18C), but were CD127+, CD45INT, RORγt+ 
and CD90+ ILCs (Figure 18D).  To analyze IL-22-producing populations in humans, 
intestinal tissues from healthy human donors were examined.  Consistent with 
observations in naïve mice, a population of IL-22+ cells was present in healthy human 
intestinal samples that lacked expression of lineage markers CD20, CD56 and CD3 
(Figure 18E), and were CD127+, CD45INT and RORγt+ (Figure 18F), a phenotype 
consistent with human IL-22-producing ILCs (Sonnenberg et al., 2011a; Spits and Di 
Santo, 2010).  IL-22+ lineage negative (Figure 18G), CD127+, CD45INT, RORγt+ ILCs 
were also constitutively found in the mLNs of health human donors (Figure 18H).  
Collectively, these data identify that the steady state compartmentalization of 
commensal bacteria is associated with the constitutive presence of IL-22+ ILC population 
in the intestine and GALT of healthy humans and mice. 
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3.4.2 Depletion of ILCs promotes peripheral bacterial dissemination and induction 
of systemic inflammation 
To test whether the constitutive populations of IL-22-producing ILCs contribute to 
compartmentalization of commensal bacteria, control or anti-CD90 mAb was 
administered to naïve Rag1-/- mice to deplete ILC populations.  Depletion of CD90+ ILCs 
resulted in a significant reduction in intestinal mRNA levels for genes encoding IL-22-
dependent anti-microbial peptides RegIIIβ (Figure 19A) and RegIIIγ (Figure 19B).  While 
tissues obtained from control-treated Rag1-/- mice did not exhibit the presence of live 
bacteria in the spleen, blood or liver (Figure 19C-E), peripheral tissues from anti-CD90 
mAb-treated Rag1-/- mice contained culturable bacteria in these organs (Figure 19C-E), 
indicating a critical role for ILCs in promoting compartmentalization of commensal 
bacteria in the steady state and preventing their dissemination to peripheral organs.  
Consistent with the presence of culturable bacteria in systemic organs, depletion of ILCs 
resulted in significantly increased levels of LPS in the liver (Figure 19F).  Some NK cells 
also express CD90 (Hurme and Sihvola, 1984); however, administration of an NK cell-
depleting mAb (anti-NK1.1) alone to Rag1-/- mice did not result in detection of culturable 
bacteria or LPS in systemic organs (Figure 19C-F).  Collectively, these data indicate a 
selective requirement for IL-22-producing ILCs in containing commensal bacteria to the 
intestinal compartment. 
 Dissemination of commensal bacteria has been proposed to cause systemic 
inflammation associated with chronic human diseases (Brenchley et al., 2006; Lescut et 
al., 1990; McGuckin et al., 2009; Parlesak et al., 2000).  To examine whether depletion 
of ILCs and subsequent peripheral bacterial dissemination elicits chronic systemic 
immune activation, anti-CD90 mAb was administered to naïve Rag1-/- mice.  Consistent 
with the presence of culturable bacteria and microbial byproducts in the periphery, ILC-
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depleted mice exhibited discrete foci of hepatic inflammation (Figure 19G, black arrow), 
as well as increased spleen size (Figure 19H), significantly increased spleen mass 
(Figure 19I) and elevated serum levels of inflammatory cytokines IL-6 (Figure 19J) and 
TNFα (Figure 19K) in comparison to control treated mice.  Collectively, these data 
indicate that ILCs regulate containment of commensal bacteria to intestinal tissues in the 
steady state, and that in the absence of ILCs, commensal bacteria disseminate to 
peripheral organs, disrupt systemic immune cell homeostasis and promote inflammation. 
 
3.4.3 ILCs regulate commensal bacterial dissemination and systemic inflammation 
in an IL-22-dependent manner 
ILCs secrete IL-22 and promote intestinal immunity and repair in an IL-22-dependent 
manner (Sonnenberg et al., 2011a; Spits and Di Santo, 2010).  To test whether IL-22 is 
critical for ILC-mediated containment of commensal bacteria to the intestine, Rag1-/- 
mice were treated with isotype or anti-IL-22 mAb.  In comparison to isotype mAb-treated 
mice, anti-IL-22 mAb-treated mice exhibited significantly decreased intestinal levels of 
mRNA encoding the anti-microbial peptides RegIIIβ (Figure 20A) and RegIIIγ (Figure 
20B).  Similar to anti-CD90 mAb-treated mice (Figure 19C-E), culturable bacteria could 
be isolated from the spleen (Figure 20C), blood (Figure 20D) and liver (Figure 20E) of 
anti-IL-22 mAb-treated mice but not isotype mAb-treated mice.  Significantly increased 
hepatic LPS (Figure 20F) was also observed in anti-IL-22 mAb-treated mice in 
comparison to isotype mAb-treated mice.  Consistent with a role for disseminating 
commensal bacteria in inducing systemic inflammation, anti-IL-22 mAb-treated mice also 
exhibited signs of systemic inflammation including hepatic inflammatory cell infiltrates 
(Figure 20G) and significantly increased splenic mass (Figure 20H).  These data 
demonstrate that neutralization of IL-22 in Rag1-/- mice is sufficient to promote bacterial 
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dissemination and systemic inflammation similar to that observed following depletion of 
ILCs, suggesting that ILCs limit peripheral dissemination of commensal bacteria in an IL-
22-dependent manner.   
 To determine whether delivery of IL-22 can be used to therapeutically prevent 
bacterial dissemination in ILC-depleted mice, a gain-of-function approach was employed 
in which anti-CD90 mAb-treated Rag1-/- mice were treated with either PBS control or 
recombinant (r) IL-22.  Administration of rIL-22 to anti-CD90 mAb-treated mice restored 
intestinal expression of mRNA encoding RegIIIβ (Figure 20I) and RegIIIγ (Figure 20J) to 
levels observed in isotype mAb-treated mice.  Consistent with a role for ILC-derived IL-
22 in limiting bacterial dissemination, ILC-depleted mice that received rIL-22 exhibited 
decreased CFUs in the spleen (Figure 20K), blood (Figure 20L) and liver (Figure 20M), 
and significantly decreased levels of LPS in the liver (Figure 20N) as compared to anti-
CD90 mAb-treated mice that received PBS.  Collectively, these data demonstrate that 
ILCs regulate containment of commensal bacteria and prevention of systemic immune 
activation in an IL-22-dependent manner, and that delivery of IL-22 can be used to 
therapeutically reduce bacterial dissemination in the absence of ILCs. 
 
3.4.4 ILCs regulate commensal bacterial dissemination and systemic inflammation 
in lymphocyte-replete hosts 
T cells can express IL-22 and promote maintenance of intestinal immunity and repair 
(Sonnenberg et al., 2010a, 2011a), and the adaptive immune system has been shown to 
control bacterial dissemination in the face of impaired innate immunity (Hooper and 
Macpherson, 2010; Slack et al., 2009).  Therefore, to test whether ILCs regulate the 
containment of commensal bacteria in lymphocyte-replete mice, CD90-disparate Rag1-/- 
chimeric mice that permit selective depletion of CD90.2+ ILCs without depleting CD90.1+ 
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lymphocytes were generated (Figure 21A).  Despite the presence of lymphocytes, 
administration of ILC-depleting anti-CD90.2 mAb resulted in bacterial dissemination as 
determined by significantly elevated levels of LPS in the liver (Figure 21B), and the 
induction of systemic inflammation as measured by inflammatory cell infiltrates in the 
liver (Figure 21C), significantly increased spleen mass (Figure 21D) and higher serum 
levels of IL-6 (Figure 21E) and TNFα (Figure 21F).  ILC-depleted lymphocyte-replete 
mice exhibited significantly higher frequencies of proliferating peripheral lymphocytes as 
measured by an increased frequency of Ki-67+ cells among CD4+ T cells (Figure 21G), 
CD8+ T cells (Figure 21H) and CD19+ B cells (Figure 21I) in the spleen.  Collectively, 
these data suggest that IL-22-producing ILCs regulate containment of commensal 
bacteria and maintain systemic immune cell homeostasis in the presence of adaptive 
immunity. 
 
3.4.5 ILC depletion results in commensal bacteria-specific systemic inflammation 
Depletion of ILCs in lymphocyte-replete hosts results in significant activation of the 
adaptive immune system (Figure 21G-I).  To determine if the adaptive immune 
responses were specific for disseminating bacteria, splenocyte cultures were 
restimulated with antigen derived from cecal-resident commensal bacteria.  Significantly 
higher frequencies of IL-6+ CD4+ T cells and TNFα+ CD4+ T cells were observed in 
stimulated splenocyte cultures from anti-CD90.2 mAb-treated chimeric mice as 
compared to isotype mAb-treated chimeric mice (Figure 22A).  Furthermore, significantly 
increased serum levels of intestinal commensal bacteria-specific IgG were detected in 
anti-CD90.2 mAb-treated mice in comparison to isotype mAb-treated mice (Figure 22B), 
demonstrating that ILC-depletion results in the generation of systemic CD4+ T cell and B 
cell responses specific for disseminating commensal bacteria.  
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 To determine whether dissemination of commensal bacteria was necessary to 
promote systemic inflammation, naïve Rag1-/- mice were administered a cocktail of oral 
antibiotics previously shown to significantly deplete intestinal bacteria (Hill et al., 2010).  
Rag1-/- mice on water alone and those receiving antibiotics were then administered 
either an isotype mAb or an anti-CD90 mAb to deplete ILCs.  Consistent with depletion 
of intestinal commensal bacteria, no culturable bacteria were present in the spleen, 
blood or liver of isotype mAb or anti-CD90 mAb-treated Rag1-/- during antibiotic 
treatment, in comparison to non-antibiotic anti-CD90 mAb-treated controls (data not 
shown).  Further, no significant increase in hepatic levels of LPS was observed in 
antibiotic-treated Rag1-/- mice following anti-CD90 mAb administration, in comparison to 
non-antibiotic controls (Figure 22C).  Antibiotic-treated anti-CD90 mAb administered 
Rag1-/- mice did not exhibit signs of systemic inflammation as splenic size (Figure 22D) 
and serum levels of IL-6 (Figure 22E) were similar in isotype and anti-CD90 mAb treated 
antibiotic administered mice.  Collectively, these data demonstrate that loss of IL-22-
producing ILCs promotes peripheral dissemination of commensal bacteria and 
subsequently commensal bacteria-dependent inflammation.  
 
3.5 Discussion 
Commensal bacteria promote numerous beneficial processes to mammalian hosts, but 
also have the potential to cause harmful chronic inflammation (Hill and Artis, 2010; 
Hooper and Macpherson, 2010).  Therefore, compartmentalization of commensal 
bacteria to intestinal tissues is necessary to maintain systemic immune cell homeostasis.  
Indeed, loss of containment of commensal bacteria has recently been proposed to 
contribute to systemic inflammation associated with numerous chronic human diseases 
including HIV infection, IBD, cancer and hepatitis (Brenchley et al., 2006; Lescut et al., 
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1990; McGuckin et al., 2009; Parlesak et al., 2000); however, the mechanisms that 
regulate this containment remain unclear.  Recent studies have identified IL-22 as a 
critical mediator of infectious and inflammatory diseases at barrier surfaces such as the 
intestine (Sonnenberg et al., 2011).  Indeed, neutralization of IL-22 can result in 
increased susceptibility to pathologic intestinal inflammation or enteric bacterial infection 
(Pickert et al., 2009; Sugimoto et al., 2008; Zenewicz et al., 2008; Zheng et al., 2008).  
Innate immune cells have been recognized to be important regulators of this IL-22-
dependent pathway of intestinal immunity and inflammation (Pickert et al., 2009; 
Zenewicz et al., 2008; Zheng et al., 2008).  Recently, ILCs have been found to be an 
important innate source of IL-22 that contributes to the regulation of intestinal immunity 
and inflammation (Buonocore et al., 2010; Sonnenberg et al., 2011a; Spits and Di Santo, 
2010).  Data presented in Chapter 2 identified a critical role for IL-22-producing ILCs in 
promoting immunity to the enteric bacterial pathogen Citrobacter rodentium.  Data 
presented in this Chapter now identify a previously unrecognized pathway by which IL-
22-producing ILCs regulate intestinal and systemic immune cell homeostasis in the 
steady state by regulating compartmentalization of commensal bacteria, limiting 
peripheral dissemination and preventing induction of systemic inflammation.  
Collectively, these studies demonstrate a novel ILC-IL-22 pathway that mediates 
intestinal immunity and limits intestinal inflammation in the context of numerous 
diseases. 
 Currently, it remains unclear what secondary mediators downstream of IL-22 or 
what additional ILC-derived factors are regulating compartmentalization of commensal 
bacteria.  IL-22 has previously been shown to be a potent inducer of mucins and anti-
microbial peptide expression in intestinal epithelial cells, which may account for the role 
of IL-22 in infection and inflammation (Sugimoto et al., 2008; Zheng et al., 2008).  
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Further, ILCs also have the capacity to express additional cytokines including IL-17A, IL-
17F, IFNγ, TNFα and lymphotoxin-β (Buonocore et al., 2010; Sonnenberg et al., 2011a; 
Takatori et al., 2009), all factors that have the capacity to regulate intestinal epithelial 
cells.  Future studies will be necessary to identify whether additional ILC-expressed 
factors and which IL-22 downstream mediators contribute to the containment of intestinal 
commensal bacteria. 
 In summary, data presented in this Chapter identifies that IL-22-producing ILCs 
are constitutively present in healthy intestine and GALT of humans and mice, provoking 
the hypothesis that this pathway may become dysregulated in chronic human diseases, 
promoting dissemination of commensal bacteria and contributing to the induction of 
systemic inflammation.  Consistent with this, IL-22 expression has been observed to be 
dysregulated in numerous chronic human diseases including HIV, cancer, IBD and 
hepatitis (Brand et al., 2007; Dambacher et al., 2008; Misse et al., 2007; Sugimoto et al., 
2008; Thompson et al., 2010a).  Further, these chronic human diseases are associated 
with systemic inflammation and induction of anti-bacterial responses with characteristics 
similar to that observed following depletion of murine ILCs (Brenchley et al., 2006; Chin 
et al., 2007; Douek et al., 2009; Fava and Danese, 2011; Lescut et al., 1990; McGuckin 
et al., 2009; Parlesak et al., 2000; Sandler et al., 2011a; Sandler et al., 2011b).  
Notwithstanding this, the identification of a pathway by which IL-22-producing ILCs 
regulate containment of commensal bacteria to limit peripheral dissemination and 
disruption of systemic immune cell homeostasis in mice could represent a novel 
therapeutic target to limit systemic inflammation associated with chronic human diseases 
and thus limit disease progression.  
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Figure 18. Innate lymphoid cells are constitutively present and a dominant source 
of IL-22 in the intestine and GALT of healthy mice and humans. (A) The frequency 
of live IL-22+ cells was examined from briefly ex vivo-stimulated cells of small intestine of 
naïve C57BL/6 mice.  The gated live IL-22+ population was stained with anti- CD3 and 
NK1.1 mAbs.  (B) The gated live IL-22+ population was stained with anti- CD127, CD45, 
RORγt and CD90 mAbs (open blue histogram) and compared to B cell populations 
(CD19+, solid grey histograms). (C) The frequency of live IL-22+ cells was examined from 
briefly ex vivo-stimulated cells of mLN of naïve C57BL/6 mice.  The gated live IL-22+ 
population was stained with anti- CD3 and NK1.1 mAbs.  (D) The gated live IL-22+ 
population was stained with anti- CD127, CD45, RORγt and CD90 mAbs (open blue 
histogram) and compared to B cell populations (CD19+, solid grey histograms). (E) The 
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frequency of live IL-22+ cells was examined from briefly ex vivo-stimulated cells of ileum 
of healthy human donors.  The gated live IL-22+ population was stained with anti- CD3, 
CD20 and CD56 mAbs.  (F) The gated live IL-22+ population was stained with anti- 
CD127, CD45 and RORγt mAbs (open blue histogram) and compared to negative 
populations (CD20+ CD56+, solid grey histograms).  (G) The frequency of live IL-22+ cells 
was examined from briefly ex vivo-stimulated cells of mLN of healthy human donors.  
The gated live IL-22+ population was stained with anti- CD3, CD20 and CD56 mAbs.  (H) 
The gated live IL-22+ population was stained with anti- CD127, CD45 and RORγt mAbs 
(open blue histogram) and compared to negative populations (CD20+ CD56+, solid grey 
histograms).  All data are representative of 2-3 independent experiments of 3 mice each 
per experiment or 5 total individual human donors.  
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Figure 19. Innate lymphoid cells limit bacterial dissemination and systemic 
immune activation in naïve mice.  Naïve C57BL/6 Rag1-/- mice were administered an 
isotype control, anti-CD90 or anti-NK1.1 mAb starting on day 0 and sacrificed on day 14.  
Fold induction of (A) Reg3b and (B) Reg3g transcript in terminal ileum epithelial from 
antibody treated mice.  Colony forming units (CFU) present in homogenates from the (C) 
spleen, (D) blood and (E) liver of antibody treated mice.  (F) LPS concentrations in 
homogenates from the liver of antibody treated mice.  (G) H&E stained histological 
sections of the liver of antibody treated mice; inflammatory cell infiltrates (black arrows).  
Spleen size (H) and mass (I) from antibody treated mice.  Serum concentrations of (J) 
IL-6 and (K) TNFα from antibody treated mice.  All data are representative of 3 
independent experiments with a minimum of 3-4 mice per group.  Data shown are the 
mean ± SEM.  * p < 0.05  ** p < 0.01.  ND, none detected.  
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Figure 20.  IL-22 limits bacterial dissemination and systemic immune activation.  
Naïve C57BL/6 Rag1-/- mice were administered an isotype control or anti-IL-22 mAb 
starting on day 0 and sacrificed on day 14.  Fold induction of (A) Reg3b and (B) Reg3g 
transcript in terminal ileum epithelial from antibody treated mice.  Colony forming units 
(CFU) present in homogenates from the (C) spleen, (D) blood and (E) liver of antibody 
treated mice.  (F) LPS concentrations in homogenates from the liver of antibody treated 
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mice.  (G) H&E stained histological sections of the liver of antibody treated mice; 
inflammatory cell infiltrates (black arrows).  (H) Spleen mass from antibody treated mice.  
Naïve C57BL/6 Rag1-/- mice were administered an isotype control or anti-CD90 mAb with 
PBS control or recombinant (r) IL-22 starting on day 0 and sacrificed on day 14.  Fold 
induction of (I) Reg3b and (J) Reg3g transcript in terminal ileum epithelial from antibody 
treated mice.  Colony forming units (CFU) present in homogenates from the (K) spleen, 
(L) blood and (M) liver of antibody treated mice.  (N) LPS concentrations in 
homogenates from the liver of antibody treated mice.  All data are representative of 2 or 
more independent experiments with a minimum of 3-4 mice per group.  Data shown are 
the mean ± SEM.  * p < 0.05  ** p < 0.01.  ND, none detected.  
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Figure 21.  Innate lymphoid cells prevent bacterial dissemination and systemic 
immune activation in lymphocyte-replete mice.  (A) Representative flow cytometry 
plots of generated CD90-disparate chimeras demonstrating depletion of recipient 
CD90.2+ cells but not donor CD90.1+ cells in the spleens of anti-CD90.2 mAb treated 
chimeras (middle) in comparison to isotype mAb treated chimeras (left). CD3 expression 
on gated CD90.2+ cells (grey shaded histogram) and CD90.1+ cells (open blue 
histogram) in the spleen of isotype mAb treated chimeras (right).  (B) LPS 
concentrations in homogenates from the liver of antibody treated chimeras.  (C) H&E 
stained histological sections of the liver of antibody treated chimeras; inflammatory cell 
infiltrates (black arrows).  (D) Spleen mass from antibody treated chimeras.  Serum 
concentrations of (E) IL-6 and (F) TNFα from antibody treated chimeras.  Frequency of 
Ki-67+ cells in gated live (G) CD4+ T cells, (H) CD8+ T cells and (I) CD19+ B cells in the 
spleens of antibody treated chimeras.  All data are representative of 2 or more 
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independent experiments with a minimum of 3-4 mice per group.  Data shown are the 
mean ± SEM.  * p < 0.05  ** p < 0.01.  
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Figure 22. Loss of innate lymphoid cells promotes commensal bacterial-driven 
systemic inflammation.  Rag1-/- chimeras were administered an isotype control or anti-
CD90.2 mAb starting on day 0 and sacrificed on day 14.  Splenocytes from antibody 
treated chimeras were stimulated in vitro with antigen (ag) isolated from cecal bacteria, 
gated on live CD4+ T cells and analyzed for the frequency of (A) IL-6+ cells (top) and 
TNFα+ (bottom) cells.  (B) Sera from antibody treated chimeras were measured for 
specificity against antigen isolated from cecal bacteria.  Naïve C56BL/6 Rag1-/- chimeras 
were continuously administered water with/without antibiotics for 14 days, and then 
administered an isotype control or anti-CD90.2 mAb for an additional 14 days. (C) LPS 
concentrations in homogenates from the liver of antibody treated mice.  Spleen size (D) 
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and serum concentrations of IL-6 (E) from antibody treated mice.  All data are 
representative of 2 independent experiments with a minimum of 3-4 mice per group.  
Data shown are the mean ± SEM.  * p < 0.05  ** p < 0.01 *** p < 0.001. 
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Chapter 4  
Pathological versus protective functions of IL-22 in airway inflammation are 
regulated by IL-17A 
 
4.1 Abstract 
Data presented in Chapter 2 and 3 of this thesis interrogated the role of IL-22 in 
maintaining intestinal barrier function and immunity in the context of steady state 
homeostasis or enteric bacterial infection.  Previous studies have identified that in 
addition to anti-microbial properties, IL-22 has both proinflammatory and tissue-
protective properties depending on the context in which it is expressed (reviewed in 
Chapter 1.2.5).  However, the factors that influence the functional outcomes of IL-22 
expression remain poorly defined.  Data presented in this Chapter demonstrate that 
following administration of a high-dose of bleomycin that induces acute tissue damage 
and airway inflammation and is lethal to wild-type (WT) mice, T helper 17 (Th17) cell-
derived IL-22 and IL-17A are expressed in the lung.  Bleomycin-induced disease was 
ameliorated in Il22-/- mice or following anti-IL-22 mAb treatment of WT mice, indicating a 
proinflammatory/pathologic role for IL-22 in airway inflammation.  However, despite 
increased bleomycin-induced IL-22 production, Il17a-/- mice were protected from airway 
inflammation, suggesting that IL-17A may regulate the expression and/or 
proinflammatory properties of IL-22.  Consistent with this, IL-17A inhibited IL-22 
production by Th17 cells, and exogenous administration of IL-22 could only promote 
airway inflammation in vivo by acting in synergy with IL-17A.  Anti-IL-22 mAb was 
delivered to Il17a-/- mice and was found to exacerbate bleomycin-induced airway 
inflammation, indicating that IL-22 is tissue-protective in the absence of IL-17A.  Finally, 
in an in vitro culture system, IL-22 administration protected airway epithelial cells from 
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bleomycin-induced apoptosis, and this protection was reversed following co-
administration of IL-17A.  These data identify that IL-17A can regulate the expression, 
proinflammatory properties, and tissue-protective functions of IL-22, and indicate that the 
presence or absence of IL-17A governs the proinflammatory versus tissue-protective 
properties of IL-22 in a model of airway damage and inflammation. 
 
4.2 Introduction 
IL-22 is a member of the IL-10 cytokine family and plays critical roles in inflammation, 
immune surveillance, and tissue homeostasis at mucosal sites (Colonna, 2009; Ouyang 
et al., 2008).  IL-22 is produced by CD4+ T helper (Th)17 cells, NK cells, CD11c+ myeloid 
cells and ILCs (Cella et al., 2009; Liang et al., 2006; Takatori et al., 2009; Zheng et al., 
2008).  The IL-22 receptor is composed of the IL-22R and IL-10R2 subunits and receptor 
ligation results in phosphorylation of STAT1, STAT3, STAT5, and activation of the p38-
MAP kinase pathway (Kotenko et al., 2001a; Lejeune et al., 2002).  The IL-22 receptor is 
found on cells of non-hematopoietic origin in the skin, kidney, liver, lung and gut, 
allowing for IL-22-mediated regulation of local epithelial, endothelial, and stromal cell 
responses following infection or exposure to inflammatory stimuli (Ouyang et al., 2008; 
Wolk et al., 2004).  Despite significant insights into IL-22-IL-22R interactions, reports on 
the in vivo functions of this pathway have been conflicting (Zenewicz and Flavell, 2008).  
For example, following infection with gram-negative bacteria, IL-22 can enhance 
maintenance of the epithelial barrier, and act in synergy with the Th17 cell co-expressed 
cytokine IL-17A to promote host protective immunity against infection (Aujla et al., 2008; 
Liang et al., 2006; Zheng et al., 2008).  In addition to anti-microbial properties, a number 
of studies have reported tissue-protective properties of IL-22 in murine models of 
inflammatory bowel disease (IBD) and hepatitis (Pan et al., 2004; Pickert et al., 2009; 
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Radaeva et al., 2004; Sugimoto et al., 2008; Zenewicz et al., 2007; Zenewicz et al., 
2008).  In contrast, other studies have demonstrated that IL-22 has 
proinflammatory/pathologic properties following Toxoplasma gondii infection, a 
CD45RBlo T cell transfer model of colitis and in mouse models of psoriasis and arthritis 
(Geboes et al., 2009; Kamanaka et al., 2011; Ma et al., 2008b; Munoz et al., 2009; 
Zheng et al., 2007). 
 Although IL-22 is known to induce expression of anti-microbial peptides following 
Klebsiella pneumoniae infection in the lung (Aujla et al., 2008), the influence of the IL-22 
pathway on the development, progression, and resolution of airway inflammation in other 
systems has not yet been examined.  Employing a model of high-dose bleomycin-
induced acute tissue damage and airway inflammation (Huaux et al., 2003; Matute-Bello 
et al., 2008; Nagai et al., 1992; Snider et al., 1978), data in this Chapter demonstrates 
that a CD4+ Th17 cell response ensues following treatment of wild-type (WT) mice, 
characterized by the production of IL-22 and IL-17A in the lung.  Administration of anti-
IL-22 neutralizing mAb in WT mice or use of Il22-/- mice revealed a reduction in 
bleomycin-induced disease, indicative of a proinflammatory/pathologic role for IL-22 in 
airway inflammation.  As IL-17A and IL-22 are co-expressed and have been shown to 
act cooperatively (Aujla et al., 2008; Liang et al., 2006), the influence of IL-17A on IL-22 
expression and function in the lung was investigated by employing Il17a-/- mice.  Il17a-/- 
mice exhibited enhanced levels of bleomycin-induced IL-22 expression due to a loss of 
IL-17A-mediated suppression of IL-22 production in Th17 cells.  Despite increased IL-22 
expression, Il17a-/- mice were protected from bleomycin-induced airway inflammation, 
indicating that IL-22 acts in synergy with IL-17A to promote airway inflammation.  
Consistent with this, exogenous IL-22 could only promote airway inflammation when co-
administered with IL-17A.  Treatment of Il17a-/- mice with anti-IL-22 mAb exacerbated 
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bleomycin-induced inflammation, supporting a tissue-protective role for IL-22 in the 
absence of IL-17A.  Furthermore, IL-22 protected airway epithelial cells against 
bleomycin-induced apoptosis, and this property was reversed with the co-administration 
of IL-17A.  Collectively, these data demonstrate a pathologic role for IL-22 in a model of 
airway inflammation and identify that IL-17A can govern the proinflammatory/pathologic 
versus tissue-protective properties of IL-22 in the lung. 
 
4.3 Methods 
4.3.1 Mice, bleomycin instillation and monoclonal antibody treatments 
C57BL/6 mice were purchased from the Jackson Laboratory (Bar Harbor, ME).  C57BL/6 
Il17a-/- mice were kindly provided by Y. Iwakura (University of Tokyo, Tokyo, Japan).  
129 Il22-/- mice were generated at Lexicon Genetics in collaboration with Pfizer and 
subsequently backcrossed to Balb/cBy at the Jackson Laboratory with colony mates 
used for all groups.  All mice were maintained in specific pathogen-free facilities at the 
University of Pennsylvania.  All protocols were approved by the University of 
Pennsylvania Institutional Animal Care and Use Committee (IACUC), and all 
experiments were performed according to the guidelines of the University of 
Pennsylvania IACUC.  Bleomycin (NOVAPLUS, Irvine, CA) was administered 
intratracheally at either a lethal high-dose of 0.009 mg/g or at a low-dose of 0.0018 
mg/g.  Mice were sacrificed at 8-10 days or at reaching 70% of their original weight.  
Mice receiving antibody treatment were injected i.p. with 0.4 mg of either IL22-01 or an 
isotype control antibody (Pfizer) every 3 days starting on day 0. 
 
4.3.2 Isolation and analysis of lung and BAL cells 
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BAL cell and lung single cell suspensions were obtained as previously described (Nair et 
al., 2009).  Cells were stained with antibodies to the following markers Gr-1, CD11b, 
Ly6G, Ly6C, F4/80, MHCII, CD4, CD8, TCRβ, and TCRγδ (eBioscience).  For analysis 
of intracellular cytokine production, cells were stimulated directly ex vivo by incubation 
for 4 h with 50 ng/mL PMA, 750 ng/mL ionomycin, and 10 µg/mL Brefeldin A (all 
obtained from Sigma-Aldrich), or stimulated for 48 hours with soluble anti-CD3 
(eBioscience) followed by analysis of cytokine secretion by ELISA.  Intracellular staining 
was performed using a FITC and PE-conjugated IL-17A antibodies, Alexa Fluor 488 
conjugated IL-17F (eBioscience), and Alexa Fluor 647 conjugated IL22-02 antibody 
(Pfizer), the latter conjugated according to manufacturer’s instructions (Molecular 
Probes).  Dead cells were excluded from analysis using a violet viability stain 
(Invitrogen).  Flow cytometry data collection was performed on a FACSCanto II (BD 
Biosciences).  Files were analyzed using FlowJo software (Tree Star Inc.).  
Cytocentrifuge preparations of BAL cells were stained with H&E (Thermo Fisher 
Scientific). 
 
4.3.3 RNA isolation, cDNA preparation and RT-PCR 
RNA was isolated from whole lung tissue using mechanical homogenization and TRIzol 
isolation (Invitrogen), according to manufacturer’s instructions.  MLE cell RNA was 
isolated using RNeasy mini kits (QIAGEN).  cDNA was generated using Superscript 
reverse transcription (Invitrogen).  Real-time PCR (RT-PCR) was performed on cDNA 
using SYBR green chemistry (Applied Biosystems) and commercially available primer 
sets (QIAGEN).  Reactions were run on a real-time PCR system (ABI7500; Applied 
Biosystems).  Samples were normalized to β-actin and displayed as a fold induction over 
naïve or untreated controls unless otherwise stated.   
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4.3.4 Histological sections and pathology scoring 
Lungs were inflated with 4% paraformaldehyde, embedded in paraffin, and 5-µm 
sections were used for staining with H&E.  Severity of bleomycin-induced pathology was 
scored according to weight loss (1-10%:1; 10-15%:2; 15-20%:3; 20-25%:4; 25-30%:5), 
and blind scoring of H&E-stained lung tissue sections according to the following 
parameters: consolidation (1-5); fibrosis (1-5); granulocyte recruitment (1-5); lymphocyte 
recruitment (1-5); for an overall score out of 25. 
 
4.3.5 ELISA and immunofluorescence staining 
Standard IL-17A sandwich ELISAs were performed using commercially available 
antibodies (eBioscience).  Sandwich ELISAs for IL-22 were performed using IL22-01 
(Pfizer) as a capture antibody and biotin-conjugated IL22-03 (Pfizer) as a detection 
antibody.  Active TGFβ was measured from lung homogenates as previously described 
(Huaux et al., 2003) using a commercially available ELISA kit (eBioscience).  
Immunofluorescence staining was performed as previously described (Nair et al., 2009) 
using a commercially available antibody for TGFβ (Santa Cruz Biotechnology, Inc.). 
 
4.3.6 Instillation of recombinant cytokines 
Recombinant cytokines IL-17A (eBioscience) and IL-22 (Pfizer) in sterile PBS were 
administered intratracheally to Il17a-/- mice daily over a 3-day period at a dose of 1 
µg/mouse.  Mice were sacrificed on day 4 for analysis of the BAL and lung. 
 
4.3.7 In vitro splenocyte activation 
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Single cell suspensions were obtained from spleens of mice and red blood cells were 
lysed.  Splenocytes were then cultured with soluble anti-CD3 and anti-CD28 (1 µg/mL, 
eBioscience) in the presence of 10 ng/mL rIL-6, 1 ng/mL rTGFβ, 10 ng/mL rIL-23, 10 
µg/mL anti-IL-4, and 10 µg/mL anti-IFNγ.  rIL-17A and rIL-22 were added to cultures at 
designated concentrations.  Following 3-5 days of stimulation, cells were re-stimulated 
with PMA and Ionomycin in the presence of BFA for 4 hours followed by staining for 
intracellular cytokines.  
 
4.3.8 Electrophoresis and immunostaining 
Analysis was performed using standard SDS-PAGE and immunoblotting techniques.  
Biotin-conjugated anti-IL-22Rα1 (R&D Systems), anti-Actin, anti-phospho-STAT3 
(Tyr705), and total anti-STAT3 (Cell Signaling Technology), were used as primary 
antibodies followed by either streptavidin conjugated HRP (R&D Systems) or donkey 
anti-rabbit conjugated streptavidin (Amersham Biosciences).  Blots were developed 
using ECL detection reagents (GE Healthcare).  
 
4.3.9 MLE cell line, in vitro apoptosis assay 
The MLE cell line (ATCC#CRL-2110) was a kind gift from Dr. Michael F. Beers 
(University of Pennsylvania) and maintained in RPMI media supplemented with 2% FBS, 
5 µg/mL insulin, 10 µg/mL transferrin, 20 nM sodium selenite, 10 nM hydrocortisone, 10 
nM β-estradiol, 10 mM HEPES, and 2 mM L-glutamine.  Following seeding and 
adherence, apoptosis was induced by administration of bleomycin (2.5 U/mL) to cultures 
or PBS as a control.  rIL-22 (Pfizer) or rIL-17A (eBioscience) was added to cultures at 
designated concentrations and incubated for approximately 8 hours before harvesting 
using trypsin-EDTA (0.05%).  Cell suspensions were subsequently stained for annexin V 
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according to the manufacturer’s protocols (BD Biosciences). Cell cultures and paraffin 
embedded lung sections were stained using the TMR red in situ cell death detection kit 
(Roche) according to the manufacturer’s protocol. 
 
4.3.10 Statistical analysis 
Results represent the mean ± SEM.  Statistical significance was determined by the 
Student’s t test unless noted differently in the figure legend (*, p < 0.05; **, p < 0.01; ***, 
p < 0.001).  
 
4.4 Results 
4.4.1 A Th17 cell response develops during bleomycin-induced airway 
inflammation 
When administered at a high-dose, bleomycin results in airway damage and acute 
inflammation, characterized by production of inflammatory mediators and infiltration of 
lymphocytes and granulocytes, resulting in the disruption of lung architecture, decreased 
pulmonary function and death (Huaux et al., 2003; Matute-Bello et al., 2008; Nagai et al., 
1992; Snider et al., 1978).  These responses have been shown to be partially dependent 
on both T cells and the cytokines IL-6 and IL-12/23p40, as depletion or genetic deletion 
of any of these factors individually attenuates bleomycin-induced disease (Maeyama et 
al., 2001; Saito et al., 2008; Sakamoto et al., 2002).  Expression of IL-6 and IL-12/23p40 
also promotes Th17 cell differentiation and survival (Bettelli et al., 2006; Mangan et al., 
2006; McGeachy et al., 2009).  However, whether Th17 cells differentiate and 
extravasate to the lung following an instillation of high-dose bleomycin is unknown. 
To test this, either PBS or a high-dose of bleomycin that is lethal for WT mice 
was intra-tracheally instilled into C57BL/6 mice and mRNA isolated from whole lung 
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tissue was analyzed for cytokines associated with Th17 cell differentiation.  Although 
levels of Il6, Tgfb1, and Il12b were not significantly increased, Il23a transcript was 
significantly elevated in samples from bleomycin-instilled mice compared to PBS 
controls (Figure 23A).  Consistent with no significant changes in Tgfb1 mRNA, no 
upregulation of active TGFβ protein could be observed in the lung tissue of mice 
receiving a high-dose (H.D.) of bleomycin as determined by ELISA (Figure 24A) or 
immunofluorescence staining (Figure 24B) in comparison to PBS-instilled controls.  
Furthermore, increased active TGFβ protein could only be observed in the lungs of mice 
receiving a low-dose (L.D) of bleomycin, which is known to induce lung fibrosis (Figure 
24A-B).   
An increase in mRNA encoding the Th17 effector cytokines Il17a and Il22 was 
observed in the lungs of bleomycin-instilled mice (Figure 25A).  However, bleomycin-
induced inflammation was not associated with expression of IL-17F, as IL-17F could not 
be detected in the lungs by real-time PCR (data not shown), or intracellular staining 
(Figure 26A) compared to in vitro differentiated Th17 cells (Figure 26B).  
A previous study reported that following high-dose bleomycin instillation, TCRγδ+ 
cells were a dominant source of IL-17A (Braun et al., 2008).  To identify the cellular 
sources of IL-17A following bleomycin exposure, lung cell suspensions from bleomycin-
instilled C57BL/6 mice were isolated, stimulated briefly ex vivo and analyzed by flow 
cytometry for surface markers and intracellular cytokines.  Although 21% of the total IL-
17A+ cells were found to be TCRγδ+ cells, TCRβ+ cells constituted 65% of the total IL-
17A+ cells (Figure 25B, upper left and middle).  The majority of TCRβ+ cells that 
expressed IL-17A were CD4+, indicating that bleomycin induced a dominant CD4+ 
TCRβ+ Th17 cell response (Figure 25B, upper right).  Although unclear at present, 
differences in local environment stimuli, origin of mice, or the source, dose and kinetics 
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of administered bleomycin may contribute to whether TCRγδ+ or TCRαβ+ T cells are the 
dominant sources of IL-17A in the airway following bleomycin exposure.   
Analysis of IL-22+ cell populations revealed that pre-dominantly CD4+ TCRβ+ T 
cells produced IL-22 following bleomycin exposure (Figure 25B, bottom).  Although 
these data do not definitively rule out other cellular sources of IL-17A and IL-22, they 
indicate that CD4+ TCRβ+ T cells are the dominant source of both cytokines following 
instillation of high-dose bleomycin.  To determine if the observed IL-17A+ or IL-22+ CD4+ 
T cell populations were increased following bleomycin exposure, total numbers of 
cytokine-positive cells in the lungs were quantified.  In comparison to mice receiving 
PBS, mice exposed to bleomycin exhibited a significant increase in the total number of 
CD4+ T cells that expressed IL-17A or IL-22 (Figure 25C), and there were significantly 
elevated levels of IL-17A and IL-22 protein in supernatants of lung cultures following 
polyclonal T cell stimulation (Figure 25D).  To examine whether IL-17A and IL-22 were 
co-expressed in CD4+ Th17 cells following exposure to bleomycin, TCRβ+ CD4+ T cells 
from the bronchioalveolar lavage (BAL) and lung were analyzed by flow cytometry.  In 
comparison to PBS-instilled controls, bleomycin-instilled mice exhibited a significant 
increase in the frequency of TCRβ+ CD4+ T cells that expressed IL-17A alone, IL-22 
alone, or co-expressed IL-17A and IL-22 in the BAL (Figure 25E, top, Figure 25F).  
Additionally in the lung, bleomycin-exposed WT mice exhibited a significant increase in 
the frequency of TCRβ+ CD4+ T cells that expressed IL-17A alone, and a trend towards 
an increase in the frequency of those that co-expressed IL-17A and IL-22 (Figure 25E, 
bottom).  Collectively, these data demonstrate that following bleomycin instillation, a 
CD4+ Th17 cell response develops in WT mice, characterized by expression of IL-17A 
and IL-22 in the airway. 
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4.4.2 Neutralization of IL-22 protects mice from bleomycin-induced airway 
inflammation 
IL-22 has proinflammatory and tissue-protective properties in a number of different 
disease settings (Zenewicz and Flavell, 2008).  To interrogate the influence of IL-22 on 
acute airway damage and inflammation, bleomycin-exposed C57BL/6 mice were treated 
with either isotype control or anti-IL-22 neutralizing mAb.  In comparison to PBS-instilled 
mice that had a BAL cellularity of 20 x 103 ± 9 x 103, bleomycin-instilled, isotype control 
mAb-treated mice exhibited a marked increase in cellular recruitment to the BAL (Figure 
27A).  Examination and differential quantification of H&E-stained cytocentrifuge BAL 
preparations isolated from isotype control mAb treated bleomycin-instilled mice revealed 
that the cellular infiltrate was composed of neutrophils (Figure 27B, white arrow), 
lymphocytes and macrophages (Figure 28A).  In addition, a population of Gr-1+ SSChi 
neutrophils was found in dissociated lung tissue isolated from bleomycin-instilled mice 
(Figure 27C).  The Gr-1+ cells in the lung of bleomycin-treated WT mice were confirmed 
to be neutrophils as the majority co-expressed CD11b (Figure 29A), Ly6C (Figure 29B), 
Ly6G (Figure 29C), and lacked expression of F4/80 (Figure 29D) and MHCII (Figure 
29E).  Examination of H&E-stained lung sections from bleomycin-instilled mice revealed 
leukocyte infiltration (Figure 27D, black arrows) and disruption of lung architecture 
(Figure 27D, white arrows).  Associated with airway inflammation, weight loss was 
observed in bleomycin-instilled mice (Figure 27E).   
 In contrast, administration of anti-IL-22 neutralizing mAb to bleomycin-exposed 
mice resulted in a reduction in the total number of inflammatory cells infiltrating into the 
BAL (Figure 27A).  A marked reduction in neutrophilia was observed by microscopic 
examination of BAL cell preparations (white arrows, Figure 27B, Figure 28A), and a 
significant reduction in both the frequency and total number of neutrophils was observed 
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by flow cytometric analysis of dissociated lung tissue in those mice receiving an anti-IL-
22 neutralizing mAb (Figure 27C).  Histological analysis revealed that blockade of IL-22 
also resulted in reduced leukocyte recruitment (Figure 27D, black arrows), and less 
disruption of lung architecture (Figure 27D, white arrows).  Associated with decreased 
inflammation, anti-IL-22-treated mice were protected from bleomycin-induced weight 
loss (Figure 27E).  A pathological score combining weight loss and histological changes 
revealed that blockade of IL-22 significantly protected mice from bleomycin-induced 
pathology (Figure 27F).   
 Consistent with anti-IL-22 mAb treatment of WT mice, bleomycin-treated Il22-/- 
mice exhibited a decrease in cell recruitment to the BAL (Figure 30A), a reduction in 
airway neutrophilia (Figure 30B-C), less severe disruption in lung architecture (Figure 
30D), significantly reduced weight loss (Figure 30E), and a significant reduction in 
pathology scoring (Figure 30F) compared to bleomycin-exposed Il22+/+ littermate 
controls.  Taken together, these data indicate that IL-22 production is pathologic in 
bleomycin-induced airway inflammation, promoting inflammatory cell recruitment, 
disruption of lung architecture, and weight loss. 
 
4.4.3 Airway inflammation is reduced in Il17a-/- mice despite an increase in 
bleomycin-induced IL-22 expression 
IL-22 and IL-17A are co-expressed by Th17 cells, and can act cooperatively in the 
induction of anti-microbial peptides and inflammatory mediators (Aujla et al., 2008; Liang 
et al., 2006).  To test whether the expression or functions of IL-22 in the lung were 
dependent on the presence of IL-17A, bleomycin was instilled into WT and Il17a-/- mice.  
Flow cytometric analysis of the BAL revealed a significant increase in the frequency of 
IL-22+ CD4+ T cells from bleomycin-instilled Il17a-/- mice compared to WT mice (Figure 
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31A-B).  In addition, there were significantly increased levels of IL-22 in supernatants of 
polyclonally-stimulated lymphocytes isolated from the lungs of bleomycin-instilled Il17a-/- 
mice compared to WT mice (Figure 31C).  To test if IL-17A regulates IL-22 expression, 
splenocytes were isolated from naïve WT or Il17a-/- mice and polyclonally stimulated 
under conditions permissive for Th17 cell differentiation.  There was a marked increase 
in both the frequency and mean fluorescent intensity (MFI) of IL-22+ CD4+ T cells in 
splenocyte cultures from Il17a-/- mice compared to WT cultures (Figure 32A).  
Furthermore, addition of rIL-17A to splenocyte cultures from Il17a-/- mice suppressed the 
frequency and MFI of IL-22+ CD4+ T cells in a dose-dependent manner (Figure 32B), 
resulting in a significant decrease in IL-22 protein levels in culture supernatants (Figure 
32C).  Conversely, IL-22 did not appear to regulate expression of IL-17A, as bleomycin 
instilled Il22-/- mice produced equivalent levels of IL-17A to WT mice (Figure 32D), and 
addition of rIL-22 to splenocyte cultures isolated from Il22-/- mice did not suppress IL-17A 
production (Figure 32E).  Collectively, these results indicate that IL-17A can inhibit 
expression of IL-22 in Th17 cells. 
Given that the in vivo neutralization of IL-22 reduced bleomycin-induced 
inflammation in WT mice, it was hypothesized that the elevated IL-22 levels in 
bleomycin-instilled Il17a-/- mice would correlate with exacerbated inflammation.  
However, there was a reduction in the cellularity of the BAL in Il17a-/- mice compared to 
WT mice following bleomycin instillation (Figure 33A).  Further, there was a marked 
reduction in the bleomycin-induced neutrophil responses in the BAL of Il17a-/- mice 
compared to WT mice (Figure 33B, white arrows, Figure 28B), correlating with a 
significant reduction in the frequency and total number of neutrophils in the lung 
parenchyma (Figure 33C).  The decreased inflammatory cell recruitment in the BAL and 
lung of Il17a-/- compared to WT mice was associated with reduced leukocyte infiltrates 
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(Figure 33D, black arrows), less disruption of lung architecture (Figure 33D, white 
arrows), and protection from bleomycin-induced weight loss (Figure 33E).  Pathological 
scoring confirmed that the absence of IL-17A significantly protected mice from 
bleomycin-induced disease (Figure 33F), thereby demonstrating that abrogation of IL-
17A also protects mice from bleomycin-induced airway inflammation.  
Previous studies demonstrated that IL-22 acts synergistically with IL-17A to 
promote inflammation and provide protection in the context of infection with a gram-
negative pathogen (Aujla et al., 2008), while administration of rIL-22 alone failed to 
promote neutrophil recruitment into the airway (Liang et al., 2007).  Therefore, it was 
hypothesized that blockade of either IL-17A or IL-22 protected against bleomycin-
induced disease because the proinflammatory properties of IL-22 require synergy with 
IL-17A.  To test this hypothesis either rIL-17A alone, or rIL-22 alone, or rIL-17A and rIL-
22 in combination was intra-tracheally instilled into Il17a-/- mice.  Instillation of either IL-
22 alone or IL-17A alone resulted in a significant increase in lung expression of Il6, but 
not of the neutrophil chemoattractant Cxcl1 (Figure 34A).  Consistent with this, 
instillation of either IL-17A or IL-22 alone did not result in a significant increase in 
frequency (Figure 34B-C) or total number (Figure 34D) of neutrophils in the BAL or lung.  
In contrast, co-administration of both IL-17A and IL-22 resulted in a significant increase 
in mRNA expression encoding Il6 and Cxcl1 in the lungs of mice (Figure 34A).  
Examination of the BAL and lungs revealed that mice receiving co-administration of both 
IL-17A and IL-22 exhibited a significant increase in the frequency (Figure 34B-C), and 
total number (Figure 34D) of neutrophils recruited to the airway.  Collectively, these 
results indicate that in vivo IL-22 alone is not proinflammatory in the airway, however, IL-
22 can act synergistically with IL-17A to promote expression of inflammatory cytokines 
and chemokines, leading to the recruitment of neutrophils to the airway. 
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4.4.4 IL-22 is tissue-protective in the absence of IL-17A 
As Il17a-/- mice exhibited elevated levels of IL-22 yet failed to develop bleomycin-induced 
inflammation, it was hypothesized that the function of IL-22 in airway inflammation may 
differ in the absence of IL-17A.  To test this hypothesis, anti-IL-22 neutralizing mAb was 
administered to bleomycin-instilled Il17a-/- mice.  Consistent with earlier findings (Figure 
33), Il17a-/- mice receiving an isotype control antibody demonstrated minimal signs of 
bleomycin-induced inflammatory cell recruitment (Figure 35A-C), less disruption in lung 
architecture (Figure 35D), and reduced weight loss (Figure 35E) compared to WT 
controls.  In contrast, administration of anti-IL-22 neutralizing mAb to bleomycin-instilled 
Il17a-/- mice resulted in a significant increase in cell recruitment to the BAL (Figure 35A) 
and correlated with increased neutrophilia in the BAL (Figure 35B, white arrows, Figure 
28C) and lung (Figure 35C).   
Microscopic examination of H&E-stained lung sections revealed increased 
leukocyte infiltration (Figure 35D, black arrows) and elevated disruption in lung 
architecture (Figure 35D, white arrows) in anti-IL-22 treated Il17a-/- mice.  Epithelial cells 
in lung tissue examined from Il17a-/- mice in which IL-22 was neutralized demonstrated 
increased hyperplasia and loss of normal morphology in comparison to isotype control-
treated Il17a-/- mice following bleomycin administration (Figure 35D, grey arrows), 
indicating that IL-22 may influence integrity of the epithelial barrier in the absence of IL-
17A.  Neutralization of IL-22 led to exacerbated weight loss in bleomycin-instilled Il17a-/- 
mice compared to isotype control-treated Il17a-/- mice (Figure 35E) and pathological 
scoring confirmed a significant increase in bleomycin-induced inflammation and tissue 
destruction in Il17a-/- mice following blockade of IL-22 (Figure 35F).  Blockade of IL-22 in 
Il17a-/- mice established a level of bleomycin-induced disease comparable to that 
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observed in WT mice, as no statistically significant differences in the BAL cellularity, 
neutrophil recruitment, weight loss, or pathology scoring were observed between 
bleomycin-treated WT and anti-IL-22 mAb-treated Il17a-/- mice (data not shown).  The 
loss of IL-22-mediated protection in Il17a-/- mice revealed a pathway of bleomycin-
induced inflammation that was independent of both IL-22 and IL-17A.  Notwithstanding 
this, these data indicate that IL-17A may govern the proinflammatory and pathologic 
properties of IL-22 in the lung.  Specifically, in the presence of IL-17A, IL-22 appears to 
promote proinflammatory and pathologic outcomes, whereas in the absence of IL-17A, 
IL-22 appears to confer a tissue-protective role in this model of airway damage and 
inflammation.  
 
4.4.5 IL-17A regulates IL-22-mediated protection from bleomycin-induced airway 
epithelial cell apoptosis 
IL-22 acts on cells of non-hematopoietic origin and has been shown to promote epithelial 
cell repair mechanisms (Aujla et al., 2008; Pickert et al., 2009; Wolk et al., 2004).  Given 
that administration of anti-IL-22 neutralizing mAb to Il17a-/- mice increased bleomycin-
induced epithelial cell hyperplasia and disruption of lung alveolar architecture (Figure 
35D, grey arrows), it was hypothesized that IL-22 may protect epithelial cells from 
bleomycin-mediated damage.  To test this, the murine pulmonary epithelial cell line 
MLE-12 was employed (Wikenheiser et al., 1993), which expressed Il22ra mRNA 
transcripts (Figure 36A) and IL-22Rα protein (Figure 36B).  Treatment with rIL-22 led to 
STAT3 phosphorylation (Figure 36C), confirming that this cell line is responsive to IL-22.  
To test whether IL-22 influenced bleomycin-induced damage, bleomycin was added to 
epithelial cell cultures in the presence or absence of rIL-22.  Administration of bleomycin 
resulted in disrupted epithelial cell morphology and a loss of confluency as examined by 
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microscopy (Figure 36D, middle panel).  These visual alterations correlated with an 
induction of epithelial cell apoptosis, as determined by TUNEL staining (Figure 36E, 
middle panel).  However, addition of rIL-22 resulted in a striking reduction in bleomycin-
induced disruption of cell morphology (Figure 36D, right panel) and decreased epithelial 
cell apoptosis identified by TUNEL staining (Figure 36E, right panel).  To quantify the IL-
22 mediated protection, airway epithelial cell cultures were stained with a mAb 
recognizing Annexin V and analyzed by flow cytometry.  Addition of rIL-22 significantly 
protected epithelial cells from bleomycin-induced apoptosis (Figure 36F-G), and this 
protection was dose-dependent (Figure 36G).  IL-22-mediated protection was also 
associated with significantly increased levels of mRNA transcripts encoding the anti-
apoptotic genes Bcl2 and Bcl2l1 in comparison to cultures that did not receive IL-22 
(Figure 36H). 
 As IL-17A regulated the functional consequences of IL-22 expression in vivo, it 
was hypothesized that IL-17A may influence IL-22-mediated protection of airway 
epithelial cells from bleomycin-induced apoptosis in vitro.  Analysis of airway epithelial 
cells by real-time PCR and ELISA revealed the absence of IL-17A expression in PBS 
and bleomycin-treated airway epithelial cells (data not shown), indicating that there was 
no source of endogenous IL-17A in this system.  As observed previously, administration 
of rIL-22 protected epithelial cells from bleomycin-induced apoptosis (Figure 36I, 25% 
increase in protection) compared to PBS controls.  However, the addition of exogenous 
IL-17A to cultures enhanced bleomycin-induced apoptosis of airway epithelial cells 
relative to PBS controls (Figure 36I, 15% decrease in protection).  Co-administration of 
rIL-17A and rIL-22 to cultures prevented IL-22-mediated protection and instead 
enhanced bleomycin-induced apoptosis relative to PBS controls (Figure 36I, 18% 
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decrease in protection).  Collectively, these results indicate that IL-17A regulates the 
ability of IL-22 to protect airway epithelial cells from bleomycin-induced apoptosis. 
 To test whether the ability of IL-17A to regulate IL-22-mediated tissue-protection 
in vivo was associated with alterations in epithelial cell apoptosis, TUNEL staining was 
performed on lung sections of bleomycin-instilled WT and Il17a-/- mice that were treated 
with an isotype control or with an anti-IL-22 neutralizing antibody.  Bleomycin-instilled 
WT mice treated with an isotype-control antibody exhibited a marked increase in 
apoptotic bodies in comparison to PBS-instilled controls (Figure 36J).  Consistent with a 
pathologic role of IL-22 in bleomycin-induced airway inflammation, blockade of IL-22 
(WT + anti-IL-22 mAb) resulted in a reduction of bleomycin-induced apoptotic bodies 
throughout the lung tissue (Figure 36J).  In contrast, blockade of IL-22 in the absence of 
IL-17A (Il17a-/- + anti-IL-22 mAb) demonstrated a marked increase in apoptotic bodies 
compared to isotype treated controls (Figure 36J).  Taken together, these results 
indicate that IL-17A governs the ability of IL-22 to protect airway epithelial cells from 
bleomycin-induced apoptosis in vivo. 
 
4.5 Discussion 
Although significant advances have been made in characterizing the expression of IL-22 
and IL-22R and the signal transduction pathways that are activated, there are conflicting 
reports on the biological consequences of IL-22 expression in murine models of 
inflammation.  For example, IL-22 production can be either pathologic or tissue-
protective depending on the disease model examined (Zenewicz and Flavell, 2008).  
The results of the present study demonstrate that IL-22 expression can promote 
inflammation following bleomycin-induced airway inflammation.  Critically, the functional 
outcomes of IL-22 expression in the lung were governed by co-expression of IL-17A.  
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When co-expressed in vivo, IL-17A and IL-22 acted synergistically to promote 
chemokine expression, neutrophil recruitment, and airway inflammation.  Conversely, in 
the absence of IL-17A, IL-22 expression was no longer proinflammatory and pathologic, 
but rather conferred tissue-protective functions by promoting the integrity of the epithelial 
barrier.  Therefore, differential spatial and temporal expression of IL-17A and IL-22 may 
explain the divergent functions of IL-22 reported in different models of infection or 
inflammation. 
 Following bleomycin exposure, a Th17 cell response developed, characterized 
by expression of IL-17A and IL-22 in the lung and BAL.  Previous studies have identified 
that many of the factors that promote the differentiation of Th17 cells have been linked in 
the pathogenesis of bleomycin-induced airway inflammation, including IL-6 and IL-
12/23p40 (Maeyama et al., 2001; Saito et al., 2008; Sakamoto et al., 2002).  Consistent 
with a proinflammatory role for Th17 cells, neutralization of either Th17 cell-associated 
effector cytokine, IL-22 or IL-17A, was sufficient to provide protection against bleomycin-
induced airway inflammation in WT mice, suggesting that a functional synergy between 
both cytokines can promote disease.  Synergy between IL-22 and IL-17A has previously 
been observed in vitro (Liang et al., 2006) and in vivo following infection with the 
pulmonary pathogen Klebsiella pneumoniae (Aujla et al., 2008).  This synergy promoted 
the production of inflammatory mediators and anti-microbial peptides (Liang et al., 2006), 
and was found to be beneficial for the host following pulmonary infection (Aujla et al., 
2008).  However, it was also found that administration of exogenous IL-22 itself was 
insufficient to promote neutrophil recruitment to the airway (Liang et al., 2007), 
suggesting that IL-17A was required for the proinflammatory properties of IL-22.  
Consistent with this, it was demonstrated that exogenous IL-22 is only able to promote 
inflammation in the airway in the presence of IL-17A.  It is possible that in mouse models 
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of psoriasis, arthritis and protozoan infection, in which IL-22 was reported to be 
proinflammatory (Geboes et al., 2009; Ma et al., 2008; Munoz et al., 2009; Zheng et al., 
2007), the same synergy between IL-22 and IL-17A is operating to promote 
inflammation.  
 In the absence of IL-17A, it was found that there were increased levels of IL-22 
following bleomycin instillation.  This finding was consistent with previous studies that 
also observed increased IL-22 mRNA in the absence of IL-17A in a murine model of 
colitis (O'Connor et al., 2009), or decreased IL-22 mRNA in splenocyte cultures with the 
addition of exogenous IL-17A (Smith et al., 2008; von Vietinghoff and Ley, 2009).  In in 
vitro studies, it was demonstrated that IL-17A could suppress the expression and 
secretion of IL-22 from Th17 cells in a dose-dependent manner.  It has also been 
reported that IL-17A can inhibit IL-17F expression by Th17 cells (von Vietinghoff and 
Ley, 2009), suggesting a common pathway for IL-17A-mediated inhibition of Th17 cell 
effector cytokine expression.  However, it has not yet been determined whether IL-17A is 
acting directly on the Th17 cells or through an accessory cell and further investigation 
must be conducted to determine the mechanisms through which the suppression of IL-
22 production occurs. 
Despite elevated expression of IL-22 in the absence of IL-17A, Il17a-/- mice were 
not susceptible to bleomycin-induced disease, which is consistent with a loss of the 
proinflammatory properties of IL-22.  However, blockade of IL-22 in the absence of IL-
17A exacerbated bleomycin-induced disease, indicating a tissue-protective role for IL-22 
in airway inflammation in the absence of IL-17A.  Consistent with this hypothesis, it was 
found that rIL-22 could protect airway epithelial cells from bleomycin-induced apoptosis 
in both in vitro and in vivo assays.  Further, IL-22-mediated protection from epithelial cell 
apoptosis was reversed in the presence of IL-17A.  Previous reports proposed a 
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constitutive tissue-protective function for IL-22 in murine models of IBD and hepatitis 
(Pan et al., 2004; Pickert et al., 2009; Radaeva et al., 2004; Sugimoto et al., 2008; 
Zenewicz et al., 2007; Zenewicz et al., 2008).  However, following bleomycin-induced 
airway inflammation, IL-22 exhibited a constitutive proinflammatory effect in WT mice 
and was only tissue-protective in the absence of IL-17A.  One possible explanation for 
the constitutive proinflammatory effects of IL-22 in bleomycin-exposed WT mice in 
comparison to a constitutive tissue-protective role for IL-22 reported in murine models of 
inflammation in the intestine or liver may be due to differential co-expression of IL-17A 
and IL-22 in distinct tissues.  For example, following bleomycin instillation the majority of 
IL-22-expressing cells in the lung co-expressed IL-17A and promoted inflammation.  In 
contrast, subsets of gut resident NK cells and skin-resident CD4+ T cells are reported to 
express IL-22 but do not co-express IL-17A (Cella et al., 2009; Duhen et al., 2009; 
Satoh-Takayama et al., 2008; Trifari et al., 2009).  Collectively, these reports support a 
model in which production of IL-22 by these cell populations in the absence of IL-17A 
may be important in promoting tissue-protective responses.  Therefore, the cellular 
sources, anatomical location and cytokine co-expression profile of resident and recruited 
cell populations may influence the functional properties of IL-22 and provide an 
explanation for the distinct functional roles of IL-22 in models of infection and 
inflammation in distinct peripheral tissues. 
 When anti-IL-22 mAb was administered in the absence of IL-17A, bleomycin-
induced disease was comparable to that in WT mice and independent of IL-17A and IL-
22.  It is possible that other Th17 cell-derived cytokines such as IL-17F or TNFα may 
play a significant role in this context, as well as other non-related inflammatory cytokines 
such as IFNγ, all of which have been shown to contribute to airway inflammation in other 
model systems (Liang et al., 2007; Lukacs et al., 1995; Segel et al., 2003; Yang et al., 
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2008).  Additionally, a recent report identified that in a model of bleomycin-induced 
fibrosis, IL-17A can act cooperatively with TGFβ to promote disease (Wilson et al., 
2010b).  In the present study, the influence of IL-17A and IL-22 on bleomycin-induced 
tissue damage and acute airway inflammation occurred independently of any significant 
changes in production of TGFβ protein (data not shown).  Notwithstanding that, future 
studies in a model of fibrosis will be required to examine the potential functional 
interactions between IL-17A, IL-22, and TGFβ in the development and/or progression of 
disease. 
 Based on the in vitro and in vivo findings reported here, it could be hypothesized 
that IL-17A regulates the functional consequences of IL-22 expression by three 
mechanisms.  First, IL-17A regulates the in vivo and in vitro expression levels of IL-22 by 
inhibiting IL-22 production from Th17 cells.  Second, IL-17A promotes the 
proinflammatory properties of IL-22 by acting in synergy to induce expression of 
inflammatory cytokines, chemokines and neutrophil recruitment.  Third, IL-17A prevents 
tissue-protective functions of IL-22 by suppressing the anti-apoptotic effects of IL-22 on 
epithelial cells.  Therefore, this complex regulation of IL-22 by IL-17A may underlie how 
IL-22 can promote both pathologic or tissue-protective outcomes depending upon the 
context in which it is expressed.  
 The ability of IL-22 to be either pathologic or protective, depending on the context 
in which it is expressed, is a property shared by other cytokines that signal through 
STAT3 including IL-6 and IL-27, which can either promote or regulate inflammation 
dependent upon the cytokine milieu and regulation of signal transduction (Villarino et al., 
2004; Yasukawa et al., 2003).  It is probable that the interplay between IL-17A and IL-22 
signaling pathways will determine the balance between proinflammatory versus tissue-
protective outcomes.  IL-22 is known to signal through the STAT3 and p38 MAP Kinase 
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pathways, while IL-17A signals predominantly through the NFκB pathway (Gaffen, 2009; 
Kotenko et al., 2001a; Lejeune et al., 2002).  The STAT3 and NFκB pathways regulate a 
wide range of biologic processes including cell growth, differentiation, and apoptosis, 
and complex interactions have been reported between these two transcription factors 
(Alonzi et al., 2001; Bollrath and Greten, 2009; Uskokovic et al., 2007).  Therefore future 
investigation into the interplay between the signal transduction pathways and target 
genes of both IL-17A and IL-22 will likely yield further insight into the ability of IL-17A to 
regulate the functional consequences of IL-22 expression.  Notwithstanding this, the 
results of the present study demonstrate that IL-22 can promote disease in a model of 
airway inflammation, and support a model in which IL-17A regulates the levels of 
expression, proinflammatory properties, and tissue-protective properties of IL-22, 
thereby determining the functional consequences of IL-22 expression in the lung.  
Differential temporal and spatial co-expression of IL-17A and IL-22 may underlie the 
conflicting reports of the biological effects of IL-22 in distinct disease models, and may 
offer selective therapeutic potential in treatment of Th17 cell-associated inflammatory 
diseases. 
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Figure 23. Th17 cell differentiation and effector cytokines are increased following 
bleomycin-instillation. C57BL/6 mice were intra-tracheally instilled with PBS or 
bleomycin (Bleo) and sacrificed on day 8.  Lung cDNA was analyzed by RT-PCR for Il6, 
Tgfb1, Il23a, and Il12b.  All data are representative of 3 or more independent 
experiments with a minimum of 3-4 mice per group.  Data shown are the mean ± SEM.  * 
p < 0.05.  
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Figure 24. TGFβ protein is not upregulated in a high-dose of bleomycin-induced 
damage and acute airway inflammation.  Mice were intra-tracheally administered 
PBS, a high-dose (H.D.) of bleomycin, or a low-dose (L.D.) of bleomycin.  (A) Following 
6 days, mice were sacrificed and total lung homogenates were measured for active 
TGFβ protein by ELISA.  (B) Following 10 days, mice were sacrificed and lung sections 
were stained for TGFβ protein by Immunofluorescence.  Bar, 25 µm.  Data are from 1 
experiment of 3 mice per group.  Data shown are the mean ± SEM.  * p < 0.05, **p < 
0.01.  
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Figure 25.  A Th17 response develops following bleomycin-induced airway 
inflammation.  C57BL/6 mice were intra-tracheally instilled with PBS or bleomycin 
(Bleo) and sacrificed on day 8.  (A) cDNA prepared from lungs was analyzed by RT-PCR 
for Il17a and Il22 expression.  (B) Live lung cells from bleomycin-instilled mice were 
 138 
analyzed for the frequency of IL-17A+ and IL-22+ T cells.  Populations are sequentially 
gated on total live cells (left), total cytokine positive cells (middle), and TCRβ+ cells 
(right).  (C) Total numbers of IL-17A+ and IL-22+ CD4+ T cells obtained from the lungs of 
PBS or bleomycin-treated mice.  (D) Lung cell suspensions were stimulated with anti-
CD3 mAb for 48 hours and supernatants were analyzed for IL-17A and IL-22 secretion 
by ELISA.  (E) CD4+ T cells from the BAL and lung cells were analyzed for the frequency 
of IL-17A+ and IL-22+ cells by flow cytometry.  (F) Frequency from individual mice of IL-
17A+, IL-22+, and IL-17A+/IL-22+ CD4+ T cells in the BAL.  All data are representative of 3 
or more independent experiments with a minimum of 3-4 mice per group.  Data shown 
are the mean ± SEM.  Significance was determined using the Mann-Whitney test.  * p < 
0.05.  
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Figure 26. IL-17F expression is not increased following bleomycin-instillation.  
C57BL/6 mice were intra-tracheally instilled with PBS or bleomycin (Bleo) and sacrificed 
on day 10. (A) Total lung cells were analyzed for the frequency of IL-17F+ cells.  (B) 
Splenocytes from naïve WT mice were activated under Th17 permissive conditions for 4 
days and analyzed for the frequency of IL-17F+ CD4+ T cells by flow cytometry.  All data 
are representative of 2 independent experiments with a minimum of 3-4 mice per group.  
 140 
 
Figure 27.  Administration of anti-IL-22 monoclonal antibody protects mice from 
bleomycin-induced airway inflammation.  C57BL/6 mice were intra-tracheally instilled 
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with bleomycin, treated with an isotype control (Iso) or anti-IL-22 (αIL-22) mAb, and 
sacrificed on day 10. (A) BAL cell counts.  Neutrophil infiltration was assessed by (B) 
H&E staining of BAL cell cytocentrifuge preparations (neutrophils highlighted by white 
arrows; Bar, 10 µm) and by (C) flow cytometry of lung cells for the frequency (left panel) 
and total number (right panel) of Gr-1+ cells.  (D) H&E staining of histological lung 
sections demonstrating peri-bronchial leukocyte infiltrate (black arrows), and disruption 
of lung architecture (white arrows). Bar, 100 µm.  (E) Weight loss of individual mice was 
plotted as a percentage of starting weight.  (F) Total pathology score.  All data are 
representative of 3 or more independent experiments with a minimum of 3-5 mice per 
group.  Data shown are the mean ± SEM.  * p < 0.05, ** p < 0.01.  
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Figure 28.  Differential counts of BAL cells.  Differential counts of H&E-stained BAL 
cytocentrifuge preparations.  All data are representative of 3 or more independent 
experiments with a minimum of 3-5 mice per group.  
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Figure 29.  Gr-1+ SSChi cells express surface markers consistent with neutrophils.  
Gr-1+ SSChi cells elicited by intra-tracheal instillation of bleomycin express (A) CD11b, 
(B) Ly6C, and (C) Ly6G, and are negative for (D) F4/80 and (E) MHCII.  Data are 
representative of 2 independent experiments with a minimum of 3 mice per group.  
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Figure 30. Il22-/- mice are protected from bleomycin-induced airway inflammation.  
Il22+/+ and Il22-/- mice were intra-tracheally instilled with bleomycin and sacrificed on day 
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5.  (A) BAL cell counts. Neutrophil infiltration was assessed by (B) H&E staining of BAL 
cell cytocentrifuge preparations (neutrophils highlighted with white arrows; Bar, 10 µm) 
and by (C) flow cytometry of lung cells for the frequency of Gr-1+ cells.  (D) H&E staining 
histological lung sections demonstrating peri-bronchial leukocyte infiltrate (black arrows), 
and disruption of lung architecture (white arrows). Bar, 100 µm.  (E) Weight loss of 
individual mice was plotted as a percentage of starting weight.  (F) Pathology scoring of 
mice.  All data are representative of 2 independent experiments with a minimum of 5-6 
mice per group.  Data shown are the mean ± SEM.  * p < 0.05, **p < 0.01, ***p < 0.001.  
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Figure 31. IL-17A partially regulates bleomycin-induced expression of IL-22.  Wild-
type (WT) and Il17a-/- mice were intra-tracheally instilled with bleomycin and sacrificed 
on day 10.  (A) CD4+ BAL T cells were analyzed for the frequency of IL-22+ cells by flow 
cytometry.  (B) Frequency of individual mice for IL-22+ CD4+ T cell increases in the BAL.  
(C) Lung cell suspensions were stimulated with anti-CD3 mAb for 48 hours and 
supernatants were analyzed for IL-22 secretion by ELISA.  All data are representative of 
2 or more independent experiments with a minimum of 3-5 mice per group.  Data shown 
are the mean ± SEM.  Significance was determined using the Mann-Whitney test.  * p < 
0.05.  
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Figure 32. IL-17A regulates IL-22 expression. (A) Splenocytes from naïve WT and 
Il17a-/- mice were activated under Th17 permissive conditions for 4 days and analyzed 
for the frequency of IL-22+ CD4+ T cells.  (B) Splenocyte cultures from Il17a-/- mice were 
activated under Th17 cell permissive conditions for 4 days with the addition of 
designated concentrations of rIL-17A and analyzed for the frequency of IL-22+ CD4+ T 
cells by flow cytometry and (C) cell-free supernatants were analyzed for IL-22 secretion 
by ELISA.  (D) Wild-type (WT) and Il22-/- mice were intra-tracheally instilled with 
bleomycin and sacrificed on day 5 and CD4+ BAL T cells were analyzed for the 
frequency of IL-17A+ cells.  Data are representative of 2 or more independent 
experiments with a minimum of 3-5 mice per group.  (E) Splenocyte cultures from Il22-/- 
mice were activated under Th17 permissive conditions for 4 days with the addition of 
designated concentrations of rIL-22 and analyzed for the frequency of IL-17A+ CD4+ T 
cells by flow cytometry.  Data are representative of 2 or more independent experiments 
with triplicate wells per condition.  Data shown are the mean ± SEM.  ** p < 0.01.  
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Figure 33.  Il17a-/- mice are protected from bleomycin-induced pulmonary 
inflammation. Wild-type (WT) or Il17a-/- mice were intra-tracheally instilled with 
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bleomycin and sacrificed on day 10.  (A) BAL cell counts.  Neutrophil infiltration was 
assessed by (B) H&E staining of BAL cell cytocentrifuge preparations (neutrophils 
highlighted with white arrows; Bar, 10 µm) and by (C) flow cytometry of lung cells for the 
frequency (left panel) and total number (right panel) of Gr-1+ cells.  (D) H&E staining of 
histological lung sections demonstrating peri-bronchial leukocyte infiltrate (black arrows), 
and disruption in lung architecture (white arrows). Bar, 100 µm.  (E) Weight loss of 
individual mice was plotted as a percentage of starting weight.  (F) Total pathology 
score.  All data are representative of 3 or more independent experiments with a 
minimum of 3-5 mice per group.  Data shown are the mean ± SEM.  ** p < 0.01, *** p < 
0.001.  
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Figure 34.  IL-22 and IL-17A act synergistically to promote airway inflammation 
and neutrophil recruitment.  Il17a-/- mice were intra-tracheally instilled with rIL-22 
alone, rIL-17A alone, or both cytokines in combination. (A) cDNA prepared from lungs 
was analyzed by RT-PCR for Il6 and Cxcl1 expression. Neutrophil infiltration was 
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assessed by (B) H&E staining of BAL cell cytocentrifuge preparations (highlighting 
neutrophils with white arrows; Bar, 10 µm, and by (C) flow cytometry of lung cells for the 
frequency of Gr-1+ cells.  (D) Total numbers of neutrophils in the BAL and lung.  All data 
are representative of 2 independent experiments with a minimum of 3 mice per group.  
Data shown are the mean ± SEM.  * p < 0.05, **p < 0.01, ***p < 0.001.  
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Figure 35.  Blockade of IL-22 reverses protection of Il17a-/- mice from bleomycin-
induced pulmonary inflammation.  Il17a-/- mice were intra-tracheally instilled with 
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bleomycin, treated with an isotype control (Iso) or anti-IL-22 (αIL-22) mAb, and sacrificed 
on day 10. (A) BAL cell counts.  Neutrophil infiltration was assessed by (B) H&E staining 
of BAL cell cytocentrifuge preparations (highlighted by white arrows; Bar, 10 µm) and by 
(C) flow cytometry of lung cells for the frequency (left panel) and total number (right 
panel) of Gr-1+ cells.  (D) H&E staining of histological lung sections demonstrating 
peribronchial leukocyte infiltrate (black arrows), disruption in lung architecture (white 
arrows), and epithelial hyperplasia (gray arrows). Bar, 100 µm.  (E) Weight loss of 
individual mice was plotted as a percentage of starting weight.  (F) Total pathology 
score.  All data are representative of 3 or more independent experiments with a 
minimum of 3-5 mice per group.  Data shown are the mean ± SEM.  * p < 0.05. 
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Figure 36. IL-17A regulates the tissue-protective properties of IL-22.  (A) cDNA 
prepared from MLE cells and splenocytes (Spl) was examined for the presence of Il22ra 
transcripts by RT-PCR.  (B) Immunoblot of MLE cell and total splenocyte (Spl) lysates 
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with antibody for IL-22Rα and β-actin.  (C) MLE cells were stimulated with recombinant 
IL-22 (rIL-22, 10 ng/mL) for the indicated times before lysis and immunostaining for 
phopho-STAT3 (pSTAT3) and total STAT3 (tSTAT3).  (D) For imaging, MLE cell were 
treated overnight with bleomycin in the absence (Bleo) or presence (+rIL-22) of rIL-22.  
Induction of apoptosis was identified by (E) in situ TUNEL staining or (F) flow cytometry 
analysis for the frequency of Annexin V+ cells.  Bar, 10 µm.  (G) Frequency of Annexin 
V+ cells with the addition of increasing concentrations of rIL-22.  (H) cDNA from 
bleomycin-treated MLE cells in the presence or absence of rIL-22 (100 ng/mL) was 
prepared and analyzed for Bcl2 and Bcl2l1 transcripts by RT-PCR.  (I) Percent 
protection with the addition of rIL-17A (10 ng/mL) and rIL-22 (10 ng/mL) was determined 
based on the frequency of Annexin V+ cells above or below that obtained with bleomycin 
alone (set at 0).  (J) In situ TUNEL staining of paraffin embedded lung tissue.  Red, 
TUNEL; Blue, DAPI.  Bar, 10 µm.  Data from in vitro studies are representative of 2 or 
more independent experiments with triplicate wells per condition.  Data shown are the 
mean ± SEM.  * p < 0.05, **p < 0.01, ***p < 0.001.  
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Chapter 5 
Summary, Discussion and Future directions 
 
5.1 Proximal and distal propagation of the ILC-IL-22 pathway 
The recently identified ILC-IL-22 pathway is analogous with the functional properties of  
CD4+ Th17 cells.  Both cellular pathways require the lineage specifying transcription 
factor RORγt, express the IL-23R and have the capacity to produce IL-22 (Ivanov et al., 
2006; Sonnenberg et al., 2011; Takatori et al., 2009).  Both pathways are also implicated 
in promoting immunity and/or inflammation at mucosal sites (Mangan et al., 2006; 
Ouyang et al., 2008; Spits and Di Santo, 2010).  In contrast to the Th17 cell pathway, IL-
22-expressing ILCs are constitutively RORγt+ and IL-23R+, and do not require TCR-
dependent recognition of cognate antigen in the context of MHC class II for their 
development, differentiation or effector functions (Sonnenberg et al., 2011; Takatori et 
al., 2009).  Further, several subsets of IL-22-producing ILCs have been reported to lack 
expression of the effector cytokine IL-17A distinguishing them from Th17 cells (Cella et 
al., 2009; Satoh-Takayama et al., 2008; Sonnenberg et al., 2011; Spits and Di Santo, 
2010).  The differences between these pathways are significant, and likely account for 
the functional significance of each cell population.  The presented data in Chapter 2 
demonstrate that ILCs are a necessary and sufficient source of IL-22 during the first 6 
days following Citrobacter rodentium infection.  Kinetic analysis of IL-22 production 
revealed that ILCs express IL-22 production rapidly within 2 days following infection, 
while T cell production of IL-22 is not evident until day 6 post-infection, a time point at 
which IL-22 is not longer essential for host protective immunity.  This is likely mediated 
by the ability of ILCs to immediately produce IL-22 following exposure to IL-23, in 
comparison to Th17 cells which require differentiation and antigen recognition phases 
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prior to inducing IL-22 expression (Sonnenberg et al., 2011).  Therefore the ability of 
ILCs to rapidly and directly respond to cytokine stimulation is critically important in the 
context of enteric bacterial infection in which it is necessary to produce IL-22 within the 
first few days of infection.  In an immune-competent mouse, the likely function of rapid 
IL-22 production by ILCs is to limit early bacterial dissemination and replication, to permit 
sufficient time for the generation of a robust antigen-specific adaptive immune responses 
to develop resulting in clearance of the pathogen and the generation of immunologic 
memory.  In support of this, IL-22 was no longer required for resistance to infection 
following the first 6 days of infection, or at any time point following secondary challenge 
with Citrobacter rodentium (unpublished data).  At these stages of infection, replication 
and dissemination of Citrobacter rodentium is likely controlled by IL-22-independent T 
cell responses and immunoglobulin secretion. 
 In Chapter 2, IL-23 was found to be essential in promoting early infection-
induced production of IL-22 by ILCs and innate immunity to Citrobacter rodentium. In 
addition to cytokine production, IL-23 is important in the terminal differentiation and 
proliferation of Th17 cells (McGeachy et al., 2009).  Although it is unclear of whether IL-
23 is directly promoting the terminal differentiation and proliferation of IL-22-producing 
ILCs, data presented in Chapter 2 demonstrate decreased frequencies of infection-
induced ILCs and IL-22+ ILCs in IL-23-deficient mice.  Previous studies have shown that 
IL-23-induced proliferation was associated with IL-22 but not IL-17A production in Th17 
cells (Liang et al., 2006), suggesting that IL-23-induced proliferation may be a 
requirement for infection-induced expression of IL-22 by ILCs.  These data collectively 
suggest that IL-23 is a critical inducer of cytokine production and effector functions of 
ILCs following infection. 
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 While the infection-induced population expansion and production of IL-22 by ILCs 
were critically dependent on IL-23, no defects in ILC frequency or cytokine production 
were observed in uninfected Il23a-/- mice, suggesting that the development and 
differentiation of IL-22-producing ILCs in the steady state does not require IL-23.  
Results presented in Chapter 3 demonstrate that the ILC-IL-22 pathway is critical in 
containing commensal bacteria to intestinal and gut-associated lymphoid tissues to 
maintain systemic immune cell homeostasis in the steady state.  These two findings 
suggest that factors other than IL-23 are regulating ILC populations and production of IL-
22 to contain commensal bacteria in the absence of infection.  A number of additional 
factors can induce the population expansion and IL-22 production by ILCs, including the 
cytokines IL-1β, IL-2, IL-7 and lymphotoxin-β (Hughes et al., 2010; Ota et al., 2011; 
Schmutz et al., 2009; Sonnenberg et al., 2011; Tumanov et al., 2011).  Aryl hydrocarbon 
receptor (AhR) agonists and microbial-derived signals may also directly influence IL-22-
producing ILCs (Crellin et al., 2010b; Takatori et al., 2009) and previous reports have 
identified that commensal bacteria can influence ILC responses in the intestine (Satoh-
Takayama et al., 2008; Sawa et al., 2011; Sonnenberg et al., 2011).  Therefore, in the 
steady state cytokine-, environmental- or commensal bacteria-dependent pathways may 
regulate IL-22 expression to promote containment of intestinal commensal bacteria.    
This provokes a scenario in which acquisition of commensal bacteria and/or exposure to 
environmental agents induces a pathway to maintain steady state levels of ILC activation 
and IL-22 production for the containment of commensal bacteria, and upon pathogenic 
challenge IL-23 is expressed to rapidly enhance the ILC-IL-22 response and provide 
innate immunity against pathogenic bacteria (Figure 37).  
 The cellular targets and effector mechanisms through which ILC-derived IL-22 
promotes steady state containment of commensal bacteria and innate immunity 
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following infection currently remain unclear.  IL-22R expression is thought to be 
restricted to non-hematopoietic cells (Tachiiri et al., 2003; Wolk et al., 2004), suggesting 
that IL-22 is acting on intestinal epithelial cells or other resident stromal cell populations.  
Although unlikely, it is possible that IL-22 is acting on distal targets such as keratinocytes 
or hepatocytes, or on a currently undefined IL-22R+ hematopoietic cell.  The 
development of models to conditionally delete IL-22R on specific cell lineages will be 
required for the identification of the cellular targets of ILC-derived IL-22 in the context of 
homeostasis or infection.   
 The processes induced by IL-22 that promote anti-bacterial immunity in target 
cell lineages also remain poorly defined.  Previous studies demonstrated that IL-22 could 
elicit expression of RegIIIγ, a secreted C-type lectin anti-microbial peptide, in epithelial 
cell lineages (Cash et al., 2006; Zheng et al., 2008).  Further, administration of 
exogenous RegIIIγ could partially limit host morbidity of Citrobacter rodentium-infected 
IL-22-deficient mice (Zheng et al., 2008), implicating induction of anti-microbial peptides 
as one mechanism of IL-22-induced innate immunity.  RegIIIγ has been reported to 
preferentially bind and kill gram-positive bacteria (Cash et al., 2006).  As Citrobacter 
rodentium is a gram-negative bacterium, this suggests that either RegIIIγ has an 
unknown anti-microbial specificity for Citrobacter rodentium, or that gram-positive 
commensal bacteria are also playing a role in the pathogenesis of Citrobacter rodentium 
infection.  IL-22 also induces expression of several other mediators that may promote 
containment of commensal bacteria and provide innate immunity.  Specifically, IL-22 can 
induce epithelial cell expression of mucin proteins (Sugimoto et al., 2008), which aid in 
the formation of mucus layers in the intestine.  Previous studies have demonstrated that 
mice deficient in mucin genes exhibit increased commensal bacteria-driven intestinal 
inflammation and increased susceptibility to Citrobacter rodentium infection (Bergstrom 
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et al., 2010; Johansson et al., 2008).  IL-22 also induces expression of inflammatory 
cytokines and chemokines by epithelial cells that have been implicated in neutrophil 
recruitment to the intestine and control of bacterial replication (Aujla et al., 2008; Wang 
et al., 2010), as well as genes involved in tissue-protection and repair of the epithelium 
in numerous models of intestinal inflammation (Aujla et al., 2008; Pickert et al., 2009; 
Sugimoto et al., 2008; Zenewicz et al., 2008).  Finally, IL-22 and ILCs are implicated in 
the induction, organization and maintenance of intestinal cryptopatches (CPs) and 
isolated lymphoid follicles (ILFs) (Eberl et al., 2004; Ota et al., 2011; Tsuji et al., 2008).  
These processes involve interactions of lymphotoxin-β on the surface of RORγt+ ILCs 
with the lymphotoxin-β receptor on intestinal epithelial cells (Ota et al., 2011; Tsuji et al., 
2008; Tumanov et al., 2011; Wang et al., 2010).  This is a process that depends on the 
presence of commensal bacteria (Bouskra et al., 2008), and is capable of promoting 
innate immunity (Ota et al., 2011) and supporting the generation of mucosal IgA (Tsuji et 
al., 2008).  Further investigation will be required to determine the proximal and distal 
mechanisms of the ILC-IL-22 pathway in the context of homeostasis and infection.  
Based on current knowledge it is likely that multiple factors outlined above are involved.  
Taken together, studies presented in this thesis and previously published reports 
illustrate a pathway in which cytokine, environmental and microbial factors regulate the 
generation and magnitude of an ILC-IL-22 response to propagate numerous 
downstream mediators required for the containment of commensal bacteria in the steady 
state and the induction of innate immunity following exposure to bacterial pathogens 
(Figure 37). 
 
5.2 Regulation of IL-22 expression and function by proinflammatory 
cytokines 
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The results presented in Chapter 4 demonstrate that IL-17A can regulate the 
proinflammatory pathologic versus tissue-protective functions of IL-22.  When co-
expressed in vivo, IL-17A and IL-22 synergistically promoted inflammation.  However, in 
the absence of IL-17A, IL-22 was no longer proinflammatory, but rather IL-22 promoted 
tissue-protective responses.  This may be a regulatory feature shared by other 
proinflammatory cytokines as it has also been found that IL-22 can synergistically or 
additively promote inflammation when co-administered with the IL-17F, TNFα or 
oncostatin-M (Aujla et al., 2008; Eyerich et al., 2009; Guilloteau et al., 2010; Liang et al., 
2006).  The data presented in Chapter 4 are the first to offer a potential explanation to 
reconcile recent reports identifying both proinflammatory and tissue-protective functions 
for IL-22 in murine models of immunity and inflammation.  For example, IL-22 was found 
to promote pathologic inflammation in mouse models of psoriasis, arthritis, Toxoplasma 
gondii infection and CD45RBlow T cell-induced colitis (Geboes et al., 2009; Kamanaka et 
al., 2011; Ma et al., 2008; Munoz et al., 2009; Zheng et al., 2007), while IL-22 was also 
found to provide tissue-protection in mouse models of fibrosis, gram-negative bacterial 
infection, hepatitis, DSS-induced colitis and CD45RBhi T cell-induced colitis (Aujla et al., 
2008; Pan et al., 2004; Pickert et al., 2009; Radaeva et al., 2004; Simonian et al., 2010; 
Sugimoto et al., 2008; Zenewicz et al., 2007; Zenewicz et al., 2008; Zheng et al., 2008).  
Therefore the differential functions of IL-22 in these published studies may be partially 
explained by context-dependent differences in the temporal or spatial expression of 
proinflammatory cytokines, thus regulating the functional outcome of IL-22 expression.  
In future studies it will be important to examine the co-expression and kinetics of IL-22 
production with proinflammatory cytokines in murine models and human diseases.   
 In addition to regulating the functional outcomes of the IL-22-IL-22R pathway, 
data presented in Chapter 4 suggest that IL-17A may also regulate expression levels of 
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IL-22.  This finding is important as it suggests that cytokines synergistically promoting 
inflammation with IL-22 may also be actively suppressing IL-22 expression, and 
therefore also regulating or self-limiting inflammation.  It remains unclear whether other 
proinflammatory cytokines shown to synergistically promote inflammation with IL-22, 
such as IL-17F, TNFα or oncostatin-M (Aujla et al., 2008; Eyerich et al., 2009; Guilloteau 
et al., 2010; Liang et al., 2006), can also regulate expression of IL-22.  Further, these 
synergistic and inhibitory influences on IL-22 expression or function may not always be 
pathologic.  For example, synergistic induction of neutrophil recruiting chemokines and 
anti-microbial peptides by IL-22 and IL-17A is beneficial in the context of a bacterial 
infection (Aujla et al., 2008), and in other contexts it may be important to limit excessive 
IL-22-driven tissue repair processes by co-expression of IL-17A. 
 The cellular targets and mechanisms through which IL-17A influences the 
function and expression of IL-22 currently remain unclear.  As discussed in Chapter 
1.2.2, IL-22 is recognized by the IL-22R1 and IL-10R2 subunits expressed 
predominantly of non-hematopoietic cells (Kotenko et al., 2001a; Xie et al., 2000).   IL-
17A is recognized by the high affinity IL-17RA subunit expressed ubiquitously in 
hematopoietic and non-hematopoietic cells, and the low affinity IL-17RC subunit 
expressed at lower levels in hematopoietic cells and at higher levels in non-
hematopoietic cells (Gaffen, 2009; Kuestner et al., 2007; Yao et al., 1995).  This 
suggests that IL-17A may regulate the proinflammatory versus tissue-protective 
functions of IL-22 by acting on the same non-hematopoietic cellular target (Figure 38).  
Consistent with this, IL-17A and IL-22 can synergistically upregulate expression of 
proinflammatory genes on primary epithelial cells or cell lines (Aujla et al., 2008; 
Boniface et al., 2005; Eyerich et al., 2009; Liang et al., 2010; Wolk et al., 2006), and in 
Chapter 4 it was demonstrated that IL-17A can directly inhibit the ability of IL-22 to 
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protect epithelial cells from bleomycin-induced apoptosis.  This is likely mediated by 
interactions between the signaling pathways of IL-22 and IL-17A.  IL-22 signals via 
STAT3 and the p38 MAP Kinase pathways, while IL-17A signals predominantly through 
the NFκB pathway (Gaffen, 2009; Kotenko et al., 2001a; Lejeune et al., 2002), and 
previous studies have suggested that these two signal transduction pathways may 
interact to differentially influence gene transcription (Alonzi et al., 2001; Bollrath and 
Greten, 2009; Uskokovic et al., 2007).  The mechanisms through which IL-17A limits 
expression of IL-22 are less clear.  It is possible that IL-17A is either acting directly on 
the cellular source of IL-22 to inhibit expression, or that IL-17A is acting indirectly via an 
accessory hematopoietic or non-hematopoietic cell to influence IL-22 expression by 
production of secondary mediators (Figure 38).  Additional studies will be required to 
determine the direct interactions between the IL-17A and IL-22 signal transduction 
pathways that influence the functional differences in gene expression of proinflammatory 
versus tissue-reparative mediators, as well as the pathways by which IL-17A can 
negatively influence the production of IL-22. 
 Although the mechanisms through which IL-17A influences the function and 
expression of IL-22 remain unclear, these findings may have important implications for 
delineating the functions IL-22-producing cell populations.  It has recently been 
appreciated that there are innate and adaptive sources of IL-22 that do not co-express 
IL-17A.  For example, Th17 cells, Tc17 cell, NKT cells, γδ T cells and some subsets of 
IL-22-producing ILCs co-express IL-17A and IL-22, while Th22 cells, Tc22 cells and 
most subsets of IL-22-producing ILCs express IL-22 but not IL-17A (Colonna, 2009; 
Sonnenberg et al.; Spits and Di Santo, 2010).  The data presented in Chapter 4 
suggests that cell populations that co-express IL-17A and IL-22 would be 
proinflammatory, while populations that express IL-22 in the absence of IL-17A may 
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promote non-inflammatory tissue-protection.  This is consistent with recent findings 
demonstrating proinflammatory roles for Th17 cells and an ILC population that co-
expresses IL-17A and IL-22 in intestinal inflammation (Ahern et al., 2010; Buonocore et 
al., 2010; Ouyang et al., 2008; Sonnenberg et al., 2011), while ILCs and T cells which 
only express IL-22 may promote tissue repair and immunity (Cella et al., 2009; Eyerich 
et al., 2009; Satoh-Takayama et al., 2008; Sawa et al., 2011; Sonnenberg et al., 2011).  
It would also be predicted in comparison to IL-17A co-expressing cells, those that lack 
IL-17A expression would produce higher levels of IL-22.  This could be beneficial in the 
context of immunity and tissue repair, and supports data in Chapter 2 and Chapter 3 in 
which IL-22-producing ILCs but not Th17 cells are essential in promoting IL-22-
dependent intestinal immunity and homeostasis.  However, IL-22-producing cells could 
also promote inflammatory diseases in which high levels of IL-22 are detrimental to the 
host response, such as in psoriasis, in which it has recently been identified that 
increased frequencies of Th22 cells are present in the peripheral blood and skin of 
psoriatic patients (Eyerich et al., 2009; Kagami et al., 2010).  Future studies are 
necessary to clarify the factors that promote the development and effector functions of 
IL-22 and IL-17A co-expressing cells versus cell populations that express either of the 
cytokines.  One candidate that may be involved is the aryl hydrocarbon receptor (AhR) 
as it has previously been found to be essential for IL-22 production but not IL-17A 
(Veldhoen et al., 2008).  Collectively, published studies and data presented in this thesis 
suggest that co-expression of IL-17A may dictate the expression and functions of IL-22, 
and thus control the balance between immunity, inflammation and tissue-repair at 
mucosal sites. 
 
5.3 Therapeutic manipulation of the ILC-IL-22 pathway in human disease 
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Data presented in Chapter 2 and Chapter 3 of this thesis identify a critical role of the 
ILC-IL-22 pathway in promoting innate immunity and tissue homeostasis in the intestine, 
and Chapter 4 implicates a critical role for IL-22 in airway inflammation and tissue-repair 
in murine hosts.  Further, data in Chapter 3 identified the constitutive presence of IL-22-
producing ILCs in the GALT and intestinal tissues from healthy human donors.  A 
number of other studies have also identified IL-22 producing ILCs in lymphoid and 
mucosal tissues of humans (Cella et al., 2009; Cupedo et al., 2009; Hughes et al., 
2009). Further, the IL-22 pathway has been found to be impaired or dysregulated in 
numerous human diseases, including IBD, HIV, psoriasis, atopic dermatitis, arthritis, 
cystic fibrosis and cancer (Brand et al., 2006; Liu et al., 2007; Shen et al., 2009; 
Thompson et al., 2010; Wolk et al., 2007).  Although no therapies currently exist to 
directly target ILCs or IL-22, these data collectively suggest that therapeutic 
manipulation of the ILC-IL-22 pathway may be technically feasible and beneficial in the 
context of numerous chronic human diseases. 
 Although not directly targeting IL-22, some clinical trials may be indirectly 
affecting this pathway, such as the neutralization of IL-23 and IL-12 activity with a mAb 
that binds to the common p40 subunit of these cytokines (Cua et al., 2003; Langrish et 
al., 2004).  It would be predicted that treatment with this mAb could limit IL-23-induced 
IL-22 expression.  Results of these clinical trials demonstrated that treatment with anti-
IL-12/23p40 mAb provided beneficial outcomes in patients with active Crohn’s disease 
and psoriasis (Kauffman et al., 2004; Mannon et al., 2004).  Although the outcomes of 
these clinical trials are likely not solely due to impairment of IL-22 expression, they 
provide some proof-of-principle that targeting the IL-22-IL-22R pathway may be a viable 
option in the treatment of certain human inflammatory diseases.  It is possible that the 
generation of therapies that selectively target the IL-22-IL-22R pathway will be more 
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beneficial than those that target IL-12 and IL-23, permitting direct intervention in tissue 
immunity, inflammation and repair.   
 Data presented in Chapter 2 of this thesis suggest that promoting the ILC-IL-22 
pathway during enteric bacterial infection could be utilized to drive host protective 
immunity.  This could be accomplished by directly administering IL-22R agonists, agents 
that would stimulate an IL-22+ ILC-response or direct administration of downstream 
effector molecules to promote innate immunity.  In the absence of adaptive immunity, 
this ILC-IL-22 pathway is capable of limiting replication and translocation of pathogenic 
bacteria, thus promoting host survival for several weeks beyond initial infection.  
Therefore, therapeutic manipulation of the ILC-IL-22 pathways may be of particular 
importance in the treatment of patients with an impaired adaptive immune response 
such as AIDS, transplant-recipient and cancer patients, which often have a high rate or 
morbidity and mortality from secondary bacterial infections (Bonnet et al., 2007; Lewden 
et al., 2008; Wallace et al., 1993), and would benefit from an enhanced innate immune 
response.   
. In addition to pathogenic bacteria, data presenting in Chapter 3 demonstrate the 
importance for the ILC-IL-22 pathway in promoting containment of commensal bacteria 
to the GALT and intestinal tissues and limiting disruption of systemic immune cell 
homeostasis.  Loss of containment of commensal bacteria and induction of systemic 
inflammation are hallmarks and potentially contributing factors to the pathogenesis of 
numerous chronic human diseases including HIV infection, IBD, hepatitis and cancer 
(Brenchley et al., 2006; Lescut et al., 1990; McGuckin et al., 2009; Parlesak et al., 2000; 
Chin et al., 2007; Douek et al., 2009; Fava and Danese, 2011; Sandler et al., 2011a; 
Sandler et al., 2011b).  This suggests that targeting the ILC-IL-22 pathway may be 
beneficial in these chronic inflammatory diseases.  Results presented in Chapter 3 show 
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that exogenous administration of IL-22 limits peripheral dissemination of commensal 
bacteria and associated byproducts.   Further, one recent report identified that 
exogenous IL-7 is able to enhance tissue-protection and promote viral clearance in 
chronically infected mice (Pellegrini et al., 2011).  Although it was proposed that multiple 
mechanisms were involved in this beneficial outcome, one mechanism included 
increased expression of IL-22 (Pellegrini et al., 2011).  IL-7 can promote expansion of IL-
22-producing ILCs (Meier et al., 2007; Schmutz et al., 2009), and therefore this may be 
one possible therapeutic pathway to promote ILC-IL-22 responses in the treatment of 
chronic inflammatory diseases.  Although it is not directly known whether ILC-IL-22 
responses are disrupted in chronic human diseases, promotion of ILC-IL-22 responses 
will likely aid in limiting dissemination of commensal bacteria and preventing disruption 
of systemic immune cell homeostasis, thus limiting systemic inflammation and promoting 
immunity and tissue-protection in chronic human diseases. 
 Data presented in Chapter 4 of this thesis suggest that one method of targeting 
the IL-22 pathway may be through manipulation of regulatory cytokines such as IL-17A.  
IL-17A was found to promote the proinflammatory functions and limit the tissue-
protective functions and expression levels of IL-22.  Therefore it may be useful to 
promote or limit IL-17A expression depending on the desired functions of IL-22.  In the 
context of infection, it may be useful to promote expression of IL-17A to synergistically 
enhance IL-22-driven neutrophil recruitment and anti-microbial peptide expression (Aujla 
et al., 2008; Liang et al., 2006; Zheng et al., 2008).  In contrast, it may be beneficial to 
inhibit IL-17A in chronic inflammatory diseases to increase expression of IL-22 and limit 
the proinflammatory functions and thus promoting the tissue-protective functions of IL-
22.  However, the in vivo manipulation of IL-22 may be more challenging, given that 
other inflammatory cytokines may also influence the functions of IL-22 (Aujla et al., 2008; 
 168 
Eyerich et al., 2009; Guilloteau et al., 2010; Liang et al., 2006).  Therefore it may also be 
valuable to further characterize the IL-17A and IL-22 dual-expressing cell populations 
versus IL-22 single-expressing cellular populations.  For example, Powrie and 
colleagues recently characterized increases in IL-17A+IL-22- and IL-17A-IL-22+ ILC 
populations in patients with different forms of IBD (Geremia et al., 2011), and other 
groups have identified the presence of Th22 cells and Th17 cells in several human 
diseases (Eyerich et al., 2009; Kagami et al., 2010; Nograles et al., 2009; Shen et al., 
2009).  Future investigation into the cell lineage relationships, developmental 
requirements, activation pathways and plasticity of these cellular populations will be 
beneficial in profiling chronic inflammatory diseases in patients.  Further, this information 
will aid in identification of therapeutic targets to promote or inhibit IL-22-producing 
populations that co-express or lack IL-17A expression.  Collectively, published studies 
and data presented in this thesis suggest that targeting the ILC-IL-22 pathway, or other 
factors that regulate IL-22 expression such as IL-17A, may be beneficial and permit a 
shift in the balance of immunity, inflammation and tissue homeostasis in numerous 
chronic human diseases. 
  
5.4 Concluding remarks 
The data presented in this thesis demonstrate critical roles for ILCs and IL-22 in the 
regulation of immunity, inflammation and tissue homeostasis at mucosal sites.  Chapter 
2 identified a necessary and sufficient role for IL-22-producing ILCs in innate immunity to 
an enteric bacterial pathogen of mice.  Chapter 3 identified a critical role for IL-22 and 
ILCs in promoting containment of commensal bacteria, limiting their peripheral 
dissemination and as a result, maintaining systemic immune cell homeostasis in the 
periphery.  Chapter 4 identified IL-17A as a critical regulator of the expression and 
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functions of IL-22 in the context of inflammation and tissue-protection.  Collectively, the 
findings presented in this thesis advance the understanding of the biology of IL-22 and 
innate lymphoid cells, demonstrate the existence of novel immunoregulatory networks, 
and identify novel targets that may be utilized in the treatments of chronic diseases to 
increase protective immunity, limit chronic inflammation and maintain tissue homeostasis 
at mucosal sites. 
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Figure 37.  The ILC-IL-22 pathway in intestinal immunity and homeostasis.  In the 
steady state, it is unclear whether the ILC-IL-22 pathway is regulated by cytokines, 
commensal microbial signals or environmental signals to promote expression of IL-22 
and contain commensal bacteria to the intestine.  Follow infection, IL-23 production by 
accessory cells promotes infection-induced IL-22 production by ILCs to promote rapid 
innate immunity. 
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Figure 38. IL-17A influences the function and expression of IL-22.  Proposed 
mechanism of how IL-17A regulates the function and expression levels of IL-22 in innate 
and adaptive immune cell populations. 
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